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Abstract	
Enteroendocrine	cells	(EECs)	are	chemosensitive	cells	of	the	gastrointestinal	epithelium	that	
exert	 a	 wide	 range	 of	 physiological	 effects	 via	 production	 and	 secretion	 of	 hormones	 in	
response	 to	 ingested	 nutrients,	 bacterial	 metabolites	 and	 systemic	 signals.	 Glucagon-like	
peptide-1	(GLP-1)	is	one	such	hormone	secreted	from	so-called	L-cells	found	in	both	the	small	
and	 large	 intestines.	 GLP-1	 exerts	 an	 anorexigenic	 effect	 and	 together	 with	 glucose-
dependent	insulinotropic	polypeptide	(GIP),	restores	postprandial	normoglycaemia	through	
the	incretin	effect.	These	effects	are	exploited	by	GLP-1	analogues	in	the	treatment	of	type	2	
diabetes.	GLP-1	may	also	contribute	to	weight-loss	and	remission	of	type	2	diabetes	following	
bariatric	surgery	which	increases	postprandial	GLP-1	excursions.	
	
Here	we	investigated	stimulus	secretion	coupling	in	L-cells.	A	novel	2D	culture	system	from	
murine	 small	 intestinal	 organoids	was	 established	 as	 an	 in	 vitro	model.	 This	was	 used	 to	
characterise	 synergistic	 stimulation	 of	 GLP-1	 secretion	 in	 response	 to	 concomitant	
stimulation	by	bile	acids	through	the	Gs-protein	coupled	receptor	GPBAR1	and	free	fatty	acids	
through	the	Gq-coupled	receptor	FFAR1.		
	
Roughly	half	of	 colonic,	but	not	 small	 intestinal,	 L-cells	 co-produce	 the	orexigenic	peptide	
insulin-like	 peptide	 5	 (INSL5).	 This	 hitherto	 poorly	 examined	 subpopulation	 of	 L-cells	was	
characterised	 through	 transcriptomic	 analysis,	 intracellular	 calcium	 imaging	 (using	a	novel	
GCaMP6F-based	 transgenic	 mouse	 model),	 LC/MS	 peptide	 quantification	 and	 3D	 super	
resolution	microscopy	(3D-SIM).	Based	on	the	observed	prevalent	co-storage	of	GLP-1,	PYY	
and	INSL5	in	secretory	vesicles	and	similar	secretory	responses	of	both	hormones	to	a	range	
of	different	 stimuli	 strengths	 (including	 short	 chain	 fatty	acids,	angiotensin	 II	 and	arginine	
vasopressin	(AVP))	it	was	concluded	that	GLP-1,	PYY	and	INSL5	are	co-secreted,	rather	than	
being	selectively	recruited	by	different	stimuli.		
	
To	further	characterise	the	diversity	of	colonic	EECs,	single	cell	RNA-sequencing	(scRNA-seq)	
was	performed	on	 cells	 isolated	 from	mice	with	 a	pan-EEC	 fluorescent	marker	 (NeuroD1-
Cre:Rosa26-EYFP).	 This	 illustrated	 that	 INSL5-producing	 L-cells	 form	 one	 of	 two	
	 II	
transcriptomically	 distinct	 subpopulations	 of	 L-cells	 in	 the	 murine	 colon,	 with	 the	 other	
distinguished	 by	 expression	 of	 neurotensin	 (Nts).	 Another	 major	 EEC	 subpopulation,	
enterochromaffin	 (EC)	 cells	 could	 be	 split	 into	 three	 groups,	 mechanosensitive	 and	 pro-
inflammatory	EC	cells	distinguished	respectively	by	Piezo2	and	Tac1	expression	and	a	third	
Sct-expressing	group.	 Immunofluorescent	 labelling	and	RT-qPCR	analysis	 revealed	that	 the	
Nts-expressing	and	Insl5-expressing	L-cell	subpopulations	are	proximally	and	distally	enriched	
in	 the	murine	 colon,	 respectively.	 In	 primary	 cultures,	 angiotensin	 II	 and	 AVP	 stimulated	
INSL5,	GLP-1	and	PYY	but	not	NTS	secretion,	correlating	with	selective	expression	profiles	of	
the	cognate	receptors	in	the	L-cell	subpopulations.	
	
In	 summary,	 the	 work	 presented	 suggests	 that	 different	 L-cell	 subpopulations	 exist	 that	
respond	 to	 different	 stimuli,	 but	 that	 hormones	 co-expressed	 in	 individual	 L-cells	 are	 co-
released	upon	stimulation.	Differences	in	receptor	expression	between	these	subpopulations	
and	other	EEC-populations	might	be	exploitable	for	selective	hormone	recruitment	for	the	
therapy	of	diabetes,	obesity	and	other	diseases.	
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Chapter	1.	Introduction	
1.1. Obesity	and	type	2	diabetes		
 Global	epidemics		
The	global	prevalence	of	both	obesity	and	type	2	diabetes	has	increased	dramatically	since	
the	end	of	the	second	world	war.	In	large	part	this	has	been	due	to	increased	food	availability	
and	calorie	 intake	combined	with	an	 increase	 in	 sedentary	behaviour	 (i.e.	 reduced	calorie	
expenditure).	In	the	UK,	26%	of	adults	were	estimated	to	be	obese	in	2016,	whilst	in	2017	an	
estimated	3.7	million	people	were	 living	with	diagnosed	diabetes	and	12.3	million	were	at	
increased	risk	of	developing	type	2	diabetes	[1,2].	The	estimated	annual	cost	to	the	NHS	was	
£13.75bn	 for	obesity	management	 in	 2012	and	£6.1bn	 for	 diabetes	management	 in	 2014	
[3,4].	A	large	percentage	of	these	costs	derive	from	treatment	of	complications,	highlighting	
the	need	for	more	effective	therapeutic	interventions	for	obesity	and	type	2	diabetes.	
	
 Pathophysiology		
Obesity	 is	 characterised	 by	 abnormally	 high	 levels	 of	 adipose	 deposition	 whilst	 type	 2	
diabetes	 is	 characterised	 by	 insulin	 resistance	 and	 pancreatic	 beta	 cell	 dysfunction	 [5,6].	
Under	 normal	 physiological	 conditions,	 post-prandial	 insulin	 secretion	 from	 beta-cells	
counteracts	the	increase	in	glycaemia	seen	following	glucose	absorption	from	a	meal.	This	is	
achieved	by	 a	 combination	of	 insulin-stimulated	 glucose	uptake	by	peripheral	 tissues	 and	
glycogen	 synthesis	 in	 the	 liver	 [7].	 Insulin	 resistance	 in	 type	 2	 diabetes	 attenuates	 the	
glycaemia-lowering	 actions	 of	 endogenous	 insulin	 to	 insufficient	 levels	 to	 restore	
normoglycaemia	and	hence	leads	to	the	pathological	state	of	hyperglycaemia.		
	
Obesity	and	type	2	diabetes	are	strongly	associated.	In	fact,	obesity	is	a	predictive	risk	factor	
of	developing	insulin	resistance	and	type	2	diabetes	and	both	conditions	cause	cardiovascular	
issues.	Reflecting	these	associations,	the	term	metabolic	syndrome	is	used	to	denote	patients	
that	suffer	a	combination	of	obesity,	type	2	diabetes	and	hypertension	[8].	As	well	as	issues	
with	mobility,	patients	with	metabolic	 syndrome	are	more	 likely	 to	suffer	 from	peripheral	
neuropathy,	heart	failure	and	an	increased	risk	of	ischaemic	stroke	[8–10].		
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1.2. Pharmacological	treatments	of	obesity:	
Beyond	dietary	and	exercise	interventions,	a	limited	number	of	pharmacological	treatments	
are	 available	 for	 obesity.	 Unfortunately,	 some	 of	 these	 weight	 loss	 treatments,	 such	 as	
rimonabant,	amphetamine	derivatives	and	sibutramine	have	been	withdrawn	from	sale	due	
to	 associated	 adverse	 effects	 [11–13].	 A	 subset	 of	 anti-obesity	 drugs,	 including	 examples	
which	have	been	withdrawn	from	sale,	are	described	below:	
	
 Pancreatic	lipase	inhibitors	-	orlistat	
Orlistat	is	an	inhibitor	of	pancreatic	lipase	(which	is	involved	in	lipid	digestion)	that	reduces	
the	absorption	of	lipids	from	the	small	intestine	and	induces	a	modest	loss	in	body	weight.	
Additionally,	orlistat	 treatment	 reduces	 the	 incidence	of	obese	patients	developing	 type	2	
diabetes	[14,15].	This	preventative	action	of	orlistat	has	been	associated	with	weight	 loss,	
reduced	plasma	levels	of	free	fatty	acids,	increased	incretin	secretion	and	modulated	release	
of	adipocytokines	[16].	
	
 Amphetamine	derivatives		
Amphetamines	derivatives	are	a	group	of	psychoactive	agents	which	have	historically	been	
prescribed	 for	 weight-loss	 due	 to	 their	 ability	 to	 suppress	 appetite.	 Pharmacologically,	
amphetamine	mediates	competitive	inhibition	of	monoamine	reuptake	and	displacement	of	
monoamines	sequestered	into	secretory	vesicles,	increasing	monoaminergic	(dopaminergic,	
serotonergic	 and	 noradrenergic)	 neurotransmission	 [17].	 This	 increased	 monoaminergic	
neurotransmission	 can	 reduce	 food	 intake.	 Enhancement	 of	 dopaminergic	
neurotransmission,	for	example,	can	reduce	appetite	by	increasing	hypothalamic	expression	
of	 the	 anorexigenic	 neuropeptide	 cocaine	 and	 amphetamine	 regulated	 transcript	 (CART)	
whilst	decreasing	expression	of	the	orexigenic	neuropeptide	Y	(NPY)	[18].	Although	effective	
as	 a	weight	 loss	medication,	 amphetamines	 are	 highly	 addictive	with	 serious	 side	 effects	
associated	with	long	term	use	somewhat	limiting	their	modern	day	clinical	use	[12].		
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 Sibutramine	
Like	 amphetamine	 derivatives,	 sibutramine	 enhances	 monoaminergic	 neurotransmission.	
However,	unlike	amphetamine	derivatives,	sibutramine	achieves	this	by	blocking	monoamine	
reuptake	without	displacement	of	stored	monoamines.	Sibutramine	induced	enhancement	
in	monoaminergic	neurotransmission	is	thought	to	induce	weight	loss	by	increasing	energy	
expenditure	whilst	 suppressing	appetite	 [19].	Unfortunately,	 sibutramine	has	 largely	been	
withdrawn	from	clinical	use	including	in	the	Europe	and	USA	due	to	association	with	increased	
morbidity	 from	 cardiovascular	 disease.	However,	 these	 issues	 appear	 largely	 restricted	 to		
obese	patients	with	pre-existing	cardiovascular	issues	with	minimal	associated	risk	to	those	
without	[13,20].	This	suggests	that	sibutramine	treatment	should	be	reconsidered	for	obese	
patients	without	pre-existing	cardiovascular	issues.	
	
 CB1	receptor	inverse	agonists	-	rimonabant	
Representing	an	alternative	pharmacological	approach	for	obesity	treatment,	drugs	targeting	
the	cannabinoid	type	1	receptor	(CB1)	have	been	developed	such	as	rimonabant.	Activation	
of	CB1	in	hypothalamic	neurons	has	an	orexigenic	effect	linked	to	the	sensitisation	of	neurons	
producing	 the	 appetite	 stimulating	 neuropeptide	 orexin	 and	 attenuated	 expression	 of	
anorexigenic	neuropeptides	such	as	corticotropin-releasing	hormone	(CRH)	[21].	Conversely,	
inverse	agonism	of	CB1	by	 rimonabant	mediates	an	anorexigenic	effect	 that	 likely	 reflects	
increased	 activity	 of	 neurons	 producing	 anorexigenic	 over	 orexigenic	 neuropeptides.	
Unfortunately	 rimonabant	was	withdrawn	 from	sale	due	 to	severe	psychiatric	 side	effects	
that	were	observed	post-market	release	[11,22].		
	
 Dual	treatment	with	naltrexone	and	bupropion	
A	 more	 recently	 approved	 drug	 treatment	 is	 combined	 administration	 of	
naltrexone/bupropion.	 Bupropion	 is	 an	 antidepressant	 that	 boosts	 noradrenergic	 and	
dopaminergic	 neurotransmission	 by	 blocking	 reuptake	 of	 noradrenaline	 and	 dopamine	
respectively.	 These	 neurotransmitters	 stimulate	 pre-opiomelanocortin	 (POMC)	 neurons	 of	
the	arcuate	nucleus	(in	the	hypothalamus)	that	produce	the	anorexigenic	neurotransmitter	
alpha-MSH	and	the	autoinhibitory	peptide	beta-endorphin.	When	combined	with	naltrexone,	
	 4	
a	µ-opioid	receptor	antagonist	which	is	thought	to	enhance	POMC	neuron	activity	by	blocking	
autoinhibition	by	beta-endorphin,	bupropion	induces	modest	weight	loss	[22].		
	
 Lorcaserin	
Lorcaserin	is	a	specific	agonist	of	the	5-HT2C	receptor	and	was	approved	by	the	FDA	for	clinical	
use	as	an	anti-obesity	drug	in	2012	[23].	Lorcaserin	exerts	appetite	suppression	believed	to	
derive	 from	 simulation	 of	 anorexigenic	 POMC	 neurons	 within	 the	 arcuate	 nucleus	 [24].	
Preferential	activation	of	5-HT2C	receptors	over	5-HT2B	receptors	by	lorcaserin	avoids	known	
cardiovascular	 issues	 associated	 with	 5-HT2B	 receptor	 activation	 [25].	 Such	 issues	 have	
previously	 led	 to	 the	withdrawal	 of	 other	 anti-obesity	 drugs	with	 a	 serotonergic	mode	of	
action	such	as	fenfluramine	[23].	
	
 Incretin	mimetics	
Incretin	mimetics,	which	imitate	the	actions	of	the	gut	peptide	glucagon-like	peptide	1	(GLP-
1),	 such	 as	 liraglutide	 have	 recently	 been	 approved	 by	 the	 FDA	 for	 obesity	 treatment	 in	
addition	to	their	pre-existing	approval	for	type	2	diabetes	treatment	(discussed	later)	[26].	
The	weight	loss	triggered	by	these	injectable	drug	agents	derives	from	appetite	suppression	
(reducing	calorie	intake)	predominantly	mediated	by	stimulation	of	GLP-1	receptors	(GLP1Rs)	
within	the	central	nervous	system	(particularly	those	of	glutamatergic	neurons)	[27–30].	To	
maintain	 a	 therapeutic	dose,	 liraglutide	must	be	 injected	once/twice	daily.	 Recent	 clinical	
trials	have	focussed	on	the	potential	of	incretin	mimetics	with	longer	biological	half-lives	(and	
therefore	longer	lasting),	such	as	semaglutide,	which	could	be	administered	once	a	week	for	
obesity	 treatment	 [31].	 Use	 of	 such	 longer	 lasting	 injectable	 agents	would	 likely	 improve	
current	levels	of	patient	compliance	to	obesity	treatment	with	incretin	mimetics.	
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1.3. Pharmacological	treatments	of	type	2	diabetes	
In	 common	with	 obesity,	 type	 2	 diabetes	 can	 be	 partly	managed	 by	 dietary	 and	 lifestyle	
alterations.	 However,	 there	 are	 also	 a	 number	 of	 pharmacological	 options	 including	 the	
classical	use	of	insulin	analogues,	metformin,	sulphonylureas	and	glinides	and	newer	drugs	
such	as	incretin	mimetics	and	dipeptidyl	peptidase-4	(DPP-4)	inhibitors	[32].	These	examples	
and	their	mechanisms	of	actions	are	briefly	discussed	below:	
	
 Metformin	
The	therapeutic	benefits	of	metformin	treatment	are	thought	to	derive	from	a	combination	
of	suppressed	hepatic	glucose	production	(by	gluconeogenesis),	sensitisation	of	peripheral	
tissues	 to	 insulin	 and	 promotion	 of	 beta-cell	 function.	 Activation	 of	 adenosine	
monophosphate-activated	protein	kinase	(AMPK)	appears	key	to	the	effects	of	metformin	on	
hepatic	 gluconeogenesis	 and	 insulin	 sensitivity.	 However,	 the	 precise	 pharmacological	
mechanisms	underlying	metformin	therapy	have	not	been	resolved,	despite	over	60	years	of	
clinical	application	[33,34].		
	
 Insulin	
Insulin	 and	 its	 analogues	 are	 the	 traditional	 first	 line	 treatment	 for	 type	 1	 diabetes,	
compensating	for	the	loss	of	endogenous	insulin	resulting	from	autoimmune	induced	beta-
cell	 death.	 In	 contrast,	 most	 type	 2	 diabetics	 produce	 endogenous	 insulin	 on	 an	 insulin	
resistant	 background.	 The	 production	 of	 endogenous	 insulin	makes	 therapeutic	 dosing	 of	
insulin	 analogues	 more	 complex	 for	 type	 2	 than	 type	 1	 diabetes.	 Subsequently,	 insulin	
analogues	tend	to	be	utilised	10-15	years	after	 initial	diagnosis,	 following	behavioural	and	
other	 pharmacological	 interventions	 [35].	 Furthermore,	 patient	 compliance	 to	 insulin	
treatment	 is	 lower	 than	 for	 orally	 administrable	 drugs	 since	 insulin	 injections	 cause	
discomfort	and	potentially	life-threatening	episodes	of	hypoglycaemia	[36].	Recent	advances	
in	 the	closed-loop	 insulin	pump,	also	known	as	 the	 ‘artificial	pancreas’,	may	help	alleviate	
dosing	issues.	This	system	constantly	monitors	glycaemic	levels	and	adjusts	the	administered	
dose	of	insulin	accordingly	avoiding	the	need	for	regular	self-administered	insulin	injections	
[37].	 This	 system	 was	 initially	 designed	 for	 treatment	 of	 type	 1	 diabetes,	 but	 by	 using	
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computational	modelling	 of	 endogenous	 insulin	 release	 it	 is	 hoped	 that	 it	 can	 be	 applied	
successfully	to	type	2	diabetics	[38].	
	
 KATP	channel	inhibitors	-	sulphonylureas	and	glinides		
Sulphonylureas	 (such	 as	 glimepiride)	 and	 glinides	 (such	 as	 nateglinide)	 restore	
normoglycaemia	 in	 type	 2	 diabetic	 patients	 through	 stimulation	 of	 endogenous	 insulin	
secretion	 from	 pancreatic	 beta-cells.	 Stimulation	 of	 insulin	 secretion	 by	 these	
pharmacological	 agents	 results	 from	 inhibition	 of	 beta-cell	 ATP-sensitive	 potassium	 (KATP)	
channels	causing	plasma	membrane	depolarisation	and	increased	insulin	exocytosis	[39,40].	
Although	 effective	 insulin	 secretagogues,	 sulphonylureas	 (in	 common	 with	 insulin	
administration)	 can	 trigger	 a	 dangerous	 state	 of	 abnormally	 low	 glycaemia	 known	 as	
hypoglycaemia	[6].	More	recent	drug	development	efforts	in	the	diabetes	field	have	focussed	
on	 minimising	 hypoglycaemic	 risk	 whilst	 delivering	 therapeutic	 benefit.	 To	 this	 end,	 the	
incretin	mimetics	and	DPP-4	inhibitors	have	been	developed.	
	
 Incretin	mimetics	
Newer	anti-diabetes	drugs	 include	 incretin	mimetics,	such	as	exenatide,	which	 imitate	the	
actions	of	the	gut	peptide	glucagon-like	peptide	1	(GLP-1)	to	restore	normoglycaemia	through	
the	 incretin	 effect.	 The	 incretin	 effect	 accounts	 for	 the	 higher	 levels	 of	 insulin	 secretion	
elicited	by	oral	compared	with	intravenous	administration	of	glucose	under	similar	glycaemic	
conditions.	 It	 is	exerted	by	 the	 incretin	peptides	GLP-1	and	glucose	 insulinotropic	peptide	
(GIP)	secreted	from	endocrine	cells	of	the	intestinal	epithelium	known	as	enteroendocrine	
cells	 (EECs).	 GLP-1	 and	 GIP	 can	 act	 directly	 on	 pancreatic	 islets	 to	 stimulate	 endogenous	
insulin	 secretion	 from	beta	cells	and	modulate	glucagon	secretion	 from	alpha	cells	 (GLP-1	
inhibits	 whilst	 GIP	 stimulates	 glucagon	 secretion)	 thus	 reducing	 glycaemic	 levels	 [41–43].	
Whilst	incretin	mimetic	treatment	does	not	generally	trigger	hypoglycaemia,	like	insulin	they	
are	peptides	which	must	be	administered	by	injection	influencing	patient	compliance	[44].		
	
 DPP-4	inhibitors		
By	pharmacological	inhibition	of	the	enzyme	DPP-4,	which	rapidly	inactivates	circulating	GLP-
1	and	GIP,	levels	of	endogenous	incretins	in	the	circulation	can	be	enhanced	with	associated	
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therapeutic	 benefits.	 	 Gliptins	 represent	 a	 licensed	 class	 of	 such	 DPP-4	 inhibitors.	 Unlike	
incretin	mimetics,	gliptins	can	be	orally	administered.	However,	incretin	mimetics	are	more	
effective	at	 lowering	blood	glucose	 levels	and	also	exert	a	weight	 loss	effect	which	DPP-4	
inhibitors	do	not	[45].		
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1.4. Surgical	 treatment	 of	 obesity	 and	 type	 2	 diabetes	 –	 bariatric	
surgery		
A	more	drastic	approach	to	obesity	treatment	is	bariatric	(weight-loss)	surgery.	One	of	the	
most	commonly	employed	procedures	is	the	Roux-en-Y	gastric	bypass	(RYGB)	[46].	Here	the	
upper	part	of	the	stomach	is	partitioned	from	the	rest	of	the	stomach	and	the	small	intestine	
is	divided	at	the	jejunum.	Following	this,	an	anastomosis	is	made	between	the	small	pouch	
formed	by	the	upper	stomach	and	the	jejunum	forming	the	alimentary	limb	(aka	Roux	limb)	
which	bypasses	the	majority	of	the	stomach	and	the	duodenum.	An	additional	anastomosis	
is	 formed	 between	 the	 excluded	 stomach	 and	 duodenum	 (biliopancreatic	 limb)	 and	 the	
alimentary	limb	[47].	RYGB	results	in	a	large	reduction	in	the	size	of	stomach,	enhancing	the	
postprandial	sensation	of	fullness	and	inducing	weight-loss	by	increasing	satiety	and	reducing	
food	intake	[48].		
	
RYGB	 can	 additionally	 be	 used	 to	 treat	 type	 2	 diabetes	which	 can	 lead	 to	 remission	with	
Purnell	et	al.	finding	that	68.7%	of	patients	studied	were	in	remission	3	years	post-RYGB	[49].	
The	 improvements	 in	 glycaemic	 control	 following	 RYGB	 occur	 acutely	 and	 are	 therefore	
unlikely	to	derive	solely	from	weight	loss.	The	hindgut	and	foregut	hypotheses	are	the	main	
theories	put	forward	to	explain	the	glycaemic	improvements	and	satiety	seen	following	RYGB.	
The	hindgut	hypothesis	postulates	that	by	bypassing	the	early	small	intestine	nutrients	are	
delivered	directly	to	the	distal	small	intestine	stimulating	release	of	factors	which	stimulate	
insulin	 secretion	 acting	 to	 restore	 normoglycaemia	 and	 exerting	 satiety.	 Conversely,	 the	
foregut	 hypothesis	 suggests	 that	 bypassing	 the	 early	 small	 intestine	 reduces	 secretion	 of	
inhibitory	 factors	 that	negatively	affect	glycaemic	control	 (perhaps	by	suppressing	 incretin	
release)	and	that	increase	appetite	[50,51].	These	factors	are	likely	peptides	produced	and	
secreted	by	EECs	[52].	 In	the	case	of	the	hindgut	hypothesis,	 involvement	of	proglucagon-
expressing	(GLP-1	producing)	EECs	has	been	implicated.	Under	this	theory,	nutrient	delivery	
directly	 to	 the	 distal	 small	 intestine	 which	 is	 enriched	 in	 proglucagon-expressing	 EECs	
enhancing	 GLP-1	 and	 PYY	 (another	 hormone	 co-secreted	 with	 GLP-1)	 secretion	 with	
consequential	 effects	 on	 postprandial	 insulin	 secretion	 and	 satiety	 [53].	 Investigating	 the	
nutrient	 sensing	 mechanisms	 of	 proglucagon-expressing	 EECs	 in	 particular,	 which	 is	 the	
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primary	 objective	 of	 this	 thesis,	 and	 of	 other	 EECs	 in	 general	 may	 therefore	 uncover	
mechanisms	by	which	type	2	diabetes	remission	is	achieved	following	RYGB.	
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1.5. Targeting	 the	 enteroendocrine	 system	 –	 a	 novel	 therapeutic	
approach	
Pharmacological	targeting	of	enteroendocrine	cells	may	achieve	therapeutic	benefit	through	
modulated	 secretion	 of	 endogenous	 gut	 hormones.	 Such	 an	 approach	might	 achieve	 the	
aforementioned	 clinical	 benefits	 of	 RYGB	 by	 stimulating	 the	 release	 of	 incretins	 or	
suppressing	 release	 of	 as-of-yet	 uncharacterised	 anti-incretin	 factors.	 Indeed,	 oral	
administration	of	a	class	of	known	GLP-1	secretagogues	known	as	free	fatty	acid	receptor	1	
(FFAR1)	agonists	also	capable	of	acting	as	positive	allosteric	modulators	(AgoPAMs)	reduced	
food	 intake	and	body	weight	 in	diet-induced	obese	(DIO)	mice.	AgoPAM	administration	to	
GLP1R	knockout	mice	did	not	 induce	these	effects	suggesting	that	GLP-1	release	underlies	
AgoPAM-induced	satiety	[54].	Therefore,	as	this	example	demonstrates,	characterisation	of	
the	molecular	mechanisms	regulating	secretion	from	EECs	may	aid	identification	of	novel	drug	
targets	for	obesity	and	type	2	diabetes	treatment.		
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1.6. Enteroendocrine	cells	–	chemosensitive	epithelial	cells	
EECs	represent	around	1%	of	all	epithelial	cells	of	the	gastrointestinal	tract	and	are	electrically	
excitable	cells	characterised	by	their	endocrine	products.	These	hormones	exert	a	variety	of	
physiological	effects	both	 in	a	 local	paracrine	 fashion	and	at	distant	 sites	via	 the	systemic	
circulation.	One	key	characteristic	of	EECs	is	the	ability	to	chemosense	luminal	contents	of	
the	 gastrointestinal	 tract,	 neurotransmitters	 and	 systemic	 factors	 and	modulate	 secretory	
activity	 accordingly.	 Many	 EECs,	 for	 example,	 respond	 to	 dietary	 stimuli	 such	 as	
carbohydrates,	peptides	and	lipids	regulating	satiety,	glycaemia	and	gastrointestinal	motility	
[52,55].	EEC	chemosensory	 responses	are	 largely	 regulated	by	G-protein	coupled	 receptor	
(GPCR)	signalling	and	more	specifically	the	Gq,	Gs	and	Gi	signalling	pathways	which	modulate	
exocytosis	 through	the	secondary	messengers	 IP3,	DAG	and	cAMP	(figure	1)	 [55].	Example	
modulations	 include	 changes	 to	 intracellular	 calcium	 (Ca2+)	 levels	 (critical	 to	 exocytosis)	
directly	 through	 IP3-dependent	 release	 of	 intracellular	 Ca2+	 stores	 and	 indirectly	 by	
modulating	the	activities	of	voltage-gated	calcium	channels	through	which	Ca2+	influx	occurs	
[56,57].	 An	 increase	 in	 intracellular	 Ca2+	 triggers	 secretion	 by	 acting	 on	 SNARE	 proteins	
directly	involved	in	mediating	fusion	of	secretory	vesicles	with	the	plasma	membrane	[58].		
	
EECs	can	also	chemosense	stimuli	in	a	GPCR-independent	fashion.	For	example,	L-cell	glucose-
sensing	involves	the	transporter	sodium-glucose	transport	protein	1	(SGLT1)	which	mediates	
sodium-dependent	 active	 transport	 of	 glucose	 and	 accordingly	 depolarises	 the	 plasma	
membrane	triggering	GLP-1	secretion	[59].	Likewise,	the	potent	GLP-1	secretion	triggered	by	
the	 amino	 acid	 L-glutamine	 partly	 derives	 from	 the	 electrogenic	 activities	 of	 a	 sodium-
dependent	amino	acid	transporter	(the	precise	identity	of	this	transporter	has	not	yet	been	
clarified)	[60,61].	
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Figure	 1:	 Schematic	 illustrating	 the	 Gq,	 Gs	 and	 Gi	 signalling	 pathways	 underlying	
chemosensation	 in	 enteroendocrine	 cells.	 Stimulation	 of	 the	 Gq	 pathway	 stimulates	
phospholipase	C	(PLC)	activity	which	catalyses	PIP2	hydrolysis	to	the	secondary	messengers	IP3	
and	 DAG.	 IP3	 triggers	 release	 of	 intracellular	 calcium	 stores	 which	 increases	 membrane	
excitability	(indicated	by	the	waveform)	and	triggers	secretory	vesicle	fusion.	DAG	activates	
protein	kinase	C	(PKC)	which	can	increase	membrane	excitability	by	modulating	the	activities	
of	other	proteins.	Stimulation	of	the	Gs	pathway	stimulates	adenylate	cyclase	(AC)	to	produce	
the	secondary	messenger	cAMP	from	ATP.	cAMP	activates	protein	kinase	A	(PKA)	and	EPAC	
which	in	turn	mediates	calcium	influx	including	voltage	gated	calcium	channels	(VGCCs)	and	
may	modulate	the	activities	of	proteins	involved	in	the	fusion	mechanism.	A	combination	of	
these	 downstream	 effects	 yields	 exocytosis	 of	 EEC	 peptides/factors	 (represented	 by	 red	
squares).	Stimulation	of	the	Gi	pathway,	contrastingly	to	the	Gs	pathway,	inhibits	AC	activity	
repressing	exocytosis.	Gq,	Gs	and	Gi-coupled	GPCRs	represented	respectively	by	blue,	green	
and	red	shapes	with	7	transmembrane	intersections.	Black	arrows	reflect	stimulatory	effects	
whilst	red	T-shaped	lines	indicate	inhibitory	effects.		
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1.7. Enteroendocrine	cell	subtypes	
Historically	 the	 EECs	were	 thought	 to	 produce	 one	 particular	 gut	 hormone	 and	 split	 into	
subtypes	according	to	which	gut	hormone	they	produced.	However,	this	canonical	view	has	
been	challenged	by	transcriptomic	and	immunohistological	studies	indicating	a	large	degree	
of	 overlap	 in	 the	 gut	 hormone	 profiles	 produced	 and	 secreted	 by	 the	 historical	 EEC	
subdivisions	 [62–65].	 In	 light	 of	 these	 findings	 Fothergill	 and	 Furness	 propose	 that	 a	 new	
classification	system	is	required	for	EECs	[66].	For	simplicity,	in	this	thesis	the	classical	terms	
are	 used	 to	 refer	 to	 proglucagon-expressing,	 somatostatin-expressing	 and	 serotonin-
producing	EECs	respectively	as	L-cells,	D-cells	and	enterochromaffin	(EC)	cells	(see	figure	2).	
	
	
Figure	2:	Frequency	distribution	of	enteroendocrine	cell	subtypes	through	the	human	small	
and	large	intestines.	Established	through	immunolabelling	of	key	endocrine	products	(labelled	
at	the	top)	of	each	subtype	in	samples	taken	at	the	intestinal	sites	labelled	by	blue	circles	on	
the	schematic.	Width	of	coloured	shapes	indicates	frequency	of	cell	type.	Produced	by	Fiona	
Gribble.	
	
	
	
Duodenum
Ileum
Rectum
Cell type DEC L IK NS
Colon
Jejunum
	 14	
	
	
The	following	sections	briefly	describe	the	key	gut	hormones	covered	in	this	thesis:	
	
 Proglucagon	derived	peptides	
Proglucagon-expressing	 cells,	 referred	 to	 henceforth	 as	 ‘L-cells’	 (a	 classical	 term	 for	
proglucagon-expressing	cells	of	the	gastrointestinal	tract),	are	localised	to	the	epithelium	of	
the	small	and	large	intestines	and	secrete	a	range	of	proglucagon	derived	peptides	(peptides	
derived	 from	post-translational	processing	of	 the	proglucagon	precursor	polypeptide)	 into	
the	circulation	(see	figures	2	and	3)	[67,68].	Proglucagon	and	its	derivatives	are	produced	in	
alpha-cells	 of	 the	 pancreas,	 a	 subset	 of	 central	 neurons	 and	 intestinal	 L-cells.	 Whilst	
pancreatic	alpha-cells	produce	glucagon	and	glicentin-related	pancreatic	polypeptide	(GRPP)	
from	 proglucagon,	 L-cells	 do	 not.	 Conversely,	 L-cells	 produce	 GLP-1,	 GLP-2,	 glicentin	 and	
oxyntomodulin	 which	 are	 not	 produced	 by	 alpha-cells.	 These	 differences	 in	 proglucagon	
processing	derive	 from	differential	expression	of	different	prohormone	convertases	 (Pcsk)	
that	cleave	at	different	 sites	along	 the	proglucagon	polypeptide	chain.	Alpha-cells	express	
Pcsk2	 which	 favours	 glucagon	 and	 GRPP	 production	 whilst	 L-cells	 express	 Pcsk1/3	 which	
favours	GLP-1,	GLP-2,	glicentin	and	oxyntomodulin	production	[69].	
	
Secretion	of	GLP-1	 from	L-cells	 is	 triggered	by	a	range	of	nutrients	digested	and	absorbed	
from	 the	 intestinal	 lumen	 including	 free	 fatty	 acids	 (FFAs),	 glucose	 and	 peptides	 [70–72].	
Additional	GLP-1	secretagogues	include	circulating	factors	such	as	angiotensin	II	and	arginine	
vasopressin	(AVP;	hormones	involved	in	blood	pressure	regulation	and	osmoregulation)	and	
bacterial	metabolites	such	as	SCFAs	produced	by	fermentation	in	the	distal	gastrointestinal	
tract	[73–75].	As	detailed	earlier,	GLP-1	is	an	incretin	peptide	which	restores	normoglycaemia	
postprandially	by	triggering	 insulin	secretion	and	suppression	of	glucagon	secretion.	GLP-1	
stimulated	insulin	secretion	likely	results	from	direct	activation	of	beta	cell	GLP1R.	In	contrast,	
suppression	 of	 glucagon	 secretion	 from	 alpha-cells	 may	 result	 indirectly	 from	 GLP-1	
stimulated	 somatostatin	 secretion	 from	 delta-cells	 mediating	 paracrine	 inhibition	 [76].	
Regarding	the	anorexigenic	effects	of	GLP-1,	these	effects	can	be	mediated	by	activation	of	
GLP1R	 on	 peripheral	 vagal	 afferents	 innervating	 the	 gastrointestinal	 tract	 and	 on	 central	
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neurons	 of	 the	 lateral	 hypothalamus.	 Due	 to	 the	 short	 half-life	 of	 GLP-1,	 it	 is	 likely	 that	
signalling	 through	 local	 vagal	 afferents	 is	more	 physiologically	 relevant	 to	 gastrointestinal	
GLP-1	mediated	satiation	than	direct	action	on	the	central	nervous	system	[77,78].		
	
Regarding	 the	 other	 proglucagon-derived	 peptides	 that	 are	 secreted	 together	with	GLP-1	
from	 L-cells,	 whilst	 glicentin	 has	 no	 known	 receptor	 or	 physiological	 role,	 GLP-2	 has	 an	
intestinotrophic	effect	via	the	Gs-coupled	GLP-2	receptor.	This	effect	appears	 important	to	
the	 recovery	of	 intestinal	mucosa	 following	 injury	 [79,80].	Furthermore,	oxyntomodulin	 in	
both	rodent	models	and	human	volunteers,	mediates	loss	in	body	weight	(through	appetite	
suppression	 and	 increases	 in	 energy	 expenditure)	 and	 restoration	 of	 normoglycaemia.	
Oxyntomodulin	 treatment	 also	 appeared	 to	 have	 superior	 therapeutic	 effects	 to	 GLP1R-
selective	 incretin	 mimetics.	 These	 effects	 do	 not	 appear	 to	 be	 mediated	 by	 a	 specific	
oxyntomodulin	 receptor	 (which	 has	 not	 been	 identified	 to	 date),	 but	 by	 dual	 agonism	 of	
GLP1R	and	the	glucagon	receptor	(GCGR)	by	oxyntomodulin	[80,81].	Aiming	to	replicate	the	
weight	loss	and	improvements	in	glucose	tolerance	seen	with	oxyntomodulin	administration,	
synthetic	 GLP1R/GCGR	 dual	 agonists	 have	 recently	 been	 developed,	 an	 example	 being	
MEDI0382.	In	recent	clinical	trials,	MEDI0382	administration	induced	significant	weight	loss	
and	 restored	 normoglycaemia	 in	 type	 2	 diabetic	 patients	 demonstrating	 the	 therapeutic	
potential	of	GLP1R/GCGR	dual	agonism	[82].	
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Figure	 3:	 Post-translational	 processing	 of	 the	 preproglucagon	 polypeptide	 in	 alpha	 cells,	
neurons	and	L-cells	of	the	gastrointestinal	tract.	Prohormone	convertase	2	(Psck2)	activity	in	
alpha	 cells	produces	glucagon,	GRPP,	 IP1	and	major	proglucagon	 fragment.	Contrastingly,	
Psck1/3	activity	in	neurons	and	L-cells	favours	production	of	GLP-1,	GLP-2,	oxyntomodulin,	IP2	
and	glicentin.	Figure	adapted	from	Sandoval	et	al.	(2015)	[69].	
	
 Peptide	YY	
Peptide	YY	(PYY)	is	structurally	related	to	neuropeptide	Y	(NPY)	and	activates	NPY	receptors.	
The	secreted	form	is	36	amino	acids	in	length	(PYY	1-36)	and	is	truncated	to	the	predominant	
active	form	found	in	the	circulation	PYY	3-36	by	DPP-4.	PYY	3-36	has	a	much	higher	binding	
affinity	for	NPY2R	than	the	other	NPY	receptors.	Similarly	to	GLP-1,	activation	of	NPY2R	by	
PYY	 3-36	 in	 the	 hypothalamic	 arcuate	 nucleus	 and	 vagal	 afferents	 reduces	 food	 intake	 in	
rodent	models	[83–85].	Furthermore,	both	GLP-1	and	PYY	appear	involved	in	the	‘ileal	brake’	
mechanism.	This	is	a	feed	forward	mechanism	by	which	arrival	of	nutrients	such	as	lipids	in	
the	proximal	small	intestine	trigger	GLP-1	and	PYY	release	that	attenuates	gastric	emptying,	
aiding	with	complete	digestion	and	absorption	of	ingested	nutrients	[86].	The	physiological	
effects	of	GLP-1	and	PYY	therefore	seem	to	complement	one	another	in	reducing	appetite,	
aiding	in	digestion	and	restoring	normoglycaemia	post-prandially.	Indeed	PYY	is	produced	and	
co-secreted	 into	 the	 circulation	 with	 GLP-1	 by	 L-cells	 [67,68,70–72].	 Given	 that	 recent	
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immunohistological	 examinations	of	 L-cells	 suggest	 that	PYY	and	GLP-1	 are	packaged	 into	
separate	secretory	vesicle	pools	it	is	likely	that	the	co-secretion	of	GLP-1	and	PYY	observed	
derives	from	regulation	of	the	GLP-1	and	PYY	vesicle	pools	by	common	molecular	secretory	
mechanisms	[87].	
	
 Insulin-like	peptide	5	
Recent	examination	of	colonic	L-cells	has	revealed	a	subpopulation,	representing	roughly	half	
of	large	intestinal	L-cells,	express	and	produce	the	gut	peptide	insulin-like	peptide	5	(INSL5)	
[88].	The	etymology	of	INSL5	relates	to	structural	similarities	between	insulin	and	INSL5,	with	
both	consisting	of	two	polypeptide	chains	(referred	to	as	the	A	and	B	chains)	linked	together	
by	disulphide	bonds	 [89].	Regarding	physiological	 relevance,	 INSL5	 is	 thought	to	modulate	
hepatic	glucose	production,	potentially	stimulate	insulin	secretion	from	beta	cells	and	to	act,	
in	contrast	to	GLP-1	and	PYY,	as	an	orexigenic	gut	peptide	[88,90,91].	These	actions	are	likely	
through	the	Gi-coupled	cognate	receptor	of	INSL5	relaxin	family	peptide	receptor	4	(Rxfp4)	
with	 knockout	 of	 Rxfp4	 in	 mice	 abolishing	 INSL5-induced	 increases	 in	 food	 intake	 [88].	
Whether	INSL5	is	secreted	together	with	GLP-1	and	PYY	to	known	colonic	L-cell	stimulants	is	
unknown	with	 investigations	 hampered	 by	 an	 inability	 to	 accurately	 quantify	 INSL5	 from	
secretion	and	plasma	samples	[89].		
	
 Cholecystokinin	
Cholecystokinin	(CCK)	is	a	gut	peptide	produced	and	secreted	in	response	to	luminal	stimuli	
by	a	subset	of	enteroendocrine	cells	concentrated	in	the	duodenum	canonically	referred	to	
as	I-cells.	Through	stimulation	of	CCK1	receptors	on	vagal	neurons,	like	GLP-1	and	PYY,	CCK	
can	exert	a	anorexigenic	effect.	However,	this	effect	appears	to	be	acute	as	after	24	hours	of	
continuous	administration	of	CCK	no	sustained	change	in	food	intake	is	observed	[92].	Locally,	
CCK	stimulates	the	release	of	digestive	enzymes	(from	the	pancreas)	and	bile	(by	triggering	
contraction	of	 the	gallbladder)	 into	 the	duodenum	 [93].	 The	pancreatic	enzymes	 released	
catalyse	 the	 breakdown	of	macromolecules	 such	 as	 complex	 carbohydrates,	 proteins	 and	
lipids	 into,	 respectively,	 simple	 sugars,	 amino	 acids	 and	 free	 fatty	 acids	 (together	 with	
cholesterol	and	monoglycerides)	which	are	absorbed	across	the	small	intestinal	mucosa	[94].	
Bile	 aids	 in	 this	 process	 by	 neutralising	 acidic	 chyme	 entering	 the	 duodenum	 from	 the	
	 18	
stomach	and	emulsifying	ingested	lipids	into	smaller	micelles.	CCK	therefore	plays	a	critical	
regulatory	role	in	digestion	[95].		
	
 Neurotensin	
Neurotensin	 (NTS)	 is	 a	 13	amino	acid	 long	peptide	produced	and	 secreted	by	a	 subset	of	
enteroendocrine	cells	historically	referred	to	as	N-cells	[96].	Neurotensin-producing	cells	are	
concentrated	within	the	small	intestine	in	rodents	with	lower	numbers	found	distally	in	the	
large	intestine	[97].	Whilst	N-cells	are	also	numerous	within	the	human	small	intestine,	unlike	
in	the	rodents,	they	are	very	rarely	found	in	the	large	intestine	[98,99].	Neurotensin	secretion	
is	triggered	by	many	of	the	same	dietary	stimuli	as	GLP-1/PYY	including	free	fatty	acids	and	
glucose	and	is	often	produced	and	co-released	by	the	same	cells	as	GLP-1	and	PYY	[100,101].	
Physiologically	neurotensin	mediates	a	range	of	different	effects	including	promotion	of	fatty	
acid	absorption	from	the	small	intestine,	glucose-dependent	modulation	of	insulin	secretion	
(stimulating	 or	 reducing	 insulin	 secretion	 in	 conditions	 of	 low	 and	 high	 glycaemia	
respectively),	wound	healing	and	inflammatory	responses	and	satiety	[101–105].		
	
The	proinflammatory	effects	of	neurotensin	are	thought	relevant	to	the	pathophysiology	of	
inflammatory	 bowel	 disease	 (IBD)	 with	 patients	 displaying	 elevated	 expression	 levels	 of	
neurotensin	and	neurotensin	receptor	1	[106].	Furthermore,	neurotensin	has	also	been	linked	
to	the	development	of	obesity	and	type	2	diabetes.	The	evidence	for	such	a	link	comes	from	
physiological	examinations	of	neurotensin	knockout	mice.	When	fed	a	high	fat	diet	(HFD;	used	
to	model	obesity),	the	neurotensin	knockout	mice	displayed	significantly	attenuated	weight	
gain,	 liver	 triglyceride/cholesterol	 accumulation	 and	 obesity-related	 insulin	 resistance	
compared	to	wild	type	mice	on	HFD.	In	part,	these	discrepancies	appear	to	result	from	the	
absence	of	neurotensin	facilitated	absorption	of	lipids	from	the	small	intestine.	Consistently,	
intestinal	 absorption	of	 fatty	 acids	 following	olive	 oil	 gavage	 (as	measured	by	 triglyceride	
accumulation)	was	attenuated	in	neurotensin	knockout	mice	relative	to	wild	type	mice	in	a	
manner	reversible	through	co-administration	with	neurotensin	peptide	[102].		
	
Further	evidence	of	the	clinical	relevance	of	neurotensin	comes	from	studies	investigating	the	
effect	of	RYGB	on	the	secretion	profile	of	gut	peptides.	RYGB	performed	on	rats	yielded	an	
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expected	 decrease	 in	 food	 intake	 associated	 with	 increased	 plasma	 levels	 of	 GLP-1	 and	
neurotensin.	Post-operative	pharmacological	antagonism	of	peripheral	neurotensin	signalling	
reversibly	 increased	 food	 intake	 [105].	 Complimenting	 these	 findings,	 RYGB	 in	 humans	 is	
associated	with	elevated	plasma	GLP-1	and	neurotensin	levels.	GLP-1	and	neurotensin	levels	
were	particularly	pronounced	in	patients	with	a	longer	biliopancreatic	limb	whereby	nutrients	
are	delivered	directly	to	more	distal	regions	of	the	small	intestine	rich	in	L	and	N-cells,	relative	
to	 patients	 with	 shorter	 biliopancreatic	 limbs	 [107].	 Combined,	 these	 findings	 imply	 that	
neurotensin	 may	 represent	 one	 of	 the	 aforementioned	 hindgut	 factors	 which	 enhances	
satiety	following	RYGB.	
		
 Somatostatin	
Somatostatin	is	a	cyclic	polypeptide	which	has	two	active	isoforms	derived	from	the	precursor	
peptide	preprosomatostatin,	a	28	amino	acid	variant	(SST-28)	and	14	amino	acid	variant	(SST-
14)	 produced	 by	 truncation	 of	 SST-28	 [108,109].	 Cells	 which	 produce	 and	 secrete	
somatostatin	 are	 referred	 to	 henceforth	 as	 D-cells	 (historical	 term	 for	 somatostatin-
producing	 EECs).	 Radioimmunoassay	 analysis	 identified	 that	 gastrointestinal	 somatostatin	
equates	 to	 roughly	 65%	of	 the	 total	 somatostatin	 produced	 in	 the	 body	with	 the	 highest	
concentrations	found	in	the	gastric	antrum	and	distal	colon.	The	remaining	somatostatin	is	
partitioned	 between	 delta	 cells	 in	 pancreatic	 islets	 (5%)	 and	 neurons	 of	 central	 nervous	
system	 (30%)	 [110].	 Further	 immunohistological	 studies	 imply	 that	 the	 SST-14	 isoform	
predominates	in	the	stomach,	pancreas	and	somatostatin-producing	neurons	whilst	SST-28	
predominates	in	the	small	and	large	intestines	likely	reflecting	SST-28	as	the	terminal	peptide	
product	of	preprosomatostatin	in	these	regions	[111].	Physiologically,	somatostatin	acts	as	a	
global	 inhibitor	 of	 exocrine	 and	 endocrine	 secretions	 inhibiting	 the	 release	 of	 all	
enteroendocrine	 hormones,	 pancreatic	 glucagon	 and	 insulin	 secretion	 and	 gastric	 acid	
production	 (both	 through	 direct	 action	 on	 parietal	 cells	 and	 indirectly	 through	 reduced	
secretion	of	stimulants	of	gastric	acid	secretion	such	as	gastrin).	The	inhibitory	properties	of	
somatostatin	are	harnessed	clinically	by	use	of	somatostatin	analogues	(such	as	octreotide)	
in	neuroendocrine	tumour	treatment,	suppressing	the	adverse	effects	of	ectopic	hormone	
production	 such	 as	 hypoglycaemia	 resulting	 from	 insulinoma	 [112].	 In	 addition	 to	 dietary	
nutrients,	such	as	small	peptides,	many	endocrine	and	exocrine	hormones,	including	GLP-1	
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and	CCK,	stimulate	somatostatin	secretion	 forming	negative	 feedback	 loops	 [113–115].	As	
such,	 gastrointestinal	 somatostatin	 is	 involved	 in	 a	wide	 range	 of	 physiological	 processes	
including	glucose	homeostasis,	and	regulation	of	gastric	pH	and	gastrointestinal	motility.	
	
 Serotonin	
More	 than	 90%	 of	 the	 total	 serotonin	 (5-HT)	 in	 the	 body	 is	 produced	 by	 EECs	 of	 the	
gastrointestinal	epithelium	referred	to	in	this	thesis	as	enterochromaffin	cells	(EC	cells)	[116].	
These	 cells	 are	 found	 with	 highest	 incidence	 in	 the	 pylorus	 of	 the	 stomach	 and	 a	 fairly	
consistent	 distribution	 throughout	 the	 rest	 of	 the	 GI	 tract	 [117].	 EC	 cells	 release	 5-HT	 in	
response	to	a	variety	of	different	stimuli	including	neurotransmitters,	bacterial	metabolites	
and	irritants.	The	5-HT	released	modulates	physiological	activities	via	direct	paracrine	action	
and	indirect	action	through	neuromodulation.	Serotonergic	neuromodulation	of	the	enteric	
nervous	 system	 (ENS)	 is	 known	 to	 regulate	 gut	 motility	 and	 peristaltic	 contractions	
(coordinated	waves	of	circular	and	longitudinal	smooth	muscle	contraction).	Additional	5-HT	
functions	include	paracrine	stimulation	of	gastrointestinal	secretions	with	an	example	being	
mucous	secretion	from	goblet	cells.	[118].	Clinically,	dysfunction	of	gut	serotonergic	signalling	
has	previously	been	linked	to	conditions	such	as	irritable	bowel	syndrome	(IBS),	potentially	
reflecting	the	role	of	5-HT	in	gut	motility	regulation.	Furthermore,	Bellono	et	al.	hypothesise	
that	EC	cells	may	act	as	primary	detectors	of	irritants	before	damage	to	the	mucosa	occurs	
suggesting	 that	 EC	 cells	 might	 be	 involved	 in	 gastrointestinal	 inflammatory	 responses	
[118,119].		
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1.8. Modelling	the	enteroendocrine	system	in	vitro	
In	 order	 to	 examine	 the	 secretory	 mechanisms	 of	 human	 enterendocrine	 cells	 in	 vitro,	
immortalised	 cell	 line	 models,	 primary	 murine	 and	 human	 tissue	 samples	 and	 recently	
developed	 gastrointestinal	 organoid	 models	 have	 been	 used.	 The	 following	 sections	 will	
briefly	cover	each	of	these	approaches:	
	
 Immortalised	cell	line	models	
Immortalised	cell	lines	provide	in	vitro	physiological	models	which	are	self-renewing	and	can	
easily	 be	 scaled	 up	 and	 repeatedly	 passaged	 for	 new	 experiments.	 The	 self-renewing	
properties	derive	from	genetic	mutations	which	prevent	cellular	senescence	which	normally	
prevents	cells	from	dividing	indefinitely.	Immortalised	cell	lines	can	either	be	generated	by	
artificially	inducing	these	genetic	mutations	through	genetic	engineering	or	from	cancerous	
cells	 in	 which	 such	 mutations	 have	 already	 occurred.	 Additional	 experimental	 genetic	
perturbations	 can	 also	 be	 induced.	 The	 primary	 immortalised	 cell	 line	 models	 used	 to	
replicate	L-cell	physiology	are	GLUTags,	STC-1	and	NCI-H716	cells.	GLUTags	and	STC-1	cells	
were	derived	from	tumours	of	the	murine	colon	and	small	intestine	respectively	[120,121].	
Whereas	NCI-H716	cells	were	generated	from	a	colorectal	cancer	from	a	human	patient	[122].	
Kuhre	et	al.	compared	EEC	peptide	production	and	secretory	responses	of	these	cell	lines	to	
native	L-cells.	Whilst	GLP-1	was	produced	and	released	from	all	three	cell	lines,	none	of	the	
cell	lines	produced	PYY,	the	other	main	characteristic	L-cell	peptide.	Furthermore,	all	three	
cell	 lines	 produced	 pancreatic	 glucagon	which	 is	 absent	 in	 L-cells.	 This	 is	 consistent	 with	
GLUTag	and	STC-1	expression	of	proprotein	convertase	2	(PC2)	which	is	not	expressed	in	L-
cells	 (figure	 3)	 [123].	 Thus,	whilst	GLUTag,	 STC-1	 and	NCI-H716	 cell	 are	 fairly	 inexpensive	
models	of	L-cells	they	do	not	completely	recapitulate	the	physiology	of	native	L-cells.	
	
 Primary	tissue	
Primary	 tissue	 based	 investigations	 of	 EEC	 secretory	 mechanisms	 have	 principally	 been	
conducted	through	generation	of	mixed	primary	cultures,	Ussing	chamber	experiments	and	
perfusion	 of	 isolated	 segments	 of	 gastrointestinal	 tissue.	 2D	 mixed	 primary	 cultures	 are	
generated	 from	 isolated	 gastrointestinal	 secretory	 glands	 and	 have	 been	 successfully	
generated	from	all	regions	of	the	murine	and	human	gastrointestinal	tracts	enabling	analysis	
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of	EEC	peptide	secretory	and	secondary	messenger	 responses	 	 [114,124].	Ussing	chamber	
experiments	allow	measurements	of	ionic	fluxes	across	strips	of	gut	epithelium	suspended	
between	isolated	apical	(replicating	the	lumen)	and	basolateral	(replicating	the	extracellular	
fluid)	chambers	of	buffer	and	subsequent	identification	of	active	transport	processes	[125].	
Furthermore,	the	polarity	of	sensory	transduction	by	EECs	can	be	determined	by	application	
of	 stimuli/and	 or	 antagonists	 of	 specific	 transporters	 to	 either	 the	 apical	 or	 basolateral	
chambers	(which	is	not	possible	in	the	2D	primary	cultures)	[126].	The	epithelial	polarity	of	
EEC	responses	can	also	be	examined	using	buffer	perfused	isolated	sections	of	intestine	with	
the	 added	 advantage	 that	 the	 structural	 integrity	 of	 the	 intestine	 and	 the	 blood	 vessels	
supplying	it	are	largely	preserved	(for	Ussing	chamber	experiments	intestinal	tissue	must	be	
opened	up	and	flattened	and	usually	the	muscle	layers	and	vasculature	are	removed).	This	
allows	 stimuli	 to	 be	 directly	 administered	 either	 to	 the	 lumen	 or	 intravascularly	 [127].	 A	
further	benefit	 of	 the	perfused	 intestine	 system	derives	 from	preservation	of	 the	 smooth	
muscle	layers	enabling	characterisation	of	the	mechanisms	underpinning	gut	motility	[128].	
	
 Gastrointestinal	organoids	
The	lifespan	of	the	gastrointestinal	epithelial	cells	is	roughly	3-5	days	with	continual	turnover	
driven	by	division	and	differentiation	of	 stem	cells	 found	within	 the	base	of	 the	 intestinal	
secretory	glands	(crypts/pits)	[129].	One	population	of	such	intestinal	stem	cells	are	marked	
by	expression	of	 leucine-rich	repeat-containing	G-protein	coupled	receptor	5	 (LGR5+	cells)	
which	is	involved	in	Wnt	signalling	[130].	By	culturing	isolated	LGR5+	cells	or	gastrointestinal	
glands	 in	media	 that	 replicates	 the	 in	 vivo	 stem	cell	niche	 (different	 for	each	 region)	 self-
renewing	mini-guts	replicating	the	structural	composition	and	polarity	of	native	epithelium	
termed	organoids	can	be	generated	[130,131].		
	
Proliferation	 and	 differentiation	 of	 LGR5+	 cells	 is	 regulated	 by	 exposure	 to	 various	
modulators,	principally	by	the	signalling	peptides	Wnt,	bone	morphogenetic	protein	(BMP),	
epidermal	growth	factor	(EGF)	as	well	as	direct	cell-cell	Notch	signalling	(figure	4)	[131].	The	
typical	 composition	 of	 small	 intestinal	 organoid	 media	 (subsequently	 referred	 to	 as	 ENR	
media)	reflects	this	with	inclusion	of	EGF,	the	BMP	inhibitor	Noggin	and	R-spondin1	which	
promotes	Wnt	signalling	[132].	Inclusion	of	EGF	in	organoid	media	promotes	proliferation	of	
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stem	 cells	 and	 progenitor	 cells	 whilst	 suppressing	 apoptosis	 [133].	 Likewise	Wnt	 activity,	
which	is	promoted	by	R-spondin,	promotes	LGR5+	proliferation	and	stemness	maintaining	a	
pool	of	stem	cells	at	the	base	of	intestinal	crypt	[131].	Repression	of	BMP	signalling	by	Noggin	
promotes	crypt	fission	 in	vivo	and	is	required	for	 long	term	maintenance	and	passaging	of	
organoids	[130,134].	BMP	signalling	can	also	determine	the	hormone	repertoire	produced	by	
small	 intestinal	 enteroendocrine	 cells	 according	 to	 placement	 along	 the	 crypt-villus	 axis	
where	a	gradient	of	BMP	exists	with	highest	 levels	 found	 in	 the	villus	 [132].	 	Additionally,	
Notch	signalling	drives	LGR5+	stem	cells	towards	an	enterocyte	fate	through	upregulation	of	
Hes1	expression.	Hes1	represses	expression	of	Math1	and	Dil1	which	drive	LGR5+	cells	toward	
a	secretory	cell	fate,	including	enteroendocrine	cells.	Reflecting	this,	inclusion	of	inhibitors	of	
Notch	signalling,	such	as	DAPT	and	DBZ,	in	the	organoid	culture	media	decreases	numbers	of	
LGR5+	 stem	 cells	 whilst	 increasing	 the	 numbers	 of	 enteroendocrine	 and	 goblet	 cells	
[135,136].	
	
Regarding	 the	 use	 of	 gastrointestinal	 organoids	 to	 investigate	 enteroendocrine	 cell	
physiology,	Petersen	et	al.	have	shown	that	L-cells	of	both	murine	and	human	small	intestinal	
organoids	exhibit	similar	secretory	responses	to	SCFAs	and	glucose	as	native	L-cells	and	imply	
that	organoid-derived	L-cells	recapitulate	native	L-cell	physiology.	This	suggests	that	intestinal	
organoids	provide	a	valid	platform	for	 investigating	enteroendocrine	cell	physiology	which	
combines	the	advantages	of	using	cell	lines	(e.g.	indefinite	propagation,	genetic	modification)	
with	those	of	using	primary	tissue	(e.g.	contains	all	epithelial	cell	types,	preserves	polarity).		
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Figure	 4:	 Schematic	 illustrating	 LGR5+	 cell	 differentiation	 into	 mature	 absorptive	 cells	
(enterocytes/colonocytes)	and	secretory	cells	(enteroendocrine	cells,	goblet	cells	and	Paneth	
cells).	 Wnt,	 epidermal	 growth	 factor	 (EGF)	 and	 Notch	 signalling	 promote	 LGR5+	 cell	
proliferation	whilst	bone	morphogenetic	protein	(BMP)	inhibits	proliferation.	Notch	signalling	
additionally	 promotes	 Hes1	 expression	 which	 represses	 expression	 of	 the	 secretory	 cell	
determinants	 Math1	 and	 Dil1.	 Secretory	 precursors	 can	 provide	 a	 reserve	 population	 of	
intestinal	stem	cells,	dedifferentiating	to	stem	cells	upon	tissue	injury.	Key	transcription	factors	
marking	 each	 cell	 population	 are	 indicated	 in	 blue	 and	 red	 text.	 Green	 arrows	 indicate	
stimulatory	activity	whilst	T-shaped	red	lines	indicate	inhibitory	activity.	Based	on	Brunschwig	
et	al.	(2003),	Grun	et	al.	(2015),	Haramis	et	al.	(2004),	Kim	et	al.	(2016),	Li	et	al.	(2011),	Noah	
et	al.	(2011),	Suzuki	et	al.	(2010),	Yamane	et	al.	(2016),	Van	es	et	al.	(2012)	and	Buczacki	et	al.	
(2013)		[65,133,134,137–143].		
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1.9. Hypotheses	explored	in	this	thesis	
The	 investigations	 detailed	 in	 chapters	 3,	 4	 and	 5	 were	 designed	 to	 expand	 the	 current	
understanding	 of	 enteroendocrine	 cell	 physiology	 with	 a	 focus	 on	 L-cell	 secretory	
mechanisms	by	testing	the	following	hypotheses:	
	
Chapter	3:		
1. Co-activation	of	the	Gs-coupled	bile	acid	receptor	GPBAR-1	and	the	Gq-coupled	receptor	
for	 medium	 chain	 fatty	 acids	 (MCFAs)	 and	 long	 chain	 fatty	 acids	 (LCFAs),	 FFAR1,	
potentiates	resulting	intracellular	Ca2+	and	GLP-1	secretory	responses.	
	
Chapter	4:	
1. INSL5-expressing	L-cells	exhibit	intracellular	Ca2+	transients	and	secrete	INSL5	in	response	
to	application	of	known	GLP-1	secretagogues.	
2. INSL5	is	co-secreted	with	PYY	and	GLP-1.	
3. INSL5,	PYY	and	GLP-1	are	stored	in	separate	vesicle	populations	which	are	regulated	by	
common	release	mechanisms.	
	
Chapter	5:		
1. Colonic	enteroendocrine	cells	can	be	subdivided	beyond	the	canonical	L-cell,	D-cell	and	
EC	cell	subtypes.	
2. INSL5-expressing	L-cells	are	concentrated	in	the	distal	large	intestine.	
3. Colonic	enteroendocrine	cell	subgroups	display	functional	differences	in	GPCR	repertoire.		
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 Chapter	2.	Materials	and	Methods	
	
N.B.:	All	reagents,	unless	stipulated,	were	obtained	from	Sigma-Aldrich.	Quantities	listed	as	
percentages	refer	to	volumereagent/volumetotal.	All	statistical	analyses	were	run	on	GraphPad	
Prism	7.0	(GraphPad	Software)	unless	otherwise	stated.		
	
2.1. Solutions	and	culture	media	
	
Saline	buffer:		
	
4.5mM	KCl,	138mM	NaCl,	4.2mM	NaHCO3,	1.2mM	NaH2PO4,	2.6mM	CaCl2,	1.2mM	MgCl2,	
10mM	HEPES.	Adjusted	to	pH	7.4	with	1M	NaOH.		
	
30mM	KCl	
	
30mM	KCl,	113.6mM	NaCl,	4.2mM	NaHCO3,	1.2mM	NaH2PO4,	2.6mM	CaCl2,	1.2mM	MgCl2,	
10mM	HEPES.	N.B.	titrated	to	pH	7.4	using	1M	NaOH.		
	
Lysis	buffer	
	
0.25g	deoxycholic	acid,	0.5ml	Igepal	CA-630,	2.5ml	1M	Tris-HCl,	1.5ml	5M	NaCl,	1	EDTA-free	
protease	inhibitor	cocktail,	made	up	to	50ml	with	H2O.		
	
ENR	media	
	
Murine	50ng/ml	EGF	(Invitrogen),	100ng/ml	murine	noggin	(Peptrotech),	1µg/ml	human	R-
Spondin-1	 (Peprotech),	 1%	 penicillin/streptomycin	 (100	 units/ml;	 Invitrogen),	 2mM	 L-
glutamine	 (Invitrogen),	 N2	 supplement	 (1x;	 Invitrogen),	 1µM	 N-acetyl-L-cysteine	 (Sigma)	
diluted	in	advanced	DMEM/F-12	(ADF;	Invitrogen).		
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N.B.	 10µM	 Y-27632	 (Tocris)	 was	 added	 to	 media	 used	 to	 feed	 organoids	 immediately		
following	seeding	to	limit	anoikis.		
	
Neutralisation	media	
	
ADF	enriched	with	10%	fetal	bovine	serum	and	10µM	Y-27632.	
	
Cryopreservation	media	
	
45%	ADF,	45%	FBS,	10%	DMSO	and	10µM	Y-27632.		
	
Primary	culture	media	
	
Dulbecco’s	modified	Eagle’s	medium	(DMEM)	high	 (4500mg/L)	glucose	enriched	with	10%	
fetal	calf	serum,	1%	glutamine	and	1%	penicillin/streptomycin.	
	
Demucifying	solution	
	
10%	glycerol,	10%	0.1M	Tris	titrated	to	pH	8.2,	20%	ethanol,	30%	H2O,	92mM	NaCl	and	20mM	
DTT.	
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2.2. Animal	procedures	and	ethics	
All	animal	procedures	were	approved	by	 the	University	of	Cambridge	Animal	Welfare	and	
Ethical	Review	Body	and	carried	out	in	accordance	with	the	Animals	(Scientific	Procedures)	
Act	1986	Amendment	Regulations	(SI	2012/3039).	The	animal	work	was	performed	under	the	
UK	Home	Office	project	licence	70/7824.	Mice	were	sacrificed	by	asphyxiation	and	cervical	
dislocation.	
	
A	local	ethics	review	committee	(09/H0308/24)	approved	all	human	studies.	Human	tissue	
samples	were	obtained	from	patients	undergoing	surgical	resection	and	acquired	from	the	
Human	Research	Tissue	Bank	at	Addenbrooke’s	Hospital,	Cambridge,	UK.	All	human	tissue	
samples	were	utilised	on	the	day	of	collection.	
	
2.3. Transgenic	mice	
For	intracellular	calcium	imaging	of	organoid-derived	L-cells,	organoids	were	generated	from	
mice	specifically	expressing	the	genetically	encoded	intracellular	calcium	indicator	GCaMP3	
in	 L-cells.	 GCaMPs	 (including	 GCaMP3)	 are	 chimeric	 proteins	 consisting	 of	 circularly	
permutated	GFP,	calmodulin	and	M13	(from	myosin	light	chain	kinase)	domains	[144–146].	
Under	 the	 condition	 of	 elevated	 intracellular	 calcium	 levels,	 calcium	 ions	 binding	 to	 the	
calmodulin	moiety	of	GCaMP	causes	a	conformational	change	in	GCaMP	that	reduces	solvent	
quenching	 of	 GFP	 fluorescence	 (when	 excited	 with	 488nm	 light)	 [147].	 Thus,	 when	
intracellular	 calcium	 levels	 increase	GCaMP	 fluorescence	 (when	excited	with	488nm	 light)	
also	 increases	 providing	 a	 proxy	 measure	 for	 intracellular	 calcium	 levels.	 Selective	 L-cell	
expression	 of	 GCaMP3	 was	 achieved	 by	 crossing	 Glu-Cre12	 mice	 with	 ROSA26-GCaMP3	
reporter	 mice	 (Jax	 stock	 014538)	 [148,149].	 In	 these	 Glu-Cre12/ROSA26-GCaMP3	 mice	
expression	of	Cre	recombinase	drives	specific	expression	in	proglucagon	expressing	cells	(i.e.	
L-cells)	by	excision	of	a	floxed	stop	codon	within	the	ROSA26-GCaMP3	cassette.	
	
Transcriptomic	and	intracellular	calcium	imaging	based	scrutiny	of	Insl5-expressing	L-cells	was	
achieved	through	development	of	two	novel	transgenic	mouse	models	based	on	the	Tet-on	
system.	As	described	in	Billing	et	al.	(2018),	Insl5-rtTA	mice	were	developed	by	Frank	Reimann	
in	which	expression	of	the	reverse	tetracycline	transactivator	(rtTA)	is	placed	under	control	
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of	the	Insl5	promoter	(figure	1A).	These	Insl5-rtTA	mice	were	crossed	with	mice	expressing	
the	bidirectional	tetracycline	reporter	Tre-lacZ/GFP	to	produce	Insl5-rTA/TET-GFP	mice	[150].	
Similarly	the	Insl5-rTA	mice	were	crossed	with	TET-GCaMP6F	and	CMV-Cre	mice	generating	
Insl5-rTA/TET-GCaMP6F∆CMV	mice	 (the	 CMV-Cre	 cross	 produced	 germ	 line	 deletion	 of	 a	
floxed	stop	codon	within	the	TET-GCaMP6F	cassette)	[151].	GCaMP6F	was	developed	from	
pre-existing	 GCaMP	 variants	 by	 mutagenesis	 and	 exhibits	 greater	 sensitivity	 and	 faster	
responses	 to	 intracellular	calcium	than	GCaMP3	[152].	 In	 the	 Insl5-rTA/TET-GFP	and	 Insl5-
rTA/TET-GCaMP6F∆CMV	mice	conditional	expression	of	GFP	and	GCaMP6F	is	limited	to	Insl5-
expressing	cells	upon	administration	of	tetracyclines	such	as	doxycycline	(figure	1B)	[153].	For	
FACS-isolation	 and	model	 verification	 by	 tissue	 section	 immunofluorescent	 labelling	mice	
were	 orally	 induced	 for	 5-7	 days	 with	 3mg/ml	 doxycycline	 dissolved	 in	 drinking	 water	
supplemented	with	5%	sucrose	to	improve	palatability.		
	
Isolation	of	mature	colonic	enteroendocrine	cells	for	scRNA-seq	analysis	was	achieved	based	
on	FACS-purification	of	cells	expressing	the	enteroendocrine	cell	marker	Neurod1.	For	this,	
NeuroD1-Cre	mice	were	crossed	with	ROSA26-EYFP	mice	yielding	selective	expression	of	EYFP	
in	Neurod1-expressing	cells	via	Cre	recombinase	excision	of	a	stop	codon	within	the	ROSA26-
EYFP	cassette	[139,154].	
	
	
Figure	1:	(A)	Scaled	diagram	of	the	BAC-transgene	used	to	make	Insl5-rtTA	mice.	The	reverse	
tetracycline	 transactivator	 (rtTA)	 coding	 sequence	 replaced	 the	 Insl5-coding	 sequence.	 (B)	
Schematic	illustrating	the	tetracycline	dependent	expression	of	GFP	and	the	calcium	indicator	
GCaMP6F	 in	 Insl5-rTA/TET-GFP	and	Insl5-rTA/TET-GCaMP6F∆CMV	mice.	Dox	=	doxycycline.	
Figure	adapted	from	Billing	et	al.	(2018)	[153].	
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2.4. Fluorescence	activated	cell	sorting		
 Collagenase	Digestion	
Single	 cell	 digests	 of	 murine	 colon	 were	 prepared	 for	 FACS	 purification	 by	 collagenase	
digestion.	 For	 purification	 of	 Insl5-expressing	 cells	 digests	 from	 mice	 orally	 dosed	 with	
doxycycline	prior	 to	 sacrifice	 (as	described	previously)	were	used.	 Single	 cell	 digests	were	
produced	by	serial	incubation	of	colonic	tissue	with	1mg/ml	collagenase	(dissolved	in	calcium-
free	HBSS)	at	37°C	and	 filtration	 through	50µm	 filters	 (to	 remove	 larger	debris).	 The	 final	
digest	was	spun	at	300g	for	10	minutes,	resuspended	in	HBSS	(calcium-free)	with	10%	FBS	(to	
reduce	cell	clumping	and	adhesion	to	plasticware)	and	10µM	Y-27632	(to	prevent	anoikis)	
and	 transferred	 to	 5ml	 polypropylene	 round-bottomed	 tubes	 (Corning).	 Prior	 to	 FACS	
purification,	samples	were	spiked	with	DAPI	(to	label	dead	cells)	and	for	the	NeuroD1-EYFP	
sort	only,	DRAQ5	(live	cell	marker;	BioLegend	UK).		
	
 Flow	cytometry	
Single	 cell	 suspensions	 were	 sorted	 using	 an	 Influx	 Cell	 Sorter	 (BD	 Biosciences)	 at	 the	
Cambridge	Institute	of	Medical	Research	(CIMR)	Flow	Cytometry	Core	Facility.	DAPI-staining,	
DRAQ5-staining	 (only	 for	 the	NeuroD1-EYFP	 sort),	 side	 scatter,	 forward	 scatter	 and	 pulse	
width	gates	were	applied	 to	 remove	clustered	cells	 and	any	 cellular	debris	present.	 Insl5-
expressing	 cells	 (from	 Insl5-rTA/TET-GFP	 and	 Insl5-rTA/TET-GCaMP6F∆CMV	 mice)	 were	
isolated	 by	 GFP	 fluorescence	 into	 RLT	 plus	 lysis	 buffer	 (Qiagen)	 enriched	 with	 1%	 β-
mercaptoethanol.	 GFP-ve	 cells	 were	 also	 isolated	 as	 a	 control	 population	 for	 the	
transcriptomic	analysis	of	INSL5-producing	cells.	Neurod1-expressing	cells	(from	a	NeuroD1-
EYFP	mouse)	were	purified	by	EYFP	 fluorescence	 into	 LoBind	 tubes	 (Eppendorf)	with	40µl	
HBSS	(calcium-free),	10%	FBS	and	10µM	Y-27632.	 
	
	
	
	
	
	
	 31	
2.5. Tissue	culture	methods	
 Primary	cultures	
Excised	tissue	(both	murine	and	human)	was	collected	 in	Leibovitz’s	L-15	media.	Collected	
tissue	was	cleaned	of	contents	in	PBS	containing	CaCl2	and	MgCl2	and	any	adipose	tissue	was	
removed.	The	epithelium	layer	was	separated	from	the	outer	muscle	layers	and	vasculature	
by	manual	stripping.	Following	this	the	tissue	was	cut	into	small	chunks	~2mm2	in	size	and	
rinsed	with	PBS.	Intestinal	crypts	were	isolated	through	serial	digestion	at	37˚C	with	filtered	
collagenase	(0.25mg/ml	for	mouse	and	0.5mg/ml	for	human	tissue)	dissolved	in	high	glucose	
DMEM.	At	the	end	of	each	digest	the	tissue	was	agitated	through	shaking.	Digest	fractions	
containing	crypts	(as	examined	by	light	microscopy)	were	centrifuged	at	100g	for	5	minutes	
and	resuspended	in	primary	culture	media	(neutralising	collagenase	activity).	Subsequently	
these	fractions	were	pooled	and	filtered	through	a	100µm	filter.	Following	centrifugation	at	
100g	for	5	minutes,	 intestinal	crypts	were	resuspended	 in	primary	culture	media	enriched	
with	10µM	Y-27632	(Tocris).	These	crypt	suspensions	were	plated	on	2%	matrigel	(Corning)	
precoated	12	well	plates	for	secretion	experiments,	35mm	glass-bottomed	dishes	(MatTEK)	
for	intracellular	calcium	imaging	experiments	and	18x18mm	1.5H	glass	coverslips	(Zeiss)	for	
immunohistochemistry.	 Plated	 crypt	 suspensions	 were	 placed	 into	 a	 37˚C	 humidified	
incubator	with	5%	CO2	to	settle	overnight	prior	to	experimentation.	For	experiments	using	
Insl5-rTA/TET-GFP	and	Insl5-rTA/TET-GCaMP6F∆CMV	mice,	cultures	were	seeded	in	primary	
culture	media	with	added	2µg/ml	doxycycline	hyclate.	
	
N.B.:	For	chapter	5,	regional	murine	colonic	crypt	cultures	were	generated	by	division	of	the	
colon	into	proximal	(first	1.5-2cm	from	the	caecocolic	junction),	intermediate	and	distal	(most	
distal	2	cm	of	the	large	intestine)	segments.	Segments	from	2	mice	were	pooled	together	to	
ensure	there	was	enough	tissue	for	each	secretion	plate.	
	
 Small	intestinal	organoids	culture	
Generation	
	
Excised	murine	small	intestines	were	washed	in	ice	cold	PBS	(with	CaCl2	and	MgCl2)	using	a	
glass	 pipette	 to	 remove	 luminal	 contents.	 Following	 washing,	 the	 small	 intestines	 were	
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opened	up	using	scissors	and	cut	into	3-5mm	sections.	These	sections	were	transferred	to	ice	
cold	30mM	EDTA	(0.5M	EDTA	stock	diluted	in	PBS)	for	5	minutes.	Subsequently,	the	sections	
were	moved	 to	 fresh	PBS	 in	50ml	 falcon	 tubes	and	shaken	 for	~12	seconds.	The	 resulting	
digest	 fractions	were	 transferred	 to	 FBS	 pre-coated	 (reduces	 crypt	 adhesion)	 Petri	 dishes	
(Corning)	and	examined	under	the	light	microscope	for	villi/crypt	presence.	The	sections	were	
then	transferred	back	to	EDTA	for	a	further	4	rounds	of	EDTA	digestion.	Fractions	with	the	
greatest	crypt	yield	and	lower	 levels	of	villi	were	pooled,	passed	through	a	70µm	filter	(to	
remove	debris	and	villi)	and	centrifuged	at	100g	for	5	minutes	in	a	15ml	Falcon	tube.	Following	
centrifugation,	the	supernatant	was	discarded	and	the	crypt	pellet	was	resuspended	in	~200-
300µl	matrigel	(Corning)	and	seeded	onto	a	48-well	plate	(15-20µl	of	crypts	per	well).	These	
48-well	 plates	were	 incubated	 at	 37˚C	 for	 30	minutes	 to	 enable	matrigel	 polymerisation.	
Following	 this,	 each	well	was	overlaid	with	200-300µl	ENR	media	 (enriched	with	10µM	Y-
27632)	and	placed	in	a	37˚C	humidified	incubator	with	5%	CO2.	
	
Maintenance		
	
Organoids	were	refed	with	fresh	ENR	media	every	2-3	days	and	split	roughly	every	7	days.	For	
splits,	ENR	media	was	removed	and	organoid	wells	were	scrapped	and	collected	with	TrypLE	
express	enzyme	(Gibco)	into	a	15ml	Falcon	tube	and	incubated	in	a	water	bath	at	37°C	for	2-
3	 minutes.	 Subsequently	 the	 TrypLE	 express	 enzyme	 was	 neutralised	 by	 addition	 of	
neutralisation	media	and	titriated	with	P1000	tips.	The	digest	was	then	centrifuged	at	200g	
for	 5	minutes	 and	 the	majority	 of	 the	 supernatant	was	 discarded	 leaving	 around	 30-40µl	
solution.	Using	P200	tips	the	organoid	pellet	was	mechanically	disrupted	through	titriation.	
200-300µl	matrigel	was	added	and	the	broken-up	organoids	were	seeded	in	the	same	manner	
as	the	isolated	crypts.		
	
2D	culture	generation	
	
7-10	day	old	organoids	cultured	in	matrigel	domes	were	scrapped	and	collected	with	ice	cold	
ADF	 to	 dissolve	 the	matrigel	 matrix.	 Following	 centrifugation	 at	 200g	 for	 5	 minutes,	 the	
supernatant	 was	 discarded	 and	 organoids	 were	 enzymatically	 digested	 in	 TrypLE	 express	
enzyme	for	2	minutes	at	37°C.	The	digest	was	then	neutralised	with	neutralisation	media	and	
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titriated	to	break-up	the	organoids	 into	smaller	chunks.	These	chunks	were	centrifuged	at	
200g	for	5	minutes	and	resuspended	in	an	appropriate	volume	of	ENR	media	enriched	with	
10µl	Y-27632	and	plated	onto	2%	matrigel	precoated	48-well	plates	for	secretion	assays	and	
glass-bottomed	dishes	for	intracellular	calcium	imaging	experiments.	Plated	2D	cultures	were	
then	left	to	settle	in	a	humidified	37°C	incubator	(with	5%	CO2)	overnight	before	experimental	
use.	See	figure	2	for	a	cartoon	summarising	organoid	generation,	maintenance	and	seeding	
of	2D	cultures.	
	
	
Figure	2:	Schematic	illustrating	organoid	generation,	maintenance	and	2D	culture	seeding.	
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Cryopreservation	
	
Stocks	of	generated	organoids	were	made	through	cryopreservation.	For	this,	organoids	were	
scrapped	and	collected	using	cold	TrypLE	express	enzyme	and	immediately	neutralised	using	
neutralisation	 media.	 Following	 centrifugation	 at	 200g	 for	 5	 minutes	 and	 subsequent	
discarding	of	the	supernatant,	organoid	pellets	were	resuspended	in	an	appropriate	volume	
of	cryopreservation	media	and	aliquoted	into	cryogenic	vials.	These	vials	were	frozen	in	Mr.	
Frosty	(Thermo	Scientific)	containers	and	transferred	to	liquid	nitrogen	filled	tanks.		
	
Frozen	organoid	stocks	were	thawed	by	briefly	heating	cryogenic	vials	in	a	37°C	water	bath	
and	 transferring	 the	 contents	 to	 a	 15ml	 Falcon	 tube	 containing	 neutralisation	 media.	
Following	centrifugation	at	200g	for	5	minutes,	the	defrosted	organoids	were	resuspended	in	
matrigel	and	seeded	as	described	for	isolated	crypts.	
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2.6. Secretion	assays	
 Measuring	GLP-1	secretion	from	organoid	cultures		
	
N.B:	These	experiments	were	performed	as	a	collaborative	effort	with	Deborah	Goldspink.	
	
2D	organoid	cultures	were	washed	3	times	with	warm	saline	buffer	containing	1mM	glucose	
and	0.1%	fatty	acid	free	BSA.	 In	the	final	wash	the	cultures	were	 incubated	at	37°C	for	20	
minutes.	Subsequently,	150µl	of	drug	treatments	were	added	to	each	well	 (all	 test	agents	
were	 dissolved	 in	 wash	 buffer)	 and	 the	 plates	 were	 incubated	 at	 37°C	 for	 2	 hours	 in	 a	
humidified	 incubator.	Following	this	the	plate	was	placed	on	 ice	and	the	cell	supernatants	
transferred	to	1.5ml	tubes.	These	tubes	were	spun	at	350g	for	5	minutes	at	4°C	to	remove	
cellular	debris	and	the	supernatants	was	harvested.	Meanwhile,	150µl	lysis	buffer	was	added	
to	each	well	and	the	plate	was	left	on	ice	for	30	minutes	to	allow	for	complete	cell	lysis.	The	
lysates	were	then	collected	from	each	well	following	scraping	and	spun	at	8000g	for	5	minutes	
at	4°C	with	the	supernatants	retained.	The	treatment	and	lysate	supernatants	were	stored	at	
-70°C	prior	to	analysis.	GLP-1	quantification	was	achieved	through	the	use	of	total	GLP-1	ELISA	
kits	(MesoScale)	as	per	the	manufacturer’s	instructions.	
	
GLP-1	secretory	responses	for	each	stimulus	were	calculated	as	the	amount	of	GLP-1	secreted	
as	a	percentage	of	the	total	GLP-1	content	of	each	well	(sum	of	GLP-1	secreted	and	lysate	
GLP-1	content).	Relative	GLP-1	secretion	was	calculated	by	dividing	these	secretory	responses	
by	the	percentage	GLP-1	secretion	in	the	basal	condition	(to	control	for	inter-plate	variability).	
Statistically	 significant	 GLP-1	 responses	 (p<0.05)	 were	 identified	 by	 two-tailed	 t-tests	
assessing	deviation	of	mean	of	relative	GLP-1	secretion	from	1	(i.e.	basal	GLP-1	secretion).	
The	statistical	significance	of	inter-group	differences	in	GLP-1	responses	were	assessed	using	
one-way	ANOVA	tests	with	Dunnett’s	correction	on	log	transformed	values	(p<0.05).	In	order	
to	assess	the	effect	of	combined	GPBAR-A	and	TAK-875	treatment	on	GLP-1	secretion,	the	
actual	GLP-1	responses	to	GPBAR-A	and	TAK-875	co-application	were	divided	by	the	expected	
GLP-1	 responses	 (sum	 of	 GLP-1	 responses	 to	 isolated	 GPBAR-A	 and	 TAK-875	 treatment).	
Statistically	significant	(p<0.05)	deviation	of	these	ratios	from	1	(i.e.	no	potentiation)	were	
assessed	using	two-way	t-tests.		
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 Measuring	GLP-1,	PYY	and	INSL5	secretion	from	colonic	crypt	cultures	
	
N.B:	The	murine	and	human	secretions	detailed	in	chapter	4	were	performed	and	analysed	
by	Pierre	Larraufie.	
	
Primary	murine	and	human	colonic	 crypt	 cultures	were	washed	3	 times	with	warm	saline	
buffer	containing	1mM	glucose	and	0.001%	fatty	acid	free	BSA.	In	the	final	wash	cultures	were	
incubated	at	37°C	for	30	minutes.	The	lower	concentration	of	BSA	(relative	to	that	used	for	
the	organoid	cultures),	prevented	saturation	of	the	downstream	LC/MS	analysis	with	BSA-
derived	peptides.	Following	discarding	of	the	final	wash,	600µl	of	each	treatment	(made	up	
in	saline	buffer	with	1mM	glucose	and	0.001%	BSA)	was	added	to	each	well	and	the	plate	was	
incubated	 at	 37°C	 for	 1	 hour.	 The	 plate	 was	 then	 placed	 on	 ice	 and	 treatments	 were	
transferred	to	LoBind	1.5ml	tubes	(Eppendorf;	reduced	peptide	loss)	and	centrifuged	at	2000g	
for	5	minutes	at	4°C	to	remove	cellular	debris.	500µl	of	each	supernatant	were	collected	into	
fresh	1.5ml	LoBind	 tubes.	Meanwhile,	200µl	 lysis	buffer	was	added	 to	each	well.	After	30	
minutes	 on	 ice	 the	 plates	 were	 snap	 frozen	 and	 defrosted	 to	 ensure	 complete	 cell	 lysis.	
Lysates	were	collected	following	cell	scraping	and	spun	at	8000g	for	5	minutes	at	4°C	and	the	
supernatants	were	retained.		
	
For	LC-MS/MS	peptide	quantification,	treatment	supernatants	were	first	acidified	with	50µl	
1%	formic	acid	and	spiked	with	internal	standards.	The	samples	were	then	loaded	into	primed	
µElution	 SPE	 plates	 (Waters)	 according	 to	 the	 manufacturer’s	 instructions.	 Elution	 was	
achieved	 by	 twice	 running	 through	 20µl	 of	 methanol/acetic	 acid/water	 (60%/10%/30%)	
applying	positive	pressure.		
	
For	the	peptide	quantification	in	chapter	4,	murine	samples	were	analysed	intact	whereas	the	
human	samples	were	dried	and	reduced	and	alkylated.	Reduction	and	alkylation	was	achieved	
by	 incubation	with	 40µl	 10mM	DTT	 in	 50mM	ammonium	bicarbonate	 for	 1	 hour	 at	 60°C	
followed	by	30	minutes	with	10µl	100mM	iodoacetamide.	50µl	of	0.1%	formic	acid	(dissolved	
in	H2O)	was	 then	added.	40µl	of	sample	were	 injected.	Murine	samples	were	analysed	by	
LC/MS	on	a	high-flow	rate	and	human	samples	analysed	by	LC-MS/MS	on	a	nano-flow	rate	by	
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a	ThermoFisher	Ultimate	3000	nano	LC	system	coupled	to	a	Q	Exactive	Plus	Orbitrap	mass	
spectrometer	 (Thermo	 Scientific).	 Peptide	 quantification	 was	 achieved	 using	 XCalibur	
(ThermoFisher)	to	integrate	the	peak	area	for	selected	sets	of	m/z	values	at	specific	retention	
times	corresponding	to	amidated	GLP-1,	PYY	1-36	and	intact	INSL5	for	murine	samples	and	
the	C-chain	N-terminus	of	INSL5	for	human	samples	(fragment	most	consistently	detected).		
	
For	chapter	5,	murine	samples	were	dried	and	reduced	and	alkylated	using	50µl	DTT	and	10µl	
iodoacetamide	in	the	same	manner	as	for	human	samples.	These	samples	were	then	topped	
up	with	10µl	1%	formic	acid	and	30µl	injected	for	nano-flow	LC/MS	analysis.	In	these	samples	
the	A-chain	of	 INSL5	was	quantified	 (fragment	most	 consistently	detected)	 and	NTS	 (with	
terminal	glutamine	transformed	into	pyroglutamate)	was	additionally	quantified.	All	readings	
were	 normalised	 by	 the	 internal	 standard	 measurements.	 Total	 protein	 content	 was	
calculated	 from	 lysate	 supernatants	 using	 a	 BCA	 protein	 assay	 (Thermo	 Fisher	 Scientific)	
which	 was	 used	 to	 normalise	 secretory	 responses	 between	 different	 wells	 (account	 for	
differences	in	cellular	content).		
	
For	 chapter	 4,	 secretory	 responses	were	 normalised	 to	 basal	 secretion	 and	 the	 statistical	
significance	(p<0.05)	of	murine	colonic	crypt	secretory	responses	were	assessed	using	a	Dunn	
test.	Pair-wise	correlation	between	GLP-1,	INSL5	and	PYY	secretory	responses	were	assessed	
for	both	murine	and	human	colonic	 crypt	 cultures	using	Pearson	correlation.	RStudio	was	
used	for	these	statistical	evaluations.	
	
For	the	regionals	secretions	detailed	in	chapter	5,	given	that	in	some	cases	basal	levels	of	NTS	
and	INSL5	secretion	were	undetectable,	statistical	tests	were	run	on	the	secretory	responses	
normalised	by	total	protein	content	only.	Using	square	root	transformed	data,	statistically	
significant	 INSL5,	 PYY	 and	 NTS	 secretory	 responses	 (compared	 to	 basal	 secretion)	 were	
identified	 by	 one-way	 ANOVA	 tests.	 Likewise,	 statistical	 differences	 in	 regional	 secretory	
responses	were	assessed	using	one-way	ANOVA	tests	(with	the	exception	of	INSL5	responses	
to	angiotensin	II	and	all	NTS	secretory	responses	where	one-way	t-tests	were	used).		
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2.7. Immunohistochemistry	
 Organoid	cultures	
For	 IHC,	organoids	were	seeded	onto	coverslips	 in	a	48-well	plate.	Following	PBS	washing,	
they	were	fixed	 in	4%	PFA	(Alfa	Aesar)	 for	1.5	hours.	Afterwards	they	were	permeabilised	
using	a	wash	solution	containing	0.1%	Triton-X	100	dissolved	in	PBS	and	blocked	using	wash	
solution	 containing	 10%	 donkey	 serum	 for	 1	 hour	 at	 room	 temperature.	 They	were	 then	
incubated	with	primary	antibodies	to	proglucagon	and	GFP	(table	1)	diluted	in	wash	buffer	
with	1%	donkey	serum	overnight	at	4°C.	The	next	day,	following	further	washes	the	organoids	
were	incubated	with	donkey	secondary	antibodies	(conjugated	to	AlexaFluor	488	and	555)	
for	1	hour	at	room	temperature.	This	was	followed	by	a	10	minute	treatment	with	1:1300	
Hoescht	nuclear	stain,	further	washes	and	mounting	on	microscope	slides	using	Hydromount	
(National	Diagnostics).	
 
 Primary	cultures	
For	immunofluorescent	labelling,	primary	cultures	were	seeded	onto	2%	matrigel	precoated	
18x18mm	1.5H	glass	coverslips	(Zeiss).	They	were	fixed	for	1	hour	at	room	temperature	with	
4%	PFA	(Alfa	Aesar)	followed	by	3	PBS	washes.	The	cultures	were	then	detergent	treated	with	
0.1%	Triton-X	100	(was	used	as	wash	solution	in	subsequent	steps)	dissolved	in	PBS.	Following	
a	15	minute	block	in	10%	goat	serum	(diluted	in	PBS),	the	primary	cultures	were	incubated	at	
room	temperature	with	primary	antibodies	 to	 INSL5	and	GFP	 for	 verification	of	GCaMP6F	
induction	and	INSL5,	PYY	and	GLP-1	for	3D-SIM	analysis	(table	1)	for	45	minutes	diluted	in	
wash	solution	containing	1%	goat	serum.	Subsequently,	cultures	were	washed	for	30	minutes	
and	incubated	at	room	temperature	with	1:300	(1:100	for	cultures	imaged	by	3D-SIM)	goat	
secondary	antibodies	(conjugated	to	AlexaFluor	488,	555,	633	and	647)	for	30	minutes	with	
an	additional	10	minute	incubation	with	1:2000	Hoescht	nuclear	stain	(in	PBS).	After	further	
PBS	 washes,	 the	 coverslips	 were	 mounted	 onto	 microscope	 slides	 using	 Hydromount	
(National	Diagnostics).		
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 Tissue	sections	
Insl5-rtTA/TET-GCaMP6F∆CMV	mice	were	 orally	 treated	with	 3mg/ml	 doxycycline	 for	 5-7	
days	 prior	 to	 sacrifice	 and	whole	 colon	 excision.	 Following	 removal	 of	 adipose	 tissue	 and	
muscle	 layers	 colons	 were	 fixed	 in	 4%	 PFA	 (Alfa	 Aesar)	 overnight	 at	 4°C.	 The	 tissue	 was	
subsequently	 dehydrated	 using	 a	 sucrose	 gradient	 firstly	 by	 placement	 in	 15%	 sucrose	
(dissolved	in	PBS)	for	5-6	hours	at	4°C,	followed	by	incubation	in	30%	sucrose	(dissolved	in	
PBS)	overnight	at	4°C.	Following	dehydration,	the	tissue	was	embedded	in	OCT	creating	blocks	
for	sectioning	and	was	stored	at	 -70°C	prior	 to	 further	processing.	A	cryostat	was	used	to	
create	6-10µm	sections.	Sections	were	mounted	onto	glass	microscope	slides	for	cell	counting	
and	onto	Poly-Lysine	(VWR)	coated	18x18mm	1.5H	glass	coverslips	(Zeiss)	for	3D-SIM	analysis.		
	
Immunofluorescent	 labelling	 of	 tissue	 sections	 was	 achieved	 in	 a	 similar	 manner	 as	 for	
primary	cultures	except:	1	hour	block	steps,	overnight	 incubation	with	primary	antibodies	
(table	 1)	 to	 INSL5	 and	GFP	 for	 cell	 counting	 and	 INSL5,	GLP-1	 and	 PYY	 for	 3D-SIM	 at	 4°C	
primary	(table	1)	and	room	temperature	incubation	with	secondary	antibodies	for	1	hour.	
	
 Colonic	Wholemounts	
	
The	following	method	was	adapted	from	that	developed	by	Winton	et	al.	(1990)	[155]:	
	
Excised	colons	were	stripped	of	adipose	tissue	and	muscle	layers	(removal	of	the	muscle	layer	
greatly	 reduces	 immunofluorescent	 background).	 Colons	were	 pinned	 onto	 3%	 agar	 filled	
petri	dishes,	cut	open	and	washed	with	PBS	using	a	plastic	pipette.	The	colons	were	then	fixed	
for	3	hours	at	room	temperature	using	4%	PFA	(Alfa	Aesar)	and	subsequently	washed	with	
PBS.	Next,	residual	mucus	was	removed	from	the	fixed	tissue	by	 incubation	with	50mls	of	
demucifying	solution	for	20	minutes	at	room	temperature	followed	by	4	PBS	washes.	
	
The	fixed	colons	were	transferred	to	50ml	Falcon	tubes	containing	blocking	solution	(PBS	with	
0.1%	Triton-X	100	and	10%	goat	serum)	and	left	overnight	at	4°C.	The	following	morning	the	
colons	were	incubated	for	4	hours	at	room	temperature	with	primary	antibodies	to	PYY,	INSL5	
and	NTS	diluted	 in	wash	solution	containing	1%	goat	 serum	and	0.1%	Triton-X	100	 in	PBS	
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(table	1).	After	this	the	colons	were	placed	in	wash	solution	overnight.	Then	the	tissue	was	
incubated	with	goat	secondary	antibodies	(conjugated	to	AlexFluor	488,	555	and	633;	1:300)	
for	3	hours	at	room	temperature.	Following	further	washing	overnight	at	4°C,	the	colons	were	
incubated	with	1:2000	Hoescht	nuclear	stain	(in	PBS)	for	30	minutes	at	room	temperature	
followed	by	1	hour	period	of	PBS	washes.	Finally,	the	colons	were	divided	in	half	and	mounted	
onto	microscope	slides	using	Hydromount	(National	Diagonistics).	
	
N.B:	 all	 steps	 for	wholemount	 staining	 involving	washing	 or	 incubation	with	 primary	 and	
secondary	antibodies	involved	the	use	of	a	rocker	to	promote	washout	and	equalise	antibody	
exposure	across	the	length	of	the	tissue.		
	
	
Table	1:	 Primary	antisera	used	 for	 immunofluorescent	 labelling.	Note	1:1000	of	 the	 INSL5	
primary	antibody	was	used	for	the	3D-SIM	and	wholemount	samples	whilst	1:2000	was	used	
for	 verification	 of	 the	 Insl5-rTA/TET-GFP	 and	 Insl5-rTA/TET-GCaMP6F∆CMV	 mice	 by	 cell	
counting.	
	
	
	
	
	
	
	
	
Antigen Raised	in Concentration Source
Proglucagon Rabbit 1:200 Santa	Cruz	sc13091
GFP Goat 1:1000 AbCam	Ab5450
INSL5 Rat 1:1000/1:2000 Takeda
PYY Guinea	Pig 1:500 Progen	16066
NTS Rabbit 1:100 Merck	AB4596
GLP-1 Rabbit 1:100 AbCam	Ab22625
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2.8. Imaging	
 Confocal	microscopy	
For	cell	counting	and	verification	of	transgenic	mouse	models,	slides	were	imaged	using	the	
Leica	TCS	SP8	X	confocal	microscope	with	x20/x40/x60	objectives.	Images	are	presented	as	
individual	z-slices	(tissue	sections)	or	maximal	z-stack	projections	(organoids).		
	
Cell	counts	of	immunofluorescently	labelled	tissue	from	doxycycline-induced	Insl5-rtTA/TET-	
GCaMP6FΔCMV	mice	were	carried	out	manually	on	x20	images	using	the	Leica	Application	
Suite	X	(n=3	mice).	
	
 Intracellular	calcium	imaging	
Prior	 to	 analysis,	 primary	 and	 2D	 organoid	 cultures	 were	 equilibrated	 with	 saline	 buffer	
containing	 1mM	 glucose	 for	 30	 minutes.	 Following	 this,	 treatments	 were	 applied	 at	 a	
perfusion	 rate	 of	 1ml/minute.	 All	 treatments	 were	 made	 up	 in	 saline	 with	 added	 1mM	
glucose.	 Changes	 in	 GCaMP3/GCaMP6F	 fluorescence	 (proxy	 to	 intracellular	 Ca2+	 levels)	
emitted	upon	excitation	with	488nm	 laser	 light	were	measured	 through	a	 long-pass	 filter	
(>510nm)	every	2	seconds	using	a	Nikon	Eclipse	TE2000-5.	MetaFluor	was	used	to	coordinate	
GCaMP3/GCaMP6F	excitation	to	record	GCaMP3/GCaMP6F	emissions	from	marked	L-cells.	L-
cells	were	imaged	1-2	days	after	plating.	After	the	first	day	of	imaging,	dishes	were	topped	up	
with	primary	culture	media	(with	10µM	Y-27632	and	2µg/ml	doxycycline	hyclate)	and	ENR	
(with	 10µM	 Y-27632)	 for	 the	 primary	 and	 2D	 organoid	 cultures	 respectively.	 Intracellular	
calcium	 responses	were	 computed	 as	 ratio	 of	maximum	GCaMP3/GCaMP6F	 fluorescence	
measured	during	treatment	to	the	maximum	GCaMP3/GCaMP6F	fluorescence	during	the	30	
seconds	prior	to	treatment	(basal).	
	
To	 examine	 the	 effect	 of	 concomitant	 activation	 of	 GPBAR-1	 on	 intracellular	 calcium	
responses	to	10µM	TAK-875	and	30mM	KCl	cells	were	first	stimulated	with	either	10µM	TAK-
875	or	30mM	KCl	alone.	Following	saline	buffer	washout,	cells	were	pre-treated	with	3µM	
GPBAR-A	 (GPBAR-1	 agonist)	 for	 10	minutes	 prior	 to	 co-application	 of	 3µM	GPBAR-A	with	
10µM	TAK-875	or	30mM	KCl	for	up	to	5	minutes	depending	on	whether	responses	in	GCaMP3	
fluoresence	were	observed.	Subsequent	TAK-875/KCl	washout	was	achieved	by	a	3-5	minute	
	 42	
washout	period	with	3µM	GPBAR-A	followed	by	a	5	minute	saline	washout.	After	this	period,	
10µM	TAK-875	or	30mM	KCl	was	applied	for	a	third	time	to	allow	comparison	of	intracellular	
calcium	responses	prior,	during	and	after	3µM	GPBAR-A	co-application.	The	magnitude	of	the	
GPBAR-A	and	TAK-875	or	KCl	co-application	effect	was	calculated	by	dividing	the	observed	
fold	 change	 in	 GCaMP3	 fluorescence	 to	 co-application	 by	 the	 anticipated	 fold	 change	
(estimated	from	the	individual	GCaMP3	responses	to	GPBAR-A	during	the	30	seconds	prior	to	
TAK-875	addition	and	initial	TAK-875	application)	relative	to	basal	GCaMP3	fluorescence	(30	
seconds	prior	to	GPBAR-A	application).		
		
Statistical	significance	of	intracellular	calcium	responses	was	assessed	using	a	Kruskal-Wallis	
test	 comparing	 responses	 to	 the	 basal	 0.1%	 DMSO	 condition	 or	 Wilcoxon	 tests	 (H0:	
median=1).	Inter-group	comparisons	were	made	using	Kruskal-Wallis	tests	and	potentiation	
was	assessed	using	a	Wilcoxon	test	(H0:	median=1,	i.e.	no	synergy).		
	
 3D-SIM	imaging	of	GLP-1,	PYY	and	INSL5	vesicles		
3D	super	resolution	microscopy		
	
3D	super	resolution	microscopy	(3D-SIM)	was	used	to	examine	the	overlap	between	L-cell	
secretory	vesicles	containing	INSL5,	GLP-1	and	PYY	in	both	primary	culture	and	tissue	sections.	
This	was	facilitated	by	using	the	ELYRA	S.1	microscope	(Zeiss)	to	take	0.11µm	spaced	z-stack	
images	of	immunofluorescently	labelled	L-cells.	These	raw	images	were	processed	using	ZEN	
Black	 (Zeiss).	 For	 the	 surfaces	 analysis,	 chromatic	 abberations	 were	 adjusted	 for	 by	
comparison	 with	 similarly	 imaged	 100nm	 TetraSpeck	 fluorescent	 microspheres	
(ThermoFisher).	
	
Vesicle	analysis	by	3D	surface	mapping	
	
The	surfaces	analysis	of	overlap	between	INSL5,	GLP-1	and	PYY	vesicles	is	based	on	methods	
employed	by	Cho	et	al.	(2014)	[87].	Using	the	‘create	surfaces’	function	of	Imaris	(Bitplane),	
INSL5,	GLP-1	 and	 PYY	 vesicles	were	 rendered	 in	 3D	 from	 the	 3D-SIM	 z-stack	 images.	 The	
‘surface-surface	colocalization’	 function	was	then	applied	to	create	new	surfaces	from	the	
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overlap	in	INSL5,	GLP-1	and	PYY	surfaces.	Using	these	surfaces,	overlap	in	INSL5,	GLP-1	and	
PYY	vesicle	volume	was	calculated	as	a	percentage	of	total	vesicle	volume.	
	
Vesicle	analysis	based	on	fitted	3D	Gaussian	distributions	
	
This	analysis	was	performed	by	Christopher	Smith	using	MATLAB	and	is	described	in	Billing	et	
al.	(2018)	[6].	In	brief,	3D	Gaussian	distributions	were	fitted	onto	the	individual	channel	data	
from	the	3D-SIM	acquired	z-stack	images	[156,157].	This	enabled	the	determination	of	vesicle	
centre	points	 for	each	channel.	Chromatic	aberration	was	accounted	for	by	coinciding	the	
mean	3D	positions	of	all	 the	vesicles	 in	each	of	the	channels	for	every	 image	analysed.	To	
remove	erroneously	localised	vesicles,	if	the	positions	of	the	channel	signals	for	a	particular	
identified	 vesicle	 were	 >200nm	 apart	 they	 were	 considered	 to	 originate	 from	 different	
vesicles	and	therefore	discarded.	The	channel	intensities	of	each	image	were	normalised	to	a	
0-1	 scale	by	 reference	 to	 the	 image’s	maximum	 intensity	pixel.	 Subsequently	 the	 channel	
intensities	were	determined	for	each	vesicle	by	calculating	the	mean	pixel	intensity	within	a	
150	nm	radius	sphere	centred	at	the	identified	vesicle	centre	point,	followed	by	background	
subtraction	 (mean	 intensity	 per	 image	 per	 channel	 across	 the	 whole	 z-stack).	 If	
the	normalised	intensity	calculated	for	a	particular	channel	exceeded	0.05	then	the	vesicle	
was	deemed	to	contain	the	corresponding	peptide.	In	contrast,	if	the	channel	intensity	was	
lower	than	0.02	then	the	vesicle	was	considered	devoid	of	the	corresponding	peptide.	The	
vesicle	intensity	profiles	produced	for	each	channel	were	derived	in	the	x-axis	plane	centred	
on	the	 identified	vesicle	centre	point.	The	standard	deviation	of	1D	Gaussian	distributions	
fitted	to	these	cross-sectional	intensity	profiles	was	used	to	estimate	vesicle	size.	
	
N.B:	Search	https://bitbucket.org/cwissmiff/travis/src	for	the	code	used	for	the	3D	Gaussian	
distribution	analysis.	
	
	
	
	
	 44	
 Imaging	of	colonic	wholemounts	
Image	acquisition	
	
Wholemounts	were	imaged	using	the	Axio	Scan.Z1	system	(Zeiss).	Tiles	of	extended	depth	of	
focus	 (EDF)	 images	 were	 taken	 for	 each	 of	 the	 three	 labelled	 channels	 using	 a	 Plan-
ApoChromat	 20x/0.8	 M27	 objective,	 a	 Hamamatsu	 Orca	 Flash	 camera	 and	 an	 inbuilt	
autofocus	 function.	 The	 depths	 used	 for	 the	 EDF	 images	 were	 customised	 for	 each	
wholemount	and	depended	on	tissue	thickness.	Following	acquisition,	the	tiled	images	were	
stitched	together	with	shading	correction.		
	
Counting	of	immunofluorescently	labelled	cells	
	
Immunofluorescently	labelled	cells	within	the	wholemount	images	were	counted	using	HALO	
(Indica	Labs).	Following	manual	 removal	of	damaged	tissue	or	bubbles	within	each	 image,	
spatial	analysis	was	used	to	 identify	cells	 labelled	 in	each	of	the	three	channels	(reflecting	
staining	 for	NTS,	PYY	and	 INSL5).	Afterwards,	using	 INSL5	and	NTS	staining	as	 the	primary	
labels,	dual	 labelled	cells	were	 identified.	Following	on	from	this,	 triple	 labelled	cells	were	
identified	using	NTS	 staining	as	 the	primary	 label.	 Finally,	 the	 infiltration	analysis	 function	
(HALO)	was	applied	to	determine	the	density	distribution	of	each	type	of	cell	(single,	dual	and	
triple	labelled)	within	proximal	(P1-P2),	intermediate	(P3-P5)	and	distal	(P6-P7)	subdivisions	
of	the	wholemounted	tissue.	
	
Downstream	processing	and	statistical	analysis	of	the	cell	density	distributions	was	achieved	
using	a	combination	of	Excel	(Microsoft	Office)	and	GraphPad	Prism	7.0	(GraphPad	Software).	
One-sample	t-tests	were	used	to	detect	statistically	significant	(p<0.05)	fold	changes	in	cell	
density	in	each	region	of	colon	examined	relative	to	those	measured	in	the	proximal	colon.		
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2.9. Transcriptomic	techniques	
 Real-time	quantitative	PCR		
FACS-purified	cells	were	lysed	in	RLT	plus	buffer	with	RNA	extracted	using	the	RNeasy	plus	
micro	 kit	 (Qiagen)	 according	 to	 the	manufacturer’s	 instructions.	 TRI	 reagent	was	 used	 to	
extract	RNA	from	tissue	homogenates	(murine	colons	segmented	into	7x	1cm	pieces)	with	an	
additional	step	using	DNA-free	DNA	removal	kit	(Invitrogen)	to	remove	residual	genomic	DNA.	
	
RNA	was	reverse	transcribed	using	SuperScript	II	for	homogenate	samples	and	SuperScript	III	
for	 samples	 from	 FACS-purified	 cells	 using	 a	 Peltier	 Thermal	 Cycler-225	 (MJ	 Research)	
according	 to	 standard	 protocols.	 All	 RNA	 samples	 from	 FACS-purified	 cells	 were	 quality	
checked	by	using	a	Bioanalyser	RNA	Pico	Kit	(Agilent)	with	all	RIN	values	above	7.3.	RT-qPCR	
was	undertaken	using	the	QuantStudio	7	flex	RT-qPCR	system	(Applied	Biosystems).	The	RT-
qPCR	 reaction	 mix	 consisted	 of	 template	 cDNA,	 TaqMan	 Universal	 Master	 Mix	 (Applied	
Biosystems)	and	specific	primers	(Applied	Biosystems)	which	are	detailed	in	table	2.		
	
Relative	 expression	 was	 evaluated	 by	 calculating	 the	 difference	 in	 cycle	 threshold	 (∆CT)	
between	the	housekeeper	gene	β-actin	and	the	gene	of	 interest	 (CTβ-actin-CTGene).	With	the	
exception	of	the	regional	expression	analysis	in	the	colon,	statistical	analysis	was	carried	out	
on	2∆CT	values	using	ratio	paired	t-tests	(p<0.05).	For	examination	of	differences	in	relative	
gene	 expression	 along	 the	 colonic	 proximal-distal	 axis	 (P1-P7	 segments),	 statistically	
significant	(p<0.05)	differences	in	regional	∆CT	values,	with	reference	to	the	most	proximal	
segment	 (P1),	 were	 evaluated	 using	 repeated-measures	 one-way	 ANOVA	 with	 Dunnett’s	
correction.	
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Table	2:	Identities	of	the	TaqMan	probes	(Applied	Biosystems)	used	for	real	time	quantitative	
PCR.	
	
 Single-cell	RNA-sequencing		
10x	Chromium	system	
	
Following	 FACS	 isolation,	 3500	 EECs	 together	 with	 reverse	 transcription	 (RT)	 master	 mix	
reagents	and	gel	beads,	each	containing	primers	with	the	same	unique	barcode	and	different	
unique	molecular	 identifiers	(UMIs),	were	fed	into	a	microfluidics	chip	(see	figure	3).	3500	
cells	were	loaded	rather	than	the	total	7000	cells	FACS-isolated	due	to	cost	restrictions.	The	
flow	rate	was	optimised	to	enable	capture	of	single	cells	by	each	individual	gel	bead	forming	
gel	beads	in	emulsion	(GEMs)	separated	by	supplied	partitioning	oil.	Within	each	GEM	the	
captured	cells	were	lysed	and	RNA	transcripts	were	reverse	transcribed	into	barcoded	cDNA.	
The	first	strand	cDNA	generated	from	each	GEM	were	then	pooled	together	and	amplified	
using	PCR	yielding	a	cDNA	library	ready	for	sequencing.	
Gene Reference
β-actin Mm02619580_g1
Insl5 ﻿Mm00442241_m1
Gcg Mm01269055_m1
Pyy Mm00520716_g1
Ffar1 Mm00809442_s1
Casr Mm00443375_m1
Gpbar1 ﻿Mm04212121_s1
Agtr1a Mm01957722_s1
Avpr1b ﻿Mm01700416_m1
Ffar2 ﻿Mm02620654_m1
Bb2r Mm01157247_m1
Ppy Mm01250509_g1
Nts Mm00481140_m1
Olfr78 Mm00453733_s1	
Slc5a8 Mm00520629_m1
Cck Mm00446170_m1
Tph1 Mm01202614_m1
Sct Mm00441235_g1
Sst Mm00436671_m1
Calcrl Mm0051986_m1
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Figure	 3:	 Schematic	 illustrating	 how	 the	 10x	 Chromium	 system	 generated	 single	 cell	
transcriptomes	 from	 FACS-isolated	 enteroendocrine	 cells	 (EECs).	 Gel	 beads	 in	 emulsion	 –	
GEMs.			
	
N.B.	All	the	single-cell	RNA-sequencing	analyses	were	achieved	using	Bioconductor	Software	
Packages	on	RStudio.	
	
Library	preparation	
	
3500	FACS-purified	NeuroD1-EYFP	cells	(from	a	single	mouse	colon)	were	used	as	input	into	
the	 Chromium	 system	 (10x	 Genomics)	 producing	 cDNA	 libraries	 which	 were	 paired-end	
sequenced	by	a	HiSeq	4000	(Illumina)	at	the	Cancer	Research	UK	Cambridge	Institute	(CRUK	
CI).	Quality	control,	 read	alignment	 (with	 reference	 to	 the	mm10	genome)	and	raw	count	
quantification	 for	 each	 cell	was	 achieved	by	Brian	 Lam	using	 the	CellRanger	pipeline	 (10x	
Genomics).	Cells	with	less	than	2000	unique	molecular	identifier	(UMI)	counts	were	discarded	
yielding	transcriptomes	from	1779	cells	for	downstream	analysis.	Note	that	the	Chromium	
system	has	a	cell	capture	rate	of	up	to	65%	so	many	of	the	3500	cells	initially	inputted	were	
likely	 within	 the	 microfluidics	 chip.	 A	 mean	 of	 190279	 reads	 was	 achieved	 for	 the	 cells	
sequenced	 with	 transcripts	 from	 17621	 different	 genes	 detected	 and	 a	 median	 of	 2099	
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different	genes	detected	per	cell.	The	median	unique	molecular	identified	(UMI)	counts	per	
cell	was	5134.		
	
K-means	clustering	
	
Prior	to	clustering,	raw	counts	were	normalised	to	UMI	counts.	K-means	clustering	(k=9)	was	
then	 run	on	a	 t-distributed	stochastic	neighbour	embedding	 (t-SNE)	plot	 (seed=0,	dims=2,	
perplexity=30)	using	the	Rtsne	package	[158].	
	
Differential	expression	
	
Differential	expression	analysis	between	 identified	groups	was	conducted	using	the	edgeR	
package	 [159].	 Raw	 counts	 were	 firstly	 normalised	 using	 the	 trimmed	mean	 of	M-values	
normalisation	method	(TMM)	and	then	fitted	to	a	negative	binomial	generalised	log-linear	
model	 (using	 the	 glmFit	 function).	 Following	 this,	 gene-wise	 likelihood	 ratio	 tests	 were	
performed	(using	the	glmLRT	function)	to	examine	statistical	differences	in	gene	expression	
between	one	reference	group	and	all	the	other	groups.	These	tests	were	repeated	so	that	
gene	 expression	 was	 compared	 between	 all	 groups.	 Subsequently,	 genes	 with	 a	 false	
discovery	rate	(FDR)	above	0.01	were	excluded	and	the	top	10	most	differentially	expressed	
genes	 were	 identified	 for	 each	 group.	 Additionally,	 by	 subsetting	 genes	 encoding	 GPCRs	
(appendix	 3)	 and	 transporters,	 the	 top	 10	 most	 differentially	 expressed	 GPCRs	 and	
transporters	were	identified	for	each	group.	Visual	representation	of	differentially	expressed	
genes	 was	 achieved	 by	 plotting	 heatmaps	 of	 the	 log2	 UMI-normalised	 counts	 using	 the	
heatmap.2	function	of	the	gplots	package.	
	
Correlation	of	gene	expression	
	
To	assess	correlation	in	expression	between	pairs	of	genes	(namely	Insl5,	Gcg,	Pyy	and	Nts)	
in	 L-cells,	 Pearson’s	 product	 moment	 correlation	 coefficients	 (R)	 were	 calculated.	 For	
graphical	representation,	linear	regression	plots	were	created	of	the	correlated	pairs	of	genes	
using	ggplot.			
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 Chapter	3.	Synergy	between	FFAR1	and	GPBAR-1	
signalling	in	L-cells	
3.1. Introduction	
As	 previously	 discussed,	 luminal	 contents	 of	 the	 intestine	 and	 circulating	 factors	 can	 be	
sensed	by	 L-cells	 through	 activation	of	 both	Gq	 and	Gs	 coupled	GPCRs	 [55].	 Simultaneous	
activation	of	the	Gq	and	Gs	signalling	pathways	by	dietary	stimuli	raises	the	possibility	of	cross-
talk	 between	 the	 two	 pathways	 and	 consequential	 synergistic	 effects	 on	 secretion	 (i.e.	
greater	secretion	than	the	sum	of	the	responses	to	activation	of	the	pathways	individually).	
Ekberg	et	al.	have	identified	such	synergy	in	the	GLP-1	secretory	responses	of	small	intestinal	
L-cells	upon	concomitant	activation	of	the	Gq-coupled	free	fatty	acid	receptor	1	(FFAR1)	and	
the	Gs-coupled	GPR119	(receptor	 for	2-monoacylglycerol)	with	the	synthetic	agonists	TAK-
875	(AKA	fasiglifam)	and	AR231453	respectively	 [160].	 In	this	chapter,	 the	hypothesis	that	
synergy	 exists	 between	 the	 signalling	 pathways	 of	 FFAR1	 and	 the	 Gs-coupled	 bile	 acid	
receptor	 GPBAR-1	 is	 examined	 through	 intracellular	 calcium	 imaging	 and	GLP-1	 secretion	
assays.	Clinically,	combination	therapy	might	enable	exploitation	of	such	synergy	for	type	2	
diabetes	treatment.	This	approach	could	potentially	reduce	adverse	effects	associated	with	
monotherapy	 by	 yielding	 therapeutic	 benefits	 at	 lower	 doses	 of	 each	 individual	 drug	
administered.	
	
3.2. Aims	
1. To	 identify	potential	synergistic	effects	on	 intracellular	calcium	responses	to	FFAR1	
and	GPBAR1	co-activation	
2. To	examine	possible	synergistic	effects	on	GLP-1	secretion	to	FFAR1	and	GPBAR1	co-
activation	
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3.3. Background	
 Lipid	digestion	and	free	fatty	acid	absorption	
Animal	and	plant	derived	fatty	acids	form	an	essential	dietary	component	and	are	ingested	
as	 esters	 such	 as	 triglycerides,	 phospholipids	 and	 cholesterol.	 Ingested	 triglycerides	 are	
digested	to	2-monoacylglycerol	(2-MAG)	and	free	fatty	acids	(FFAs).	Free	fatty	acids	(FFAs)	
compose	a	group	of	hydrocarbons	divided	by	the	number	of	constituent	carbon	atoms	into	
small	 (<8	 carbons;	 SCFAs),	medium	 (8-12	 carbons;	MCFAs)	 and	 long	 (>12	 carbons;	 LCFAs)	
chain	 fatty	 acids	 [161].	 Unlike	MCFAs	 and	 LCFAs,	 volatile	 SCFAs	 are	 products	 of	 bacterial	
fermentation	in	the	large	intestine	and	contribute	~10%	total	daily	calorie	intake	in	humans	
[162].	 FFAs	 modulate	 the	 activities	 of	 EEC	 cells	 and	 consequently	 gut	 hormone	 release	
through	a	diverse	range	of	GPCRs	[86].	
	
Lipid	digestion	and	absorption	(figure	1)	occurs	primarily	in	the	small	intestine,	facilitated	by	
the	action	of	pancreatic	lipases.		Pancreatic	lipases	catalyse	the	cleavage	of	ester	bonds	thus	
liberating	free	fatty	acids	(and	2-MAG)	which	are	absorbed	across	the	epithelium	[163].	Lipase	
action	 is	 facilitated	 through	 lipid	 emulsification	 by	 bile	 acids	 produced	 by	 the	 liver	 from	
cholesterol.	Produced	bile	acids	are	stored	in	the	gallbladder	between	meals	and	enter	the	
duodenum	 via	 the	 common	 bile	 duct.	 CCK,	 released	 postprandially	 in	 the	 proximal	 small	
intestine,	 stimulates	 gallbladder	 contraction	 and	 subsequent	 bile	 secretion	 into	 the	
duodenum	[164].	These	amphipathic	molecules	act	as	surfactants	forming	small	micelles	thus	
increasing	 the	 relative	 surface	area	of	 exposed	 lipid	 for	 lipase	action	 [165,166].	 Following	
liberation,	FFAs	are	absorbed	by	enterocytes.	The	precise	mechanisms	by	which	this	uptake	
occurs	is	not	clear	but	appears	to	rely	on	a	diffusion	based	mechanism	known	as	‘flip-flop’	
and/or	protein	mediated	transport	mechanisms	[167].	Once	uptaken,	FFAs	bind	to	free	acid	
binding	 proteins	 (FABPs)	 in	 the	 cytosol	 which	 act	 as	 chaperones	 [168].	 Directed	 to	 the	
endoplasmic	 reticulum	 (ER),	 triglycerides	 are	 synthesised	 from	 the	 FFAs	 and	 2-MAG	 and	
packaged	 into	 prechylomicrons.	 Following	 Golgi	 processing,	 prechylomicrons	 are	
transformed	into	mature	chylomicrons	which	are	exocytosed	into	the	lacteals	(vessels	of	the	
lymphatic	system)	and	transport	lipids	to	various	tissues	of	the	body	[167].		
	
	 51	
Reabsorption	and	recycling	of	bile	acids	secreted	into	the	 intestinal	 lumen	(summarised	in	
figure	1)	is	highly	efficient	with	roughly	95%	of	the	secreted	bile	acids	reabsorbed	acting	to	
reduce	the	metabolic	burden	of	producing	new	bile	acids	 [126].	The	majority	of	bile	acids	
(>95%)	are	reabsorbed	by	enterocytes	through	active	transport.	The	key	protein	involved	in	
this	uptake	is	apical	sodium-dependent	bile	acid	transporter	(ASBT)	which	imports	2	sodium	
ions	for	every	bile	acid	molecule	[169].	ASBT	represents	a	potential	therapeutic	drug	target	in	
conditions	 such	 as	 functional	 constipation	 since	 ASBT	 inhibition	 attenuates	 bile	 acid	
reabsorption	 resulting	 in	 accelerated	 colonic	 transport	 [170].	 Alternatively,	 bile	 acids	
conjugated	to	taurine	or	glycine	can	be	passively	absorbed	across	the	apical	brush	border	via	
diffusion	[171].	As	with	FFAs,	bile	acids	are	sequestered	within	the	cytosol	by	ileal	bile	acid	
binding	 proteins.	 Transportation	 across	 the	 baslolateral	 membrane	 of	 bile	 acids	 into	 the	
circulation	is	achieved	by	various	solute	transporter	proteins	enabling	bile	acid	recycling	by	
hepatocytes	[95].			
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Figure	1:	 Schematic	 illustrating	 the	mechanisms	 involved	 in	 lipid	digestion	and	absorption	
within	the	small	intestine	and	receptors	involved	in	L-cell	chemosensation	of	free	fatty	acids	
(FFAs)	 and	bile	 acids	 (BAs).	 Lipids	 droplets	 entering	 the	 small	 intestine	are	 emulsified	 into	
micelles	by	released	bile	acids	enhancing	pancreatic	lipase	breakdown	of	triglycerides	(TGs)	
to	free	fatty	acids	(FFAs)	and	2-monoacylglycerol	(2-MAG).	FFAs	and	2-MAG	are	absorbed	by	
both	passive	diffusion	and	protein	mediated	mechanisms	into	enterocytes.	Triglycerides	are	
synthesised	 from	 absorbed	 FFAs	 and	 2-MAG	 and	 packaged	 into	 prechylomicrons	 in	 the	
endoplasmic	 reticulum.	 These	 prechylomicrons	 are	 subsequently	 processed	 by	 the	 Golgi	
complex	 into	 chylomicrons	 which	 are	 exocytosed	 from	 the	 basolateral	 membrane	 into	
neighbouring	 lacteals.	 FFAs	 and	 2-MAG	are	 released	 from	 circulating	 chylomicrons	 by	 the	
action	of	local	lipoprotein	lipase	(LPL).	BAs	are	co-transported	into	enterocytes	with	sodium	
ions	(2	Na+	ions	per	bile	acid	molecule)	from	the	lumen	via	apical	sodium-dependent	bile	acid	
transporter	(ASBT)	and	subsequently	across	the	basolateral	membrane	into	the	circulation	via	
protein-mediated	mechanisms.	 FFAs,	 2-MAG	and	 bile	 acids	 can	modulate	 secretion	 of	 gut	
hormones	(red	squares)	from	L-cells	through	GPCRs	on	the	basolateral	membrane.	GPCRs	are	
indicated	by	shapes	with	7	transmembrane	passes	(blue	=	Gq-coupled,	green	=	Gs-coupled	and	
red	=	Gi-coupled).	Cylindrical	shapes	indicate	transporter	proteins.		
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 L-cell	FFA	and	bile	acid	sensing	
Physiologically,	detection	of	free	fatty	acids	in	the	distal	small	intestine	acts	as	an	important	
initiation	 step	 of	 the	 ‘ileal-brake’	 mechanism	 (which	 inhibits	 gastric	 emptying)	 through	
stimulation	of	GLP-1	and	PYY	release	[86].	The	resulting	reduction	in	gastric	emptying	aids	the	
complete	digestion	and	absorption	of	ingested	nutrients	[172].	Previously,	L-cells	have	been	
found	to	express	functional	receptors	for	FFAs	and	bile	acids	including	receptors	for	medium	
and	 long	 chain	 fatty	 acids	 (e.g.	 linoleic	 acid)	 such	as	 FFAR1	 (AKA	GPR40)	 and	FFAR4	 (AKA	
GPR120)	and	the	bile	acid	receptor	GPBAR-1	(AKA	TGR5)	[126,173–175].	FFAR1	and	FFAR4	
are	primarily	Gq-coupled	GPCR	whilst	GPBAR-1	is	Gs-coupled	though	FFAR4	can	also	couple	to	
Gi	signalling	pathways	[126,176].	Ffar1	expression	has	been	identified	as	enriched	in	both	L	
and	K-cells	of	the	small	intestine.	Accordingly,	Ffar1	knockout	in	mice	significantly	attenuated	
plasma	GIP/GLP-1	responses	 to	high	 fat	diet	 (administered	via	gavage)	 [175].	Additionally,	
application	of	FFAR1/FFAR4	dual	agonists	 to	human	colonic	crypt	cultures	 triggered	GLP-1	
secretion	 [70].	 FFAR4	 appears	 to	 be	 play	 a	 less	 significant	 role	 in	 FFA-mediated	 GLP-1	
secretion,	 as	 although	 the	 FFAR4-selective	 agonist	Metabolex209	 acted	 as	 a	 weak	 GLP-1	
secretagogue	from	primary	cultures,		in	vivo	murine	GLP-1	responses	to	corn	oil	gavages	were	
abolished	in	Ffar1	but	not	Ffar4	knockout	mice	[160].	In	fact,	the	weak	GLP-1	responses	seen	
to	Metabolex209	could	derive	indirectly	from	inhibition	of	D-cell	secretion	of	somatostatin	
which	acts	as	a	global	inhibitor	of	enteroendocrine	secretions	[115,176].	
	
Interestingly,	FFAR1	appears	to	be	basolaterally	located	in	L-cells	since	in	experiments	where	
FFAR1	 agonists,	 including	 TAK-875	 and	 linoleic	 acid,	 were	 applied	 to	 perfused	 rat	 small	
intestine,	 GLP-1	 secretion	 was	 only	 triggered	 by	 vascular	 administration	 and	 not	 luminal	
administration	 [127].	 Such	 results	 imply	 that	 FFAs	 are	 not	 sensed	 by	 L-cells	 luminally	 but	
basolaterally	following	absorption.	In	support	of	this	Psichas	et	al.	suggest	that	FFA	liberation	
from	 chylomicrons	 at	 the	basolateral	membrane	by	 local	 lipoprotein	 lipase	 facilitates	 FFA	
sensing	 through	 FFAR1	 [177].	 However,	 support	 for	 this	 mechanism	 is	 compounded	 by	
evidence	 that	 orlistat	 (lipase	 inhibitor)	 does	 not	 attenuate	 GLP-1	 secretion	 from	 murine	
intestinal	 cultures	 [177].	 Furthermore,	 given	 the	 low	 bioavailability	 of	 orlistat,	 a	 study	 by	
Ellrichmann	et	al.	(2008)	on	healthy	humans	suggests	that	pancreatic	lipases	might	be	more	
significant	 to	 FFA-mediated	 GLP-1	 release	 as	 oral	 orlistat	 administration	 attenuated	
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postprandial	increases	in	plasma	GLP-1	[178].	Contrastingly,	Damci	et	al.	(2004)	found	that	
oral	 orlistat	 administration	 increased	 postprandial	 plasma	 GLP-1	 levels	 in	 type	 2	 diabetic	
patients	[179].	This	increase	in	GLP-1	release	could	derive	from	increased	delivery	of	lipids	to	
the	 L-cell	 rich	 distal	 gastrointestinal	 tract.	 It	 is	 possible	 that	 the	 discrepancies	 in	 findings	
between	 the	 Damci	 et	 al.	 (2004)	 and	 Ellrichmann	 et	 al.	 (2008)	 studies	 reflect	 nutritional	
differences	in	the	diets	employed.	The	diet	in	the	Damci	et	al.	study,	for	example,	contained	
higher	 levels	of	 fat	 than	 in	the	Ellrichmann	et	al.	study.	 In	 light	of	 the	contrasting	findings	
detailed	 here,	 more	 in	 vivo	 and	 in	 vitro	 studies	 will	 be	 required	 to	 establish	 the	 precise	
molecular	mechanisms	which	mediate	basolateral	L-cell	FFA-sensing.	
	
Functional	Ffar1	expression	has	also	been	 identified	 in	both	rodent	and	human	pancreatic	
islets	 whereby	 stimulation	 of	 FFAR1	 with	 the	 FFAR1	 specific	 agonist	 TAK-875	 enhanced	
glucose-induced	 insulin	 stimulation	 from	 isolated	 islets	 [180,181].	 Under	 physiological	
conditions	 it	 appears	 that	 glucose-induced	 production	 and	 release	 of	 20-
hydroxyeicosatetraenoic	acid	(20-HETE)	by	beta-cells	potentiates	glucose	stimulated	insulin	
secretion	in	an	autocrine	fashion	by	stimulating	FFAR1	[182].	Kalis	et	al.	(2007)	claim	that	they	
have	identified	SNPs	in	human	FFAR1	that	are	associated	with	impaired	beta	cell	function	and	
Kristinsson	et	al.	(2017)	hypothesise	that	FFAR1	signalling	may	contribute	to	obesity	and	type	
2	diabetes	pathology	[183,184].	Indeed	Tunaru	et	al.	(2018)	found	that	glucose-induced	20-
HETE	production	was	attenuated	in	islets	isolated	from	human	patients	with	type	2	diabetes	
likely	contributing	to	the	impairment	in	glucose	stimulated	insulin	secretion	seen	in	patients	
with	 type	 2	 diabetes	 [182].	 Together	 these	 results	 further	 highlight	 the	 physiological	 and	
clinical	relevance	of	FFAR1.	
	
With	 regards	 to	 the	 effects	 of	 bile	 acids	 on	 intestinal	 L-cells,	 treatment	 of	 primary	 small	
intestinal	crypt	cultures	with	bile	acids	such	as	taurodeoxycholic	acid	(TDCA)	stimulates	GLP-
1	secretion.	This	stimulation	appears	GPBAR-1	dependent	as	GPBAR-A	(a	specific	agonist	of	
GPBAR-1)	 triggers	GLP-1	 secretion	and	primary	 cultures	 generated	 from	Gpbar1	 knockout	
mouse	 did	 not	 display	 GLP-1	 responses	 to	 TDCA	 (or	 GPBAR-A).	 Acute	 L-cell	 secretory	
responses	to	bile	acids	appear	not	to	be	mediated	by	the	nuclear	receptor	for	bile	acids,	FXR	
[126].	Ussing	chamber	experiments	whereby	a	piece	of	suspended	small	intestine	epithelium	
separates	 two	 chambers	 of	 buffer,	 one	 apically	 facing	 and	 the	 other	 basolaterally	 facing,	
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enabled	the	polarity	of	the	small	intestinal	bile	acid	responses	to	be	examined.	GPBAR-A	only	
triggered	GLP-1	 secretion	when	 applied	 to	 the	 basolateral	 facing	 chamber	whereas	 TDCA	
triggered	GLP-1	secretion	when	applied	to	either	side.	However,	in	the	presence	of	an	ASBT	
(which	does	not	transport	GPBAR-A)	 inhibitor	TDCA	only	stimulated	GLP-1	secretion	when	
applied	to	the	basolateral	chamber.	These	results	suggest	that	as	with	free	fatty	acids,	bile	
acids	are	first	absorbed	across	the	small	intestinal	epithelium	and	sensed	basolaterally	[126].	
	
 Synergistic	effects	of	coactivation	of	Gq	and	Gs	signalling	pathways	on	
GLP-1	secretion	
FFAs	 and	 bile	 acids	 reach	 the	 small	 intestinal	 mucosa	 in	 parallel	 raising	 the	 prospect	 of	
concomitant	activation	of	the	Gs	and	Gq	signalling	pathways	under	physiological	conditons.	
Synthetic	 full	 agonists	 of	 FFAR1	 such	 as	 AM-1638,	which	 can	 employ	 both	 the	Gq	 and	Gs	
signalling	pathways	trigger	significantly	greater	GLP-1	secretion,	from	colonic	crypt	cultures	
and	 in	 vivo	 following	 oral	 gavage,	 than	 partial	 agonists	 like	 TAK-875	 which	 activate	 Gq-
signalling	 alone	 [173,185].	 It	 should	 be	 noted	 that	 in	 experiments	 where	 AM-1638	 was	
applied	 to	 L-cells	 in	 primary	 culture	 increases	 in	 intracellular	 cAMP	 were	 not	 observed	
contrasting	 with	 previous	 studies	 (unpublished	 data	 by	 Gwen	 Tolhurst).	 This	 discrepancy	
might	be	explained	by	utilisation	of	non-physiological	overexpression	of	Ffar1	 in	 cell	 lines	
(such	as	HEK293	and	COS7	cells)	to	assess	cAMP	responses	to	AM-1638	in	previous	studies	
[173,185].	Consequently,	it	is	unclear	whether	AM-1638	triggers	elevations	in	cAMP	through	
Gs-signalling	in	vivo.	
	
An	example	of	synergy	between	the	L-cell	Gq	and	Gs	signalling	pathways	comes	from	findings	
that	co-activation	of	FFAR1	and	the	Gs-coupled	2-MAG	receptor	GPR119	potentiates	GLP-1	
secretion	from	murine	colonic	crypt	cultures	[160].	In	vivo,	2-MAG	should	arrive	at	the	small	
intestinal	 apical	 brush	 border	 simultaneously	 with	 FFAs	 meaning	 GPR119-mediated	
potentiation	 of	 FFAR1-mediated	 GLP-1	 release	 has	 physiological	 relevance.	 TAK-875	 was	
withdrawn	from	phase	III	clinical	investigations	because	of	issues	with	liver	toxicity	and	such	
synergy	 suggests	 that	 a	 lower,	 possibly	 non-toxic,	 therapeutic	 dose	 of	 TAK-875	 could	 be	
achieved	 when	 co-administered	 with	 a	 stimulus	 of	 the	 Gs	 signalling	 pathway	 [186].	
Alternatively,	dual-agonists	of	FFAR1	and	GPR119/GPBAR-1	could	be	developed	whereby	a	
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single	drug	activates	both	receptors.	Dual-agonists	for	the	GLP-1	and	glucagon	receptors	have	
recently	 been	 developed	 for	 the	 treatment	 of	 obese	 type	 2	 diabetes	 and	 appear	 more	
effective	 at	 reducing	 body	 weight	 and	 restoring	 normoglycaemia	 than	 standard	 GLP-1	
receptor	agonists.	Glucagon	receptor	agonism	alone	acts	to	elevate	blood	glucose	levels	by	
increased	liver	glycogenolysis	and	gluconeogenesis,	however	co-agonism	of	GLP-1	receptor	
counteracts	this	adverse	effect	and	appears	to	improve	glucose	tolerance	overall	[81,82,187].			
	
The	precise	mechanism	by	which	synergy	between	the	Gq	and	Gs	signalling	pathways	arises	
has	not	been	explored	but	likely	reflects	molecular	cross-talk	between	signalling	pathways.	In	
Gs	signalling	pathways,	elevated	levels	of	cAMP	activate	the	effector	proteins	PKA	and	EPAC2.	
These	proteins	modulate	 the	activities	of	proteins	 involved	 in	exocytosis	affecting	peptide	
secretion	[188].	EPAC2	in	beta	cells	for	example	is	known	to	potentiate	glucose	stimulated	
insulin	secretion	by	increasing	the	density	of	insulin	granules	at	the	plasma	membrane	(ready	
to	be	secreted)	[189,190].	Similarly,	whilst	Gq	activation	increases	IP3	production,	leading	to	
release	of	intracellular	Ca2+	and	subsequent	exocytosis,	the	other	secondary	messenger	of	Gq	
signalling,	 DAG,	 activates	 protein	 kinase	 C	 and	 can	 directly	 activate	 certain	 TRP	 cation	
channels	which	depolarise	the	plasma	membrane	[191].	This	could	explain	how	inhibition	of	
the	protein	kinase	C	variant	PKCzeta,	significantly	attenuated	oleic	acid	(a	LCFA)	induced	GLP-
1	 secretion	 from	GLUTag	cells	 [192].	 Synergistic	 interactions	between	Gq	and	Gs	 signalling	
likely	arise	 from	 integration	of	 the	actions	of	 their	effector	proteins	 resulting	 in	 increased	
exocytotic	 activity.	 Such	 cross-talk	 has	 been	 observed	 before	 for	 example	 in	 cardiac	
fibroblasts	and	mast	cells	[193,194].	Potential	synergistic	effects	of	FFAR1	and	GPBAR-1	co-
activation	 on	 L-cell	 responses	 are	 explored	 in	 this	 chapter	 using	 the	 FFAR1	 and	GPBAR-1	
agonists	TAK-875	and	GPBAR-A.		
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3.4. Results	
	
N.B:	The	secretory	experiments	presented	here	were	carried	out	in	conjunction	with	Deborah	
Goldspink.	 Responses	 are	 quoted	 as	mean	 fold	 changes	 (from	 basal)	 ±	 SEM.	 All	 the	 fold	
changes	 in	 fluorescence	 quoted	 in	 the	 following	 sections	 reflect	median	 values	with	 95%	
confidence	interval	(CI)	in	parentheses.		
	
 Bile	 acids	 and	 FFAR1	 agonists	 elicit	 intracellular	 calcium	 responses	 in	
organoid-derived	L-cells	
Immunofluorescent	 labelling	of	proglucagon	and	GCaMP3	revealed	selective	expression	of	
GCaMP3	 in	 organoid	 cultured	 ileal	 L-cells	 (figure	 2A).	 Organoid-derived	 L-cells	 exhibited	
significant	calcium	responses	(figure	2B&C)	to	application	of	10µM	of	the	bile	acid	TDCA	which	
triggered	a	median	 fold	 increase	of	1.63	 (CI=1.07-2.04)	 in	GCaMP3	fluorescence.	Similarly,	
application	 of	 3µM	 AM-1638	 drove	 a	 1.45	 (CI=1.16-3.01)	 fold	 increase	 in	 GCaMP3	
fluorescence.	All	cells	included	in	the	analysis	responded	to	one	of	the	positive	controls	which	
were	100nM	bombesin	and	30mM	KCl.	100nM	bombesin	and	30mM	KCl	application	triggered	
1.51	 (CI=1.32-1.65)	 and	 1.35	 (CI=1.22-1.55)	 fold	 increases	 in	 GCaMP3	 fluorescence	
respectively.	 The	 0.1%	 DMSO	 vehicle	 control	 triggered	 significant	 changes	 in	 intracellular	
calcium	 levels	 (though	 the	 effect	 was	 minimal)	 resulting	 in	 a	 1.03	 fold	 (CI=1.028-1.136)	
increase	in	overall	GCaMP3	fluorescence.		
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Figure	2:	(A)	Immunohistochemistry	indicates	GCaMP3	expression	is	limited	to	L-cells	in	4	day	
old	ileal	organoids	derived	from	Glu-Cre	x	Rosa26-GCaMP3	mice.	Organoids	were	fixed	in	4%	
PFA	for	1.5	hours.	Following	this	fixed	organoids	were	incubated	overnight	at	4°C	with	primary	
antibodies	to	GFP	(raised	in	goat;	Ab5450;	1:1000)	and	proglucagon	(raised	in	rabbit;	sc13091;	
1:200).	Fluorescent	labelling	of	GCaMP3	and	proglucagon	was	achieved	by	incubation	for	1	
hour	 at	 room	 temperature	 with	 1:300	 of	 goat-raised	 secondary	 antibodies	 conjugated	 to	
AlexaFluor	488	and	555	respectively.	Nuclear	staining	was	achieved	by	a	further	10	minute	
incubation	 with	 1:1300	 Hoescht	 nuclear	 stain.	 (B)	 Representative	 trace	 from	 a	 calcium	
imaging	experiment	on	2D	monolayer	cultured	ileal	organoids	derived	from	Glu-Cre	x	Rosa26-
GCaMP3	 mice.	 (C)	 Summary	 of	 intracellular	 calcium	 responses	 recorded	 to	 0.1%	 DMSO	
(vehicle	control),	10µM	taurodeoxycholic	acid	(TDCA),	3µM	AM-1638,	100nM	bombesin	and	
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30mM	 potassium	 chloride	 (KCl).	 FI/FI0	 plotted	 on	 y-axis	 reflects	 the	 maximum	 measured	
GCaMP3	fluorescence	during	drug	application	divided	by	the	maximum	measured	during	a	30	
second	 period	 prior	 to	 drug	 application	 i.e.	 fold	 change	 in	 fluorescence.	Median	 and	 IQR	
reflected	 by	 central	 line	 and	 whiskers.	 Red	 dotted	 line	 marks	 FI/FI0=1	 i.e.	 no	 change	 in	
fluorescence	from	baseline.	n	=	number	of	cells.	Statistical	significance	assessed	using	Kruskal-
Wallis	 test	 with	 comparisons	made	 to	 the	 0.1%	 DMSO	 control	 group.	 *p<0.05,	 **p<0.01,	
***p<0.001.		
 
 GPBAR-A	potentiates	L-cell	intracellular	calcium	responses	to	TAK-875		
Application	of	10µM	TAK-875	and	3µM	GPBAR-A	 individually	triggered	significant,	 if	small,	
1.12	 (CI=1.03-1.32)	 and	 1.07	 (CI=1.02-1.42)	 fold	 increases	 in	 GCaMP3	 fluorescence	
respectively	(figure	3B).	Following	pre-incubation	with	3µM	GPBAR-A,	co-application	of	10µM	
TAK-875	 with	 3µM	 GPBAR-A	 elicited	 1.33	 (CI=1.26-1.98)	 fold	 increases	 in	 GCaMP3	
fluorescence	(figure	3B).	On	average	these	responses	were	4.91	(CI=1.28-11.81)	fold	higher	
than	the	anticipated	response	in	488	fluorescence	(sum	of	the	steady	state	GPBAR-A	and	1st	
TAK-875	 responses)	 indicating	 that	 GPBAR-A	 potentiated	 L-cell	 intracellular	 calcium	
responses	to	TAK-875	(figure	3C).	Comparison	of	responses	to	the	1st	TAK-875	(before	GPBAR-
A	addition)	and	3rd	TAK-875	(after	GPBAR-A	washout)	applications	did	not	identify	a	significant	
difference	 (p>0.05),	 suggesting	 that	 the	 potentiated	 responses	 seen	 are	 reversible	 upon	
GPBAR-A	washout	(figure	3B).	
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Figure	 3:	 (A)	 Representative	 trace	 from	 a	 calcium	 imaging	 experiment	 on	 2D	 monolayer	
cultured	ileal	organoids	derived	from	Glu-Cre	x	Rosa26-GCaMP3	mice.	Colour	coded	according	
to	drug	application.	(B)	Summary	of	the	L-cell	intracellular	calcium	responses	to	3µM	TAK-875	
and	3µM	GPBAR-A	application	individually	and	simultaneously.	GPBAR-A	steady	state	refers	
to	 the	 maximum	 fold	 change	 in	 fluorescence	 of	 GPBAR-A	 measured	 in	 the	 30	 seconds	
preceding	simultaneous	TAK-875	addition	using	30	seconds	before	GPBAR-A	application	as	
the	baseline.	FI/FI0	plotted	on	y-axis	reflects	the	maximum	measured	GCaMP3	fluorescence	
during	drug	application	divided	by	the	maximum	measured	during	a	30	second	period	prior	to	
drug	application	i.e.	fold	change	in	fluorescence.	Red	dotted	line	marks	FI/FI0=1	i.e.	no	change	
in	fluorescence	from	baseline.	n	=	number	of	cells.	Statistical	significance	assessed	between	
GPBAR-A	 steady	 state	 and	 other	 groups	 assessed	 using	 Kruskal-Wallis	 test.	 #	 indicates	
significant	(p<0.05)	individual	responses	for	each	group	assessed	via	Wilcoxon	test	examining	
deviation	of	median	values	 from	1	 (i.e.	no	change	 in	GCaMP3	 fluorescence).	 (C)	Degree	of	
potentiation	of	responses	to	TAK-875	by	co-application	with	GPBAR-A.	y-axis	reflects	the	ratio	
between	the	maximum	fold	change	in	GCaMP3	fluorescence	during	TAK-875	and	GPBAR-A	co-
application	and	the	anticipated	fold	change	in	fluorescence,	calculated	from	the	sum	of	the	
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GPBAR-A	and	TAK-875	responses	individually.	Median	and	IQR	reflected	by	central	line	and	
whiskers.	Statistics	calculated	using	a	Wilcoxon	test	assessing	deviation	from	1	(no	synergy).	
**p<0.01,	***p<0.001.	
 
 GPBAR-A	potentiates	L-cell	intracellular	calcium	responses	to	KCl	
30mM	KCl	triggered	1.10	(CI=	1.03-1.73)	fold	increases	whilst	3µM	GPBAR-A	triggered	1.11	
(CI=1.02-1.25)	 fold	 increases	 in	GCaMP3	fluorescence	 (figure	4B).	Responses	 to	30mM	KCl	
were	 significantly	 enhanced	 by	 co-application	 with	 3µM	 GPBAR-A	 with	 responses	 1.18	
(CI=1.09-1.96)	fold	above	baseline	reflecting	a	median	potentiation	of	1.47	(CI=0.84-4.39)	fold	
above	the	anticipated	response	(figure	4B&C).	As	with	TAK-875,	no	significant	difference	was	
found	between	responses	elicited	by	30mM	KCl	prior	to	GPBAR-A	application	and	following	
GPBAR-A	washout	(p>0.05;	figure	4B).	
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Figure	 4:	 (A)	 Representative	 trace	 from	 a	 calcium	 imaging	 experiment	 on	 2D	 monolayer	
cultured	ileal	organoids	derived	from	Glu-Cre	x	Rosa26-GCaMP3	mice.	Colour	coded	according	
to	drug	application.	(B)	Summary	of	the	L-cell	 intracellular	calcium	responses	to	30mM	KCl	
and	3µM	GPBAR-A	application	individually	and	simultaneously.	GPBAR-A	steady	state	refers	
to	 the	 maximum	 fold	 change	 in	 fluorescence	 of	 GPBAR-A	 measured	 in	 the	 30	 seconds	
preceding	 simultaneous	 KCl	 addition	 using	 30	 seconds	 before	GPBAR-A	 application	 as	 the	
baseline.	FI/FI0	plotted	on	y-axis	reflects	the	maximum	measured	GCaMP3	fluorescence	during	
drug	application	divided	by	the	maximum	measured	during	a	30	second	period	prior	to	drug	
application	i.e.	fold	change	in	fluorescence.	Red	dotted	line	marks	FI/FI0=1	i.e.	no	change	in	
fluorescence	 from	 baseline.	 n	 =	 number	 of	 cells.	 Statistical	 significance	 assessed	 between	
GPBAR-A	 steady	 state	 and	 other	 groups	 assessed	 using	 Kruskal-Wallis	 test.	 #	 indicates	
significant	(p<0.05)	individual	responses	for	each	group	assessed	via	Wilcoxon	test	examining	
deviation	of	median	values	 from	1	 (i.e.	no	change	 in	GCaMP3	 fluorescence).	 (C)	Degree	of	
potentiation	 of	 responses	 to	 KCl	 by	 co-application	with	 GPBAR-A.	 y-axis	 reflects	 the	 ratio	
between	 the	maximum	 fold	 change	 in	 GCaMP3	 fluorescence	 during	 KCl	 and	GPBAR-A	 co-
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application	and	the	anticipated	fold	change	in	fluorescence,	calculated	from	the	sum	of	the	
GPBAR-A	 and	 KCl	 responses	 individually.	 Median	 and	 IQR	 reflected	 by	 central	 line	 and	
whiskers.	Statistics	calculated	using	a	Wilcoxon	test	assessing	deviation	from	1	(no	synergy).	
*p<0.05,	**p<0.01,	***p<0.001.	
 
 GPBAR-A	potentiates	GLP-1	secretory	responses	to	TAK-875		
10µM	 TDCA	 and	 3µM	 GPBAR-A	 respectively	 triggered	 2.90	 ±	 0.19	 and	 4.82	 ±	 0.32	 fold	
increases	in	GLP-1	secretion	from	2D	monolayer	cultures	of	ileal	organoids	(figure	5A).	The	
positive	control	10µM	forskolin	(Fsk)/IBMX	increased	GLP-1	secretion	by	10.79	±	0.32	fold.	
Only	plates	containing	Fsk/IBMX	responsive	wells	were	included	in	the	final	analysis.		
	
10µM	 TAK-875	 application	 elicited	 1.49	 ±	 0.08	 fold	 increases	 in	 GLP-1	 secretion.	 Co-
application	of	3µM	GPBAR-A	with	10	µM	TAK-875	yielded	a	6.41	±	0.78	fold	increase	in	GLP-
1	 secretion	 reflecting	 a	 mean	 potentiation	 in	 GLP-1	 secretion	 of	 1.58	 ±	 0.17	 fold	 above	
anticipated	additive	GLP-1	secretion	(figure	5B&C).		
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Figure	5:	(A)	GLP-1	secretion	responses	(over	2	hours)	to	10µM	TDCA	(A)	and	3µM	GPBAR-A	
relative	to	the	basal	condition	(saline	buffer	enriched	with	1mM	glucose).	Two-tailed	t-test	run	
to	assess	statistical	deviation	of	means	from	1	(i.e.	basal	GLP-1	secretion).	(B)	Relative	GLP-1	
secretion	 responses	 to	 10µM	 TAK-875	 and	 3µM	 GPBAR-A	 applied	 with	 10µM	 TAK-875.	
Statistical	significance	assessed	on	log	transformed	values.	Two-tailed	t-test	used	to	assess	
deviations	in	individual	group	means	from	1	(no	change	in	secretion).	Intergroup	comparisons	
made	 using	 a	 one-way	 ANOVA	 test	 with	 Dunnett’s	 correction.	 10µM	 forskolin	 (fsk)/IBMX	
acted	as	a	positive	 control	 for	GLP-1	 secretion.	 (C)	Potentiation	of	 TAK-875	 induced	GLP-1	
secretion	by	GPBAR-A.	Values	plotted	derive	from	percentage	of	GLP-1	secretion	measured	
from	 the	 combined	 TAK-875/GPBAR-A	 condition	 divided	 by	 that	 anticipated	 from	 the	
individual	GLP-1	secretory	responses	to	TAK-875	and	GPBAR-A.	A	two-tailed	t-test	was	used	
to	assess	deviation	from	1	(no	potentiation).	**p<0.01,	***p<0.001,	#p<0.05.	n=number	of	
wells.	 Bars	 represent	 mean	 ±	 SEM.	 Red	 dotted	 line	 marks	 y=1.	 Secretions	 performed	 in	
conjunction	with	Deborah	Goldspink.	
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3.5. Discussion	
 Organoid	L-cells	replicate	native	L-cell	physiology	
The	 intracellular	calcium	and	GLP-1	secretory	 responses	 from	2D	small	 intestinal	organoid	
cultures	to	TDCA	and	GPBAR-A	application	are	consistent	with	previous	findings	by	Brighton	
et	al.	using	primary	cultures	[126].	Petersen	et	al.	also	found	that	small	intestinal	organoids	
resuspended	in	test	solutions	(i.e.	3D	structure	maintained)	display	similar	GLP-1	secretory	
responses	to	glucose	and	SCFAs	as	L-cells	in	primary	culture	[195].		Furthermore,	Zietek	et	al.	
(2015)	 used	 small	 intestinal	 organoids	 to	 examine	 GLP-1	 secretory	 responses	 to	 applied	
glucose	and	the	dipeptide	gly-sar.	Small	intestinal	organoids	developed	from	Sglt1	and	Pept1	
knockout	 mice	 exhibited	 impaired	 GLP-1	 secretory	 responses	 to	 glucose	 and	 gly-sar	
respectively.	The	Sglt1	and	Pept1	knockout	organoids	also	demonstrated	impaired	epithelial	
transport	 of	 radiolabelled	 glucose	 and	 gly-sar	 respectively	 [196].	 Therefore	 L-cells	 from	
organoid	culture	appear	to	recapitulate	intracellular	calcium	and	GLP-1	secretory	responses	
as	well	as	epithelial	nutrient	transport	mechanisms	found	in	primary	cultures	and	likely,	by	
extension,	L-cells	in	vivo.		
	
 GPBAR1	and	FFAR1	stimulation	triggers	L-cell	intracellular	Ca2+	and	GLP-
1	secretory	responses	
The	small,	but	significant,	intracellular	calcium	transients	seen	following	GPBAR-A	application	
could	result	from	coupling	of	GPBAR-1	to	Gq	activation,	even	though	GPBAR-1	is	not	classically	
coupled	to	Gq.		GPBAR-A	induced	calcium	transients	could	also	reflect	indirect	signalling	of	
GPBAR-A	via	other	cells	(since	organoid	cultures	contain	a	mixture	of	epithelial	cells)	releasing	
paracrine	 signals	 that	 trigger	 elevate	 intracellular	 calcium	 levels	 in	 neighbouring	 L-cells.	
Alternatively,	the	GPBAR-A	induced	intracellular	calcium	transients	observed	here	(figure	4B)	
may	 reflect	 incomplete	 washout	 of	 TAK-875/KCl	 prior	 to	 GPBAR-A	 application.	 Further	
intracellular	calcium	experiments	employing	longer	washout	periods	or	application	of	GPBAR-
A	prior	to	addition	of	TAK-875/KCl	would	help	explore	this	possibility.		
	
Physiologically,	bile	acids	may	also	signal	through	GPBAR-1	independent	mechanisms	since	
TDCA	appears	to	elicit	 larger	intracellular	calcium	responses	than	GPBAR-A	in	L-cells	[126].	
This	 raises	 the	possibility	 that	 a	 component	of	bile	 acid	 stimulated	GLP-1	 secretion	might	
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occur	independently	of	GPBAR-1	signalling.	However,	Brighton	et	al.	(2015)	found	that	bile	
acid	 triggered	GLP-1	 secretion	was	 abolished	 in	Gpbar1	knockout	mice	 implying	GPBAR-1	
signalling	as	essential	to	GLP-1	responses	to	bile	acids.	Thus,	it	is	unlikely	that	any	potential	
GPBAR-1	 independent	 bile	 sensing	mechanism	 triggers	GLP-1	 secretion	 in	 the	 absence	 of	
functional	GPBAR-1.	Alternatively,	the	larger	intracellular	calcium	transients	elicited	by	TDCA	
compared	to	GPBAR-A	application	may	reflect	modulation	of	GPBAR-1	signalling	by	GPBAR-1	
independent	 bile	 sensing	 mechanisms.	 Brighton	 et	 al.	 have	 ruled	 out,	 through	
pharmacological	manipulation,	 contribution	of	 farnesoid	X	 receptor	 (the	other	known	bile	
acid	 receptor	 expressed	 in	 L-cells)	 and	 the	 electrogenic	 effects	 of	 apical	 sodium-bile	 acid	
transporter	(ASBT)	to	the	intracellular	calcium	responses	to	bile	acids	[126].	
	
We	found	that	generally	AM-1638	triggered	larger	intracellular	calcium	and	GLP-1	secretory	
responses	than	TAK-875	reflecting	the	results	of	previous	studies	[173,197,198].	The	weak	
ability	of	TAK-875	to	induce	calcium	transients	could	in	part	relate	to	the	low	concentration	
of	glucose	(1mM)	used	in	the	saline	buffer	since	Sakuma	et	al.	(2016)	highlighted	that	TAK-
875	applied	to	MIN6	cells	(a	cell	line	model	of	beta	cells)	elicited	weak	intracellular	calcium	
responses	 in	 1mM	 glucose	 but	 strong	 responses	 in	 the	 presence	 of	 3mM	 glucose	 [197].	
Sakuma	et	al.	attribute	the	basis	of	this	dependency	on	glucose-dependent	closure	of	KATP	
channels	 studding	 the	 plasma	membrane.	 This	 has	 the	 effect	 of	 depolarising	 the	 plasma	
membrane	 and	 activating	 voltage	 gated	 calcium	 channels.	 L-cells	 are	 known	 to	 express	
functional	KATP	channels	and	tolbutamide,	a	sulfonylurea	drug	which	blocks	KATP,	triggers	GLP-
1	secretion	from	primary	cultured	small	 intestinal	L-cells	[59].	However,	the	importance	of	
KATP-channels	to	L-cell	responses	to	glucose	appears	to	be	minor	[148].	
	
 Co-activation	of	GPBAR-1	and	FFAR1	potentiates	L-cell	intracellular	Ca2+	
and	GLP-1	responses	
Co-application	of	GPBAR-A	 (activating	GPBAR-1)	 and	 TAK-875	 (activating	 FFAR1)	 triggered	
significantly	 greater	 than	 anticipated	 intracellular	 calcium	 and	GLP-1	 secretory	 responses.	
These	findings	imply	that	simultaneous	activation	of	the	Gs	and	Gq	signalling	pathways	has	
synergistic	effects	on	GLP-1	secretion	as	previously	suggested	by	Ekberg	et	al.	[160].	Using	
different	agonists	of	GPBAR-1	and	FFAR1,	Hauge	et	al.	have	replicated	our	findings	regarding	
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potentiation	 of	 GLP-1	 secretion	 from	 small	 intestinal	 cultures	 and	 extended	 our	 findings	
through	 in	 vivo	 studies	with	 oral	 administration	 of	 GPBAR-1	 and	 FFAR1	 agonists	 to	mice.	
These	agonists	all	elevated	plasma	levels	of	GLP-1	and	when	co-administered	resulting	plasma	
levels	of	GLP-1	exceeded	anticipated	levels	demonstrating	potentiation	in	vivo	[199].	These	
results	 indicate	that	pharmacological	exploitation	of	synergy	between	GPBAR-1	and	FFAR1	
signalling	could	have	therapeutic	benefits.	More	recent	in	vivo	work	on	mice	by	Briere	et	al.	
(2018)	 further	 highlights	 the	 clinical	 potential	 of	 combination	 therapy.	 In	 this	 study,	 co-
administration	of	a	SSTR5	antagonist	(inhibiting	SSTR5	mediated	Gi	signalling)	together	with	
GPBAR-1	and	FFAR1	agonists	(stimulating	Gs	and	Gq	signalling)	and	a	DPP-4	inhibitor	enhanced	
GLP-1	 release.	 These	 findings	 suggest	 that	 the	 synergy	 between	 GPBAR-1	 and	 FFAR1	
activation	 might	 be	 further	 enhanced	 by	 suppression	 of	 Gi-signalling	 (which	 is	 likely	 to	
increase	intracellular	cAMP	levels	further).	The	combinational	therapy	was	associated	with	
improved	glucose	tolerance	in	Leprdb/db	mice	(diabetic	mouse	model)	beyond	that	seen	with	
monotherapy	(i.e.	each	drug	administered	in	isolation)	[200].			
	
Curiously,	 L-cells	 from	 Gpbar1	 knockout	 mice	 exhibit	 attenuated	 intracellular	 calcium	
responses	 to	KCl	application	 raising	 the	possibility	 that	GPBAR-1	can	enhance	 intracellular	
calcium	 responses	 by	 raising	 intracellular	 cAMP	 levels	 in	 the	 absence	 of	 bile	 acids	
(unpublished	 data	 by	 Cheryl	 Brighton).	 GPBAR-1	 may	 possess	 constitutive	 Gs-signalling	
activity	or	endogenous	agonists	other	than	bile	acids.	Given	the	synergy	observed	between	
the	GPBAR-1	and	FFAR1	signalling	pathways,	GLP-1	responses	to	FFAs	might	be	influenced	by	
basal	activity	of	GPBAR-1.	This	could	be	investigated	by	examining	L-cell	intracellular	calcium	
and	GLP-1	secretory	responses	to	FFAR1	activation	in	Gpbar1	knockout	mice.	
	
The	synergistic	effects	mediated	by	co-activation	of	the	Gs	and	Gq	signalling	pathways	implies	
signalling	crosstalk	exists	which	enhances	exocytosis	of	GLP-1	containing	vesicles.	The	precise	
molecular	basis	of	this	crosstalk	is	unclear.	Transcriptomics	and	further	electrophysiological	
examination	 of	 ileal	 L-cells	 (in	 organoid	 culture)	 suggests	 that	 the	 non-selective	 cation	
channel	TRPC3	and	voltage	gated	calcium	channels	are	 involved	[201].	Transcripts	 for	P/Q	
calcium	channel	subunit	such	as	Cacna1a	predominate	the	calcium	channel	profiles	in	both	
ileal	and	colonic	 L-cells	 (highest	 in	 ileal	 L-cells).	Transcripts	encoding	L	and	T-type	calcium	
channel	subunits	were	also	present	but	at	lower	levels.	Consistent	with	this	profile,	in	voltage	
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clamp	studies	of	ileal	L-cells,	the	P-type	calcium	channel	blocker	ω-agatoxin	IVA	blocked	most	
measured	Ca2+	 currents	whereas	 the	L-type	calcium	channel	blocker	 isradipine	had	only	a	
marginal	effect.	However,	GPBAR-A	induced	inward	calcium	currents	(~20%	increase)	which	
were	 blocked	 by	 the	 L-type	 calcium	 channel	 blocker	 nifedipine	 implying	 L-type	 calcium	
channel	 modulation	 by	 GPBAR-A.	 This	 likely	 reflects	 downstream	 PKA	 activity	 as	
phosphorylation	by	PKA	is	known	to	increase	the	activity	of	L-type	calcium	channels	[202].		
Supporting	 this	 hypothesis,	 application	 of	 H-89	 (a	 PKA	 inhibitor)	 to	 ileal	 crypt	 cultures	
significantly	attenuated	GPBAR-A	dependent	GLP-1	secretion.	Concerning	FFAR1	signalling,	
pharmacological	 blockade	 of	 TRPC3	 using	 pyr3	 significantly	 attenuated	 TAK-875	 induced	
inward	 currents	 and	 GLP-1	 secretion	 from	 primary	 ileal	 crypt	 cultures	 [201].	 Further	
experiments	examining	the	effects	of	the	membrane	permeable	TRPC3	activator	1-oleoyl-2-
acetyl-sn-glycerol	 (OAG),	 pyr3	and	H-89	on	GLP-1	 secretion	and	 L-cell	 electrophysiological	
responses	would	allow	the	potential	roles	of	TRPC3	and	PKA	in	mediating	synergy	between	
FFAR1	and	GPBAR-1	to	be	assessed.	
	
Goldspink	et	al.	(2018)	suggest	these	results	indicate	that	co-agonism	of	FFAR1	and	GPBAR-1	
drives	 increased	L-type	voltage	gated	calcium	channel	activity	through	activation	of	TRPC3	
and	PKA-mediated	phosphorylation.	In	turn,	this	leads	to	calcium	influx	and	exocytosis	of	GLP-
1	containing	vesicles	(the	proposed	molecular	mechanism	is	illustrated	in	figure	6).	GPBAR-A	
potentiation	of	 the	 intracellular	 calcium	 responses	 to	30mM	KCl	 application	may	 similarly	
reflect	 GPBAR-A	 mediated	 modulation	 of	 L-type	 calcium	 channel	 kinetics.	 However,	 the	
proposed	mechanism	(figure	6)	is	questioned	by	evidence	that	co-application	of	the	L-type	
calcium	channel	activator	Bayk8644	with	TAK-875	did	not	trigger	synergy	in	GLP-1	secretion	
[201].	 Whilst	 Bayk8644	 is	 known	 to	 have	 off-target	 effects	 on	 voltage-gated	 potassium	
channels,	 these	 results	 could	 reflect	 alternative	 cross-talk	 mechanisms	 downstream	 of	
GPBAR-1	and	FFAR1	activation	[203].		
	
Alternative	 cAMP-dependent	 signalling	 mechanisms	 potentially	 involved	 include	 PKA	
modulation	 of	 the	 activities	 of	 SNARE	 proteins	 involved	 in	 vesicle	 docking,	 priming	 and	
exocytosis.	Such	mechanisms	are	known	to	promote	neurotransmission	and	possibly	renin	
secretion	from	juxtaglomerular	cells	[204,205].	PKA-independent	mechanisms	are	also	likely	
involved	 since	H-89	application	does	not	 completely	 abolish	GLP-1	 responses	 to	GPBAR-A	
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[201].	cAMP	is	also	known	to	directly	modulate	the	activities	of	hyperpolarisation-activated	
cyclic	 nucleotide-gated	 (HCN)	 channels.	 However,	 whilst	 cAMP	 appeared	 to	 activate	
hyperpolarisation	 currents	 in	 GLUTags,	 no	 such	 currents	 were	 observed	 in	 ileal	 L-cells	
following	GPBAR-A	addition,	 implying	these	channels	are	not	 involved	in	GPBAR-1	induced	
GLP-1	secretion	[201,206].		
	
Another	 possibility	 is	 that	 the	 PKA-independent	 effects	 of	 GPBAR-1	 activation	 observed	
involve	 the	 cAMP	effector	 EPAC2.	 EPAC2	 function	has	 been	 examined	 in	 pancreatic	 islets	
through	 knockdown	 of	 Rapgef4	 (the	 gene	 encoding	 EPAC2).	 Interestingly,	 these	 studies	
indicate	 that	a	significant	component	of	GLP-1	 induced	potentiation	of	glucose-stimulated	
insulin	 secretion	 depends	 on	 EPAC2	 activity	 (PKA	 involvement	 was	 also	 identified).	
Furthermore,	 islet	 knockdown	 of	 Rapgef4	 blunted	 potentiation	 of	 insulin	 secretion	 by	
combined	application	of	8-Br-cAMP	(a	stable	cAMP	analogue)	with	carbachol	(which	activates	
Gq-coupled	muscarinic	receptors)	or	with	high	 levels	of	external	K+.	Contrastingly,	Rapgef4	
knockdown	did	not	attenuate	responses	to	carbachol	or	high	K+	applied	 individually	[207].	
These	 results	 suggest	 that	 EPAC2	 (together	 with	 PKA)	 is	 involved	 in	 mediating	 synergy	
between	Gq	and	Gs	signalling	pathways	in	pancreatic	beta-cells.	One	can	therefore	postulate	
that	EPAC2	may	perform	an	analogous	role	in	L-cells,	mediating	synergy	between	GPBAR-1	
and	 FFAR1	 signalling.	 This	 hypothesis	 is	 questioned	by	 investigations	 by	 Islam	et	 al.	 since	
application	of	the	EPAC	activator	EPAC-selective	cAMP	analogue	(ESCA)	did	not	trigger	GLP-1	
secretion	from	GLUTag	cells.	It	should	be	noted	though	that	ESCA	was	found	to	increase	GLP-
1	production	in	GLUTag	cells	implying	that	whilst	EPAC	may	not	mediate	GLP-1	secretion	from	
L-cells	directly	it	might	modulate	the	magnitude	of	GLP-1	secretory	responses	[208].	Targeted	
knockout	of	Rapgef4	using	CRISPR-Cas9	techniques	in	intestinal	organoids	would	allow	the	
potential	 involvement	 of	 EPAC2	 in	 synergistic	 interactions	 between	 GPBAR-1	 and	 FFAR1	
signalling	to	be	assessed	and	could	be	carried	out	with	human-derived	organoids	[209,210].	
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Figure	6:	Schematic	illustrating	downstream	signalling	mechanisms	of	FFAR1	and	GPBAR-1.	
Agonists/activators	indicated	in	green	text.	Dashed	arrow	indicates	possible	Gq	activation	by	
GPBAR-1.	Inhibitors	indicated	in	red	text.	Waveform	drawn	represents	action	potential	firing.	
Exocytosis	of	GLP-1	(represented	by	red	squares)	is	triggered	downstream	of	the	illustrated	
signalling	mechanisms.		
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3.6. Concluding	remarks	
Small	 intestinal	 organoids	 provide	 a	 physiologically	 relevant	 platform	 to	 investigate	 L-cell	
physiology	 as	 evidenced	 here	 by	 observed	 intracellular	 calcium	 and	 GLP-1	 responses	 to	
known	GLP-1	secretagogues.	Using	this	platform,	synergistic	effects	of	GPBAR-1	and	FFAR1	
co-activation	 on	 both	 intracellular	 calcium	 responses	 and	GLP-1	 secretion	were	 identified	
confirming	the	primary	hypothesis	of	this	chapter.	Such	synergy	likely	occurs	physiologically	
as	 bile	 acids	 and	 FFAs	 arrive	 in	 the	 small	 intestinal	 lumen	 concomitantly.	 Further	
electrophysiological	 probing	 of	 the	 molecular	 mechanisms	 underlying	 this	 synergy	 imply	
involvement	of	TRPC3	activation	downstream	of	FFAR1	and	PKA	downstream	of	GPBAR-1.	
There	also	appears	to	be	PKA-independent	components	of	GPBAR-1	signalling	involved	that	
could	include	EPAC2	activity.	Further	experiments	utilising	pharmacological	agents,	genetic	
modification	and	electrophysiological	techniques	will	help	illuminate	the	precise	molecular	
basis	 of	 downstream	 cross-talk	 between	 the	 GPBAR-1	 and	 FFAR1	 signalling	 pathways.	
Exploitation	of	GPBAR-1/FFAR1	synergy	through	combination	therapy	or	administration	of	a	
dual	agonist	may	yield	novel	therapeutic	treatments	of	type	2	diabetics.	
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 Chapter	4.	Characterisation	of	INSL5-producing	cells	
	
4.1. Introduction	
INSL5-producing	 cells	 comprise	 roughly	 half	 of	 the	 colonic	 L-cell	 population.	 It	 has	 not	
previously	been	established	whether	these	cells	express	a	similar	or	different	repertoire	of	
GPCRs	 to	 non-INSL5	 producing	 colonic	 L-cells.	 Attempts	 to	 measure	 INSL5	 secretory	
responses	have	previously	been	hampered	by	a	 lack	of	 reliable	quantification	assays	 [88].	
Physiologically,	 INSL5	 has	 been	 implicated	 in	 regulation	 of	 appetite,	 hepatic	 glucose	
production	and	insulin	secretion	[88,90,91].	Regarding	appetite	regulation,	INSL5	is	believed	
to	have	an	orexigenic	effect,	contrasting	with	the	anorexigenic	effects	of	the	canonical	L-cell	
hormones	GLP-1	and	PYY	[88,211,212].	In	this	chapter,	novel	murine	transgenic	models	were	
used	 to	 interrogate	 the	 expression	 profile	 of	 INSL5	 cells	 and	 the	 hypothesis	 that	 GLP-1	
secretagogues	can	trigger	intracellular	Ca2+	responses	in	INSL5	cells.	Employment	of	LC/MS	
allowed	 quantification	 of	 INSL5	 secretory	 responses	 and	 also	 enabled	 simultaneous	
quantification	 of	 other	 peptide	 molecules	 including	 GLP-1	 and	 PYY.	 This	 allowed	 the	
hypothesis	 that	 INSL5	 is	 co-secreted	 with	 GLP-1	 and	 PYY	 in	 response	 to	 applied	 GLP-1	
secretagogues	to	be	tested.	Finally,	using	3D	structured	illumination	microscopy	(3D-SIM)	to	
examine	 immunofluoresecently	 labelled	 crypt	 cultures	 and	 tissue	 sections,	 the	hypothesis	
that	INSL5,	GLP-1	and	PYY	are	stored	in	separate	secretory	vesicle	pools	was	explored.		
	
4.2. Aims:	
1. To	 validate	 the	 novel	 INSL5	mouse	models	 Insl5-rtTA/TET-GFP	 and	 Insl5-rtTA/TET-	
GCaMP6FΔCMV	
2. To	compare	the	GPCR	repertoire	of	canonical	L-cells	with	that	of	INSL5	cells	
3. To	 examine	 intracellular	 Ca2+	 and	 INSL5	 secretory	 responses	 to	 known	 GLP-1	
secretagogues	
4. To	compare	the	secretory	response	profiles	of	INSL5,	GLP-1	and	PYY	
5. To	 examine	 whether	 INSL5,	 GLP-1	 and	 PYY	 are	 stored	 separately	 or	 together	 in	
secretory	vesicles		
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4.3. Background	
 Physiological	stimuli	of	colonic	L-cells:			
Secretion	of	GLP-1	and	PYY	by	L-cells	is	triggered	by	a	diverse	range	of	physiological	stimuli	as	
detailed	previously	in	chapter	1.	The	following	sections	provide	background	on	a	subset	of	
known	 colonic	 GLP-1	 secretagogues	 that	were	 utilised	 to	 examine	 INSL5	 cell	 intracellular	
calcium	and	secretory	responses:	
	
Angiotensin	II	
	
The	renin-angiotensin	system	performs	a	critical	role	in	osmoregulation	and	blood	pressure	
maintenance.	When	blood	volume	drops	(e.g.	due	to	dehydration)	renal	blood	flow	also	drops	
leading	to	a	decrease	in	blood	pressure	in	the	arterioles	supplying	the	renal	glomeruli.	This	in	
turn	 triggers	 mechanosensitive	 juxtaglomerular	 cells	 in	 the	 arteriole	 walls	 to	 release	 the	
enzyme	renin	into	the	bloodstream.	Renin	catalyses	the	cleavage	of	the	circulating	precursor	
angiotensinogen	into	angiotensin	I.	This	is	subsequently	processed	by	angiotensin	converting	
enzymes	(ACE)	when	passing	through	the	lung	circulation	to	angiotensin	II.	Angiotensin	II	acts	
to	sustain	adequate	blood	pressure	by	directly	acting	on	vascular	smooth	muscle	narrowing	
blood	vessel	 lumens	through	vasoconstriction,	stimulating	sodium	reabsorption	from	renal	
nephrons	and	triggering	the	release	of	other	osmoregulatory	hormones	including	AVP	and	
aldosterone	[213,214].	
	
In	the	context	of	the	gastrointestinal	tract,	angiotensin	II	strongly	stimulates	GLP-1	and	PYY	
secretion	 when	 applied	 to	 both	 murine	 and	 human	 colonic	 crypt	 cultures.	 Agtr1a,	 a	 Gq-
coupled	GPCR,	appears	to	be	the	key	angiotensin	receptor	variant	involved	in	colonic	L-cell	
responses	as	the	specific	Agtr1	blocker	candesartan	significantly	attenuates	GLP-1	and	PYY	
secretion.	Accordingly,	expression	of	Agtr1a	is	significantly	enriched	in	FACS-isolated	colonic	
L-cells	compared	with	the	control	cell	group	with	low	expression	(100-fold	lower)	found	in	
small	 intestinal	 L-cells	 implying	 Agtr1a	 is	 specifically	 enriched	 in	 colonic	 L-cells.	 Such	
localisation	to	the	large	intestine	may	reflect	a	suggested	role	in	reducing	net	fluid	secretion	
into	the	colonic	lumen	via	paracrine	action	of	released	PYY	[73].	
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Arginine	vasopressin	(AVP)	
	
Arginine	vasopressin	(AVP;	also	known	as	anti-diuretic	hormone)	is	produced	and	secreted	
directly	into	the	systemic	circulation	by	neurosecretory	cells	of	the	hypothalamus	in	response	
to	 a	 drop	 in	 blood	 pressure	 and/or	 hyperosmolarity.	 AVP	 counteracts	 these	 homeostatic	
perturbations	 by	 increasing	water	 reabsorption	 from	 the	 kidneys	 and	 by	 vasoconstriction	
[215].		
	
In	 the	 same	 vein	 as	 angiotensin	 II,	 AVP	 appears	 to	 reduce	 net	water	 loss	 from	 the	 distal	
gastrointestinal	tract	via	stimulation	of	PYY	secretion.	In	vitro,	AVP	stimulated	GLP-1	and	PYY	
secretion	 from	murine	and	human	colonic	crypt	cultures	 inhibited	by	the	Avpr1b	 inhibitor	
SSR.	 Avpr1b	 expression	 is	 particularly	 enriched	 in	 colonic	 L-cells	 compared	 with	 small	
intestinal	 L-cells.	Avpr1b	 is	 a	 GPCR	which	 couples	 both	 to	 Gq	 and	Gs.	 This	 is	 reflected	 by	
observed	 L-cell	 elevations	 in	 intracellular	 Ca2+	 and	 cAMP	 levels	 upon	 AVP	 application.	 In	
healthy	human	participants,	serum	levels	of	copeptin	(a	stable	equimolar	biproduct	of	AVP	
production)	 and	 PYY	 levels	 were	 found	 to	 be	 positively	 correlated	 potentially	 suggesting	
human	physiological	relevance	to	the	hypothesis	that	AVP	reduces	colonic	water	loss	through	
paracrine	PYY	action	[74].	
	
Short	chain	fatty	acids	(SCFAs)	
	
SCFAs	are	products	of	bacterial	fermentation	which	occurs	in	the	colon.	The	most	abundantly	
produced	SCFAs	are	acetate,	butyrate	and	proprionate	with	concentrations	which	can	exceed	
100mM	in	the	colon	and	acetate	being	the	most	dominant.	Acetate’s	predominance	 likely	
arises	due	to	acetate	producing	pathways	present	in	the	majority	of	bacterial	groups	whilst	
butyrate	and	proprionate	production	are	restricted	to	fewer	groups	[216].	
	
Regarding	L-cells,	SCFAs	and	specific	agonists	of	the	SCFA	receptors	FFAR2	and	FFAR3	trigger	
GLP-1	secretion	from	murine	crypt	cultures	[75,217].	FFAR2	is	a	Gq	coupled	whilst	FFAR3	is	Gi	
coupled	GPCR.	Tolhurst	et	al.	(2012)	found	that	both	Ffar2	and	FFar3	are	enriched	in	L-cells	
and	that	knockout	mice	for	Ffar2	and	Ffar3	both	exhibited	attenuated	GLP-1	responses	to	
SCFAs	with	Ffar2	knockout	having	the	larger	effect.	Pre-treatment	with	pertussis	toxin	(which	
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blocks	the	Gi)	pathway	did	not	attenuate	responses	to	proprionate	implying	that	FFAR3	can	
couple	to	other	downstream	signalling	pathways	triggering	GLP-1	secretion	or	perhaps	that	
the	Ffar3	knockout	had	downregulatory	effects	on	Ffar2	[75].	
	
MCFA/LCFAs	
	
As	 previously	 discussed,	MCFA/LCFAs	 trigger	GLP-1	 secretion	 from	 colonic	 L-cells	 through	
activation	of	FFAR1.	In	this	chapter,	the	FFAR1	full	agonist	AM-1638	was	applied	in	secretion	
and	intracellular	calcium	assays	to	assess	the	function	of	FFAR1	in	INSL5	cell	responses	[173].		
	
Bile	acids	
	
Chapter	 3	 explored	 the	 synergistic	 effects	 of	 GPBAR-1	 and	 FFAR1	 coactivation	 on	 small	
intestinal	GLP-1	secretion.	Previous	studies	have	found	that	GPBAR-1	agonists	also	act	as	GLP-
1	secretagogues	in	the	colon	[126].	In	the	setting	of	the	distal	intestine,	whilst	the	levels	of	
luminal	bile	acids	are	lower	than	in	the	small	intestine	due	to	reabsorption,	some	primary	bile	
acids	are	likely	present	together	with	secondary	bile	acids	such	as	lithocholic	acid	produced	
from	modifications	made	by	bacterial	metabolism.	These	modifications	are	an	example	of	
symbiosis	between	bacteria	and	the	host	as	the	secondary	bile	acids	are	highly	hydrophobic	
and	easily	pass	across	the	colonic	epithelium	reducing	loss	of	bile	acids	in	faeces	to	about	1-
3%	of	the	total	secreted	[218].	Secondary	bile	acids	also	have	higher	potency	at	GPBAR-1	than	
primary	 bile	 acids	 [219].	 Here	 we	 explore	 whether	 GPBAR-1	 activation	 by	 GPBAR-A	 also	
triggers	INSL5	secretion	from	colonic	L-cells.		
	
Gastrin	releasing	peptide	(GRP)	and	Neuromedin	B	(NMB)	
	
GRP	and	NMB	are	neuropeptides	related	to	the	peptide	bombesin	isolated	from	the	skin	of	
the	Bombina	bombina.	Whilst	NMB	 is	 largely	produced	by	neurons	of	 the	central	nervous	
system,	GRP	is	the	predominant	bombesin-like	peptide	produced	by	neurons	innervating	the	
small	and	large	intestine.	GRP	receptor	(GRPR)	also	known	as	BB2R	is	activated	by	both	GRP	
and	NMB	but	GRP	is	more	potent	an	agonist	[220].	This	receptor	 is	enriched	in	L-cells	and	
likely	underlies	GLP-1	responses	seen	to	bombesin	administration	from	both	murine	small	
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intestinal	cultures	and	perfused	tissue	[221].	This	GLP-1	secretion	could	underlie	the	anorectic	
effect	of	intraperitoneal	administration	of	bombesin-like	peptides	including	GRP	in	rats	which	
are	blocked	by	previous	intraperitoneal	injections	of	BB2R	antagonists	such	as	BW2258U89	
[222,223].	Whilst	bombesin	is	also	known	to	trigger	both	intracellular	calcium	responses	and	
GLP-1	secretion	in	colonic	L-cells	 its	effect	on	INSL5-producing	cells	specifically	are	unclear	
[59].			
	
 Vesicular	localisation	of	GLP-1	and	PYY	
Early	attempts	to	examine	GLP-1	and	PYY	relative	localisation	within	L-cells	using	immunogold	
labelling	 and	 electron	microscopy	 suggested	 co-storage	 between	 the	 two	 peptides	 [224].	
Habib	et	al.	also	found	overlap	between	the	GLP-1	and	PYY	vesicle	pool	in	human	colonic	crypt	
cultures	 using	 confocal	 microscopy	 [70].	 However,	 the	 resolving	 power	 of	 confocal	
microscopy	is	limited	around	the	diffraction	limit	of	200nm.	This	means	that	if	the	GLP-1	and	
PYY	vesicles	were	smaller	than	this	then	it	would	be	difficult	to	differentiate	close	together	
but	 separate	 vesicles	 of	 GLP-1	 and	 PYY	 from	 vesicles	 dual	 labelled	 for	 GLP-1	 and	 PYY	
[225,226].	
	
Subsequent	application	of	3D	structured	illumination	microscopy	(3D-SIM)	imaging	by	Cho	et	
al.	overcame	 this	diffraction	 limit	 yielding	 roughly	double	 the	 resolving	power	of	 confocal	
microscopy	[87,225].	In	this	study,	immunofluorescently	labelled	tissue	from	mouse,	rat,	pig	
and	human	intestine	GLP-1	and	PYY	were	imaged.	Images	were	thresholded	across	each	3D	
stack	by	the	brightest	background	(identified	manually)	 in	each	channel	 (corresponding	to	
GLP-1	and	PYY	labelling).	GLP-1	and	PYY	vesicles	were	subsequently	detected	and	rendered	
in	3D	based	on	fluorescence	intensity	in	each	channel	(background	subtraction	was	applied	
manually)	using	the	‘create	surfaces’	function	on	the	software	package	Imaris.	The	‘surface-
surface	colocalisation’	function	was	then	applied	to	render	regions	of	overlap	between	the	
detected	GLP-1	and	PYY	vesicles	in	3D.	Following	this	the	total	volume	of	space	occupied	by	
detected	GLP-1	and	PYY	vesicles	and	by	identified	regions	of	overlap	were	computed	as	the	
sum	of	the	individual	voxels	occupied	by	each.	By	using	these	values,	the	degree	of	overlap	
between	detected	GLP-1	and	PYY	vesicles	was	calculated	as	a	percentage	of	total	volume	(i.e.	
of	all	identified	vesicles).	Using	this	methodology,	henceforth	dubbed	the	‘surfaces	method’,	
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Cho	et	al.	found	that	the	majority	of	GLP-1	and	PYY	was	stored	separately	in	all	the	samples	
examined	with,	for	example,	only	~8%	overlap	in	the	murine	colon	[87].	The	GLP-1	and	PYY	
vesicles	in	human	L-cells	were	found	to	be	160-170nm	in	diameter	(using	the	spot	detection	
method	in	Imaris),	below	the	resolving	power	of	confocal	microscopy	but	within	the	range	of	
3D-SIM.	Mouse	GLP-1	and	PYY	vesicles	were	about	10nm	smaller.	Fothergill	et	al.	have	built	
on	these	results,	using	similar	methods	to	those	of	Cho	et	al.	to	examine	5-HT,	secretin,	CCK,	
ghrelin,	CgA	and	GLP-1	co-localisation	in	the	murine	small	intestine	and	found	separation	of	
each	 into	different	 vesicle	populations	 [227].	 These	 results	 raise	 the	possibility	 that	 INSL5	
could	be	stored	 in	a	separate	pool	of	vesicles	 from	PYY	and	GLP-1	which	are	differentially	
regulated	and	respond	to	different	stimuli.	Since	GLP-1	and	PYY	are	anorexigenic	and	INSL5	is	
orexigenic	such	differential	regulation	could	have	physiological	significance.		
	 78	
4.4. Results		
N.B:	FACS	isolation	of	INSL5	cells	was	conducted	by	staff	at	the	CIMR	Flow	Cytometry	Core.	
The	 secretion	 assays	 detailed	 here	were	 conducted	 and	 analysed	 by	 Pierre	 Larraufie	 (see	
methods	for	details	of	the	secretion	assay	and	LC-MS/MS	analysis).	Analysis	and	identification	
of	INSL5,	PYY	and	GLP-1	vesicles	based	on	3D	Gaussian	fitting	was	carried	out	by	Christopher	
Smith.		
		
 Induction	of	specific	GFP/GCaMP6F	expression	within	INSL5-producing	
cells	
Fixed	tissue	sections	from	Insl5-rtTA/TET-GFP	mice	(orally	induced	with	3mg/ml	doxycycline	
over	5-7	days)	and	crypt	cultures	generated	from	Insl5-rtTA/TET-	GCaMP6FΔCMV	reporter	
mice	(incubated	overnight	with	2µg/ml	doxycycline)	were	immunofluorescently	labelled	for	
GFP	(GCaMP6F	is	a	chimeric	protein	with	GFP	domains)	and	INSL5	(figure	1A&C).	Confocal	
imaging	of	these	samples	and	subsequent	cell	counting	revealed	that	167	of	the	232	INSL5-
positive	cells	counted	co-stained	with	GFP,	indicating	an	average	in	vivo	induction	rate	of	72%	
(figure	1B).	Similarly,	205	out	of	233	labelled	INSL5	cells	from	crypt	cultures	co-labelled	for	
GCaMP6F,	indicating	an	induction	rate	of	88%	(figure	1D).	Off-target	labelling	was	minimal	in	
examined	crypt	cultures	and	tissue	sections	with	average	rates	of	2.3%	and	1.4%	respectively	
(figure	1B&D).	
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Figure	 1:	 Verification	 of	 in	 vitro	 and	 in	 vivo	 induction	 of	 GFP/GCaMP6F	 expression	 by	
doxycycline	 administration.	 Representative	 confocal	 images	 of	 cells	 immunofluorescently	
labelled	for	INSL5	and	GFP/GCaMP6F	in	tissue	sections	from	mice	(n=3)	induced	in	vivo	(A)	and	
primary	cultures	(n=3)	induced	in	vitro	(C).	Proportion	of	cells	labelled	solely	for	INSL5	(red),	
both	INSL5	and	GFP/GCaMP6F	(yellow)	or	just	GFP/GCaMP6F	(grey)	in	tissue	sections	(B)	and	
primary	crypt	cultures	(D).	236	cells	were	manually	assessed	for	both	tissue	sections	and	crypt	
cultures	 from	 the	 confocal	 images	 taken.	 All	 cells	 were	 4%	 PFA	 fixed	 and	 subsequently	
incubated	with	INSL5	(1:2000)	and	GFP	(1:1000)	primary	antibodies	respectively	labelled	by	
goat	secondary	antibodies	(1:300)	conjugated	to	AlexaFluor	488	and	647	followed	by	exposure	
to	Hoechst	nuclear	stain	(1:2000).	Figure	adapted	from	Billing	et	al.	(2018)	[153].	
	
FACS-isolated	 GFP	 positive	 cells	 from	 colonic	 digests	 generated	 from	 both	 doxycycline	
induced	Insl5-rtTA/TET-GFP	and	Insl5-rtTA/TET-	GCaMP6FΔCMV	mice	constituted	an	average	
of	0.21	±	0.05%	(n=6	mice)	of	the	total	digest	cell	population	(an	example	FACS	output	can	be	
seen	in	figure	2C).	Since	roughly	half	of	colonic	L-cells	are	INSL5-producing,	this	proportion	is	
consistent	with	previous	FACS-analysis	of	L-cells	in	murine	colonic	digests	which	found	0.46	±	
0.07%	cells	were	tagged	when	using	a	GLP-1	antibody	[62].	RT-qPCR	confirmed	that	the	FACS-
isolated	GFP/GCaMP6F	cells	were	INSL5-producing	cells	as	they	were	significantly	enriched	
for	 Insl5,	 Gcg	 and	 Pyy	 transcripts	 (figure	 2A).	 Insl5,	 Gcg	 and	 Pyy	 transcripts	 had	 relative	
expression	levels	712,	508	and	2052	fold	higher	in	the	GFP	positive	cells	than	in	the	control	
GFP-negative	 cell	 population	 (relative	 to	 ß-actin;	 fold	measurements	 based	 on	 geometric	
means).	 Relative	 expression	 (2∆CT,	 +SEM,	 -SEM)	 was	 highest	 of	 Pyy	 (46.64,	 +4.56,	 -2.95),	
followed	by	Gcg	(8.39,	+33.6,	-19.5)	and	Insl5	(2.89,	+1.07,	-0.78).	
	
 INSL5	cells	express	cognate	GPCRs	of	known	GLP-1	secretagogues	
FACS-purified	INSL5	cells	were	enriched	for	expression	(2∆CT,	+SEM,	-SEM)	of	Agtr1a	(0.0140,	
+0.0036,	 -0.0001),	 Avpr1b	 (0.0303,	 +0.0180,	 -0.000115),	 Ffar1(0.00657,	 +0.000453,	 -
0.000002),	Gpbar1	(0.00869,	+0.000824,	-0.000040),	Grpr	(0.00261,	+0.00146,	-0.00084)	and	
Casr	(0.000541,	+0.000512,	-0.0000191)	which	encode	the	cognate	receptors	for	angiotensin	
II,	vasopressin,	MCFA/LCFAs,	bile	acids,	bombesin	and	small	peptides	respectively	(n=3	mice;	
figure	 2B).	 Relative	 expression	 of	 the	 SCFA	 receptor	 Ffar2	was	 not	 significantly	 different	
(p>0.05)	in	INSL5	cells	(0.00186,	+0.000789,	-0.000522)	compared	with	controls	(0.000683,	
+0.0000418,	-	0.000826).	
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Figure	2:	RT-qPCR	expression	analysis	of	FACS-isolated	INSL5	cells.	(A)	Expression	of	Insl5,	Gcg	
and	Pyy	(n=6	mice)	relative	to	the	housekeeper	β-actin	was	enriched	in	the	GFP	cell	population	
isolated	by	FACS.	(B)	Relative	expression	of	a	known	subset	of	colonic	L-cell	GPCRs	(n=3	mice).	
Difference	 in	 cycle	 threshold	 (ΔCT)	 was	 evaluated	 between	 the	 gene	 of	 interest	 and	 the	
housekeeper	 β-actin.	 These	 values	 were	 used	 to	 derive	 relative	 expression	 as	 2ΔCT.	 Bars	
represent	mean	relative	expression	with	error	bars	 reflecting	SEM	derived	 from	ΔCT.	Ratio	
paired	t-tests	run	on	2ΔCT	values.	Black	coloured	bars	represent	INSL5	cells	whilst	grey	coloured	
bars	represent	control	cells.	n.s.	=	p>0.05,	*p<0.05,	**p<0.01,	***p<0.001.		(C)	Representative	
FACS	 output	 indicating	 sampled	 populations	 of	 GFP	 negative	 and	 positive	 cells.	 Figures	
adapted	from	Billing	et	al.	(2018)	[153].	
	
 Physiological	 stimuli	 trigger	 intracellular	 Ca2+	 transients	 in	 cultured	
INSL5	cells	
In	calcium	imaging	experiments	significant	intracellular	calcium	responses	were	recorded	in	
INSL5	cells	to,	in	descending	order	of	median	fold	increase	in	GCaMP6F	fluorescence,	10nM	
angiotensin	II	(3.59	fold,	95%	CI=2.74-4.51;	n=50),	10nM	AVP	(1.65	fold,	95%	CI=1.48-1.96;	
n=20),	100nM	bombesin	(1.56	fold,	95%	CI=1.49-1.86;	n=76),	5mg/ml	peptones	(1.56	fold,	
95%	CI=1.35-2.08;	n=34),	2mM	butyrate	(1.18	fold,	95%	CI=1.09-1.24;	n=38)	and	1µM	AM-
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1638	(1.06	fold	95%	CI=1.02-1.16;	n=40;	figure	3C).	The	AM-1638	and	butyrate	intracellular	
calcium	responses	were	variable	between	cells	 tested,	with	responses	 (defined	as	eliciting	
more	than	a	1.1	fold	increase	in	GCaMP6F	fluorescence)	triggered	in	17/40	cells	and	25/38	
cells,	respectively	(figure	3D).	
	
Figure	 3:	 (A)	 Example	 of	 an	 immunofluorescently	 labelled	 INSL5	 cell	 which	 has	 been	
doxycycline	 induced	for	GCaMP6F	expression	 in	primary	culture	overnight.	Fixed	 in	4%	PFA	
and	 incubated	 with	 primary	 antibodies	 for	 INSL5	 (1:2000)	 and	 GFP	 (1:1000)	 respectively	
labelled	by	goat	secondary	antibodies	(1:300)	conjugated	to	AlexaFluor	488	and	647	followed	
by	treatment	with	Hoescht	nuclear	stain	(1:2000).	(B)	Representative	calcium	imaging	trace.	
(C)	 Fold	 changes	 in	 GCaMP6F	 fluorescence	 following	 addition	 of	 positive	 controls	 (10nM	
angiotensin	 II	and	100nM	bombesin).	 (D)	Fold	changes	 in	GCaMP6F	fluorescence	following	
addition	of	a	select	range	of	agonists	for	identified	Gq-coupled	GPCR	expressed	in	INSL5	cells.	
Fold	change	in	fluorescence	calculated	as	the	peak	fluorescence	achieved	during	treatment	
divided	by	baseline	fluorescence	(an	average	of	maximum	fluorescence	measured	30	seconds	
before	and	after	treatment).	Bold	lines	 in	3C	and	3C	indicate	the	median	of	calculated	fold	
changes	 in	 fluorescence.	 Statistical	 significance	 assessed	 using	 a	Wilcoxon	 test.	 **p<0.01,	
***p<0.001.	Figure	adapted	from	Billing	et	al.	(2018)	[153].	
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 GLP-1	secretagogues	induce	concomitant	PYY	and	INSL5	secretion	
The	following	GLP-1	secretagogues,	listed	from	the	strongest	to	weakest	stimulus,	triggered	
simultaneous	 INSL5	 and	 PYY	 release	 from	 murine	 crypt	 cultures	 (figure	 4A):	
forskolin/IBMX/glucose	(10µM/10µM/10mM),	arginine	vasopressin	(10nM),	AM-1638	(1µM),	
angiotensin	II	(10nM),	PMA	(1µM),	IBMX/glucose	(100µM/10mM),	GPBAR-A	(3µM),	SCFA	mix	
(3mM	 acetate,	 1mM	 butyrate	 and	 1mM	 propionate),	 bombesin	 (100nM),	 KCl	 (70mM),	 l-
glutamine	 (10mM),	 linoleic	 acid	 (100µM)	 and	 glucose	 (10mM).	 Addition	 of	 100nM	
somatostatin	(SST)	significantly	attenuated	responses	to	IBMX/glucose.	Pearson	correlation	
(R)	indicated	strong	positive	correlation	between	the	three	peptide	secretory	responses	with	
values	of	0.91	for	GLP-1/INSL5	(figure	4B),	INSL5/PYY	(figure	4C)	and	PYY/GLP-1	(figure	4D).	
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Figure	4:	(A)	Relative	secretion	of	INSL5,	GLP-1	and	PYY	from	murine	colonic	crypt	cultures	in	
response	to	a	range	of	stimuli	as	assessed	by	LC/MS	analysis.	Values	derived	from	integration	
of	the	peak	found	for	each	peptide	identified	by	retention	time	and	m/z	value.	These	values	
were	firstly	normalised	to	protein	content	assessed	by	a	BCA	protein	assay	and	subsequently	
normalised	by	secretion	in	the	basal	condition	(saline	buffer	with	1mM	glucose).	Statistically	
significant	deviation	from	basal	secretion	was	assessed	using	a	Dunn	test.	n=duplicates	from	
at	least	3	different	crypt	cultures	for	each	test	condition.	Bars	represent	mean	+	SD.	*p<0.05.	
Linear	regression	between	GLP-1/INSL5	(B),	INSL5/PYY	(C)	and	PYY/GLP-1	(D)	responses	with	
Pearson	correlation	coefficient	shown	(R)	and	each	test	condition	using	the	same	colour	code	
and	data	as	(A).	Experimental	data	collected	and	analysed	by	Pierre	Larraufie.	Figure	from	
Billing	et	al.	(2018)	[153].	
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Human	crypt	cultures	displayed	a	similar	secretion	profile	to	the	murine	crypt	cultures	with	
strong	 positive	 correlation	 between	 GLP-1,	 PYY	 and	 INSL5	 secretory	 responses.	 Pearson	
correlation	coefficients	(R)	for	GLP-1/INSL5	(figure	5A),	INSL5/PYY	(figure	5B)	and	PYY/GLP-1	
(figure	5C)	were	0.72,	0.75	and	0.9	respectively.	These	results	are	derived	from	4	different	
human	crypt	cultures	(total	of	11	crypt	cultures	were	produced	but	INSL5	was	only	detectable	
in	4).	
	
	
	
Figure	5:	INSL5,	GLP-1	and	PYY	secretory	responses	of	human	colonic	crypt	cultures	to	a	range	
of	 stimuli.	 Linear	 regression	 between	 GLP-1/INSL5	 (A),	 INSL5/PYY	 (B)	 and	 PYY/GLP-1	 (C).	
Experimental	data	collected	and	analysed	by	Pierre	Larraufie.	Figure	from	Billing	et	al.	(2018)	
[153].	
	
 The	majority	 of	 INSL5,	 GLP-1	 and	 PYY	 secretory	 vesicles	 label	 for	 all	
three	peptides	
Initial	 surfaces	 based	 analysis	 of	 INSL5,	 GLP-1	 and	 PYY	 immunofluorescent	 labelling	 in	
cultured	murine	colonic	crypts	indicated	that	roughly	~50%	of	vesicle	volume	was	labelled	for	
one	peptide	alone	whilst	~30%	was	labelled	for	two	peptides	and	the	remaining	~20%	vesicle	
volume	was	labelled	for	all	three	peptides	(n=14	cells	from	3	different	mice;	figure	6B).	The	
surfaces	analysis	was	also	applied	 to	cultured	cells	 stained	with	a	 single	primary	antibody	
against	GLP-1	and	3	secondary	antibodies,	AlexaFluor	488,	555	and	633,	with	the	expectation	
that	 the	 three	 channels	would	 strongly	 overlap	 in	 3	 dimensions.	 However,	 the	 degree	 of	
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overlap	found	was	poor	with	only	~45%	of	the	total	vesicular	volume	triple	labelled,	~15%	
dual	labelled	and	~40%	single	labelled	(figure	6H).		
	
Figure	 6:	 Surfaces	 based	 analysis	 of	 immunofluorescently	 labelled	 murine	 colonic	 crypt	
cultures.	(A)	Representative	subsection	of	labelled	GLP-1,	PYY	and	INSL5	vesicles	imaged	using	
3D-SIM	and	rendered	in	3D	using	Imaris.	(B)	Mapped	vesicle	volume	occupied	by	labelled	GLP-
1,	 PYY	 and	 INSL5	 fractionated	 by	 single,	 dual	 and	 triple	 labelling.	 (C)	 Example	 image	 of	
surfaces	rendered	on	Imaris	from	the	individual	channels	for	GLP-1,	PYY	and	INSL5	shown	in	
A.	 (D)	 Surfaces	 rendered	 from	 identified	areas	of	 triple	 labelling	 from	C.	Analysis	of	GLP-1	
labelled	with	 three	 different	 secondaries	 conjugated	 to	 Alexa	 488,	 555	 and	 633	with	 raw	
channel	data	(E),	mapped	surfaces	(F)	and	triple	positive	surfaces	(G)	shown.	(H)	Percentage	
overlap	between	volume	of	the	mapped	surfaces	for	GLP-1	labelled	with	Alexa	488,	555	and	
633.	Scale	bar	=	1µm.	Figure	adapted	from	Billing	et	al.	(2018)	[153].	
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An	alternative	methodology,	developed	by	Chris	Smith,	fitted	3D	Gaussian	distributions	onto	
the	channel	data	from	the	3D-SIM	imaging	allowing	 identification	of	 INSL5,	PYY	and	GLP-1	
vesicles	and	of	single,	dual	or	triple	labelled	vesicles	(see	methods)	[156,157].	Using	fitted	3D	
Gaussian	distributions	to	analyse	the	samples	labelled	for	GLP-1	with	AlexaFluor	488,	555	and	
633	 (the	same	samples	used	 to	examine	 the	surfaces	method)	>95%	of	 identified	vesicles	
(1175	 vesicles	 examined)	 were	 triple	 labelled,	 suggesting	 that	 this	 method	 was	 reliable	
analysis	of	co-labelled	vesicles	(figure	7C).		
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Figure	7:	Reanalysis	of	GLP-1	 labelled	with	 secondary	antibodies	 conjugated	 to	AlexaFluor	
488,	555	and	633	using	an	alternative	method	which	utilises	fitted	3D	Gaussian	distributions.	
(A)	Example	3D-SIM	image	of	immunofluorescently	stained	crypt	cultures.	Images	projected	
in	z	(scale	bar	=	3µm).	Insets	are	individual	z-planes	of	vesicle	clusters	in	each	channel	(scale	
bar	=	500nm).	(B)	Scatterplots	showing	normalised	intensity	of	the	AlexaFluor	555	and	633	
against	 AlexaFluor	 488.	 Dashed	 lines	 represent	 5%	 (+)	 and	 2%	 (-)	 of	 maximum	 intensity.	
Vesicles	with	intensities	above	5%	were	classified	as	containing	the	relevant	peptide	whereas	
those	below	2%	were	considered	empty	of	that	peptide.	(C)	Proportion	of	identified	vesicles	
labelled	with	one,	two	or	all	three	AlexFluor	conjugated	secondary	antibodies.	1175	identified	
vesicles	analysed	from	crypt	cultures	generated	from	a	single	mouse.	Analysis	conducted	by	
Christopher	Smith.	Figure	from	Billing	et	al.	(2018)	[153].	
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In	contrast	to	the	surfaces	method,	~90%	of	the	total	INSL5,	PYY	and	GLP-1	containing	vesicles	
(total	of	9860	vesicles	examined	from	16	cells)	identified	using	3D-Gaussian	fitting	were	found	
to	contain	all	three	peptides,	~5%	were	double	labelled	and	the	remaining	~5%	single	labelled	
(figure	8C).	A	similar	pattern	was	observed	in	stained	tissue	sections,	in	which	for	13/14	cells	
analysed	>80%	of	the	vesicles	(total	of	4147	vesicles	examined)	were	triple	labelled	(figure	
9C).	 The	 remaining	 cell	 however	 showed	 a	 different	 pattern	 with	 ~54%	 of	 vesicles	 triple	
labelled,	~10%	dual	 labelled	and	36%	single	 labelled	which	were	almost	all	GLP-1	 labelled	
(35.5%	GLP-1).	The	diameters	of	GLP-1	vesicles	labelled	with	AlexaFluor	488	(the	wavelength	
least	affected	by	chromatic	aberration)	were	205±92nm.	As	also	found	by	Cho	et	al.	(2014),	
we	 identified	 some	 irregular	 ‘doughnut’	 shaped	 vesicles	 in	 both	 the	 tissue	 sections	 and	
primary	cultures	(examples	can	be	seen	in	figure	10).	
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Figure	8:	Analysis	of	INSL5,	PYY	and	GLP-1	vesicle	co-labelling	in	immunofluorescently	labelled	
primary	colonic	crypt	cultures.	(A)	Example	image	of	a	z-slice	through	a	3D-SIM	imaged	cell.	
Scale	bar	=	5µm	(B)	Scatterplot	showing	normalised	intensity	of	the	PYY	and	GLP-1	channels	
against	that	of	INSL5.	Dashed	lines	represent	5%	(+)	and	2%	(-)	of	maximum	intensity.	Vesicles	
with	intensities	above	5%	were	classified	as	containing	the	relevant	peptide	whereas	those	
below	 2%	were	 considered	 empty	 of	 that	 peptide.	 (C)	 Proportion	 of	 vesicles	 for	 each	 cell	
examined	which	were	single,	double	and	triple	labelled.	The	first	digit	of	the	y-axis	labels	refers	
to	 the	 particular	 crypt	 culture	 examined	 whilst	 the	 digits	 after	 the	 full	 stop	 refer	 to	 the	
particular	 cell	 examined	within	 that	 experiment.	 9860	 identified	 vesicles	 examined	 from	4	
crypt	cultures	generated	from	4	different	mice.	(D)	Example	images	of	the	different	variants	
of	single	and	double	labelled	vesicles	together	with	triple	labelled	vesicles.	Percentages	reflect	
the	proportion	each	variant	identified	in	the	analysis.	(E)	Cross-sectional	intensity	profiles	of	
INSL5,	 PYY	 and	GLP-1	 vesicles.	 Shading	 reflects	 standard	 deviation.	 Analysis	 conducted	 by	
Christopher	Smith.	Figure	from	Billing	et	al.	(2018)	[153].	
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Figure	9:	Analysis	of	INSL5,	PYY	and	GLP-1	vesicle	co-labelling	in	immunofluorescently	labelled	
colonic	tissue	sections.	(A)	Example	image	of	a	z-slice	through	a	3D-SIM	imaged	cell.	Scale	bar	
=	3µm	(B)	Scatterplot	showing	normalised	 intensity	of	the	PYY	and	GLP-1	channels	against	
that	of	INSL5.	Dashed	lines	represent	5%	(+)	and	2%	(-)	of	maximum	intensity.	Vesicles	with	
intensities	above	5%	were	classified	as	containing	the	relevant	peptide	whereas	those	below	
2%	were	considered	empty	of	that	peptide.	(C)	Proportion	of	vesicles	for	each	cell	examined	
which	were	single,	double	and	triple	labelled.	The	first	digit	of	the	y-axis	labels	refers	to	the	
particular	tissue	section	examined	whilst	the	digits	after	the	full	stop	refer	to	the	particular	
cell	examined	within	that	experiment.	4147	identified	vesicles	examined	from	tissue	sections	
from	 4	 different	mice.	 (D)	 Example	 images	 of	 the	 different	 variants	 of	 single	 and	 double	
labelled	vesicles	together	with	triple	labelled	vesicles.	Percentages	reflect	the	proportion	each	
variant	identified	in	the	analysis.	(E)	Cross-sectional	intensity	profiles	of	INSL5,	PYY	and	GLP-1	
vesicles.	Shading	reflects	standard	deviation.	Analysis	conducted	by	Christopher	Smith.	Figure	
from	Billing	et	al.	(2018)	[153].	
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Figures	10:	Example	3D-SIM	images	across	a	single	z-plane	of	doughnut	shaped	vesicles	 in	
primary	cultured	L-cells.	Scale	bar	=	0.5µm.	An	example	doughnut	shaped	vesicle	is	indicated	
by	the	white	arrow.	 	
GLP-1	PYY	INSL5
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4.5. Discussion	
 Verification	 of	 the	 Insl5-rtTA/TET-GCaMP6FΔCMV	 and	 Insl5-rTA/TET-
GFP	mouse	models	in	vivo	and	ex	vivo	
The	results	of	the	IHC	experiments	both	from	tissue	sections	and	primary	cultures	indicate	
that	the	doxycycline	induction	of	the	GFP/GCaMP6F	fluorescent	reporter	was	almost	entirely	
limited	 to	 INSL5-producing	 cells	 with	minimal	 non-specific	 labelling.	 The	 inducible	 Tet-on	
system	minimises	non-specific	cell	labelling	issues	associated	with	other	systems	such	as	Cre-
lox	recombination	[228].	The	induction	rate	in	vivo	was	slightly	lower	than	that	in	doxycycline	
treated	ex	vivo	cultures	(72%	vs.	88%)	though	both	rates	are	consistent	with	previous	levels	
of	penetrance	observed	in	Glu-Venus	mice	(~80%)	[62].		
	
The	transcriptomic	profile	of	cells	FACS-purified	from	Insl5-rtTA/TET-GFP	and	Insl5-rtTA/TET-	
GCaMP6FΔCMV	mice	was	also	consistent	with	specific	INSL5	cell	induction	of	GFP/GCaMP6F	
expression	as	these	cells	were	enriched	for	Insl5	as	well	as	Gcg	and	Pyy	(classical	markers	of	
L-cells)	 [88].	 The	 tissue	 section	 staining	 however	 suggests	 that	 potentially	 around	 30%	of	
INSL5	cells	were	not	isolated	as	they	did	not	express	the	GFP	reporter.	This	could	mean	that	
a	subset	of	INSL5	cells	are	excluded	from	downstream	RT-qPCR	experiments.		
	
 INSL5	cells	display	intracellular	Ca2+	responses	to	GLP-1	secretagogues	
The	 results	 of	 the	 intracellular	 calcium	 imaging	 experiments	 reflect	 the	 expression	 of	
characterised	 L-cell	GPCRs	 in	 INSL5	 cells.	 In	 particular,	 on	 average	 angiotensin	 II	 and	AVP	
application	induced	the	largest	of	all	the	intracellular	calcium	responses,	larger	in	fact	than	
the	positive	control	bombesin.	Subsequently,	the	exclusion	criteria	were	widened	so	that	cells	
which	did	not	respond	to	angiotensin	II	or	bombesin	were	excluded	from	the	final	analysis.	
Interestingly,	 past	 investigations	 found	 that	 peripheral	 administration	 of	 angiotensin-
converting	enzyme	 (ACE)	 inhibitors	 such	as	 captopril	 to	 fasted	 rats	decreased	 subsequent	
food	 intake.	 The	 authors	 imply	 that	 this	 action	 is	 due	 to	 increased	 central	 angiotensin	 II	
concentrations	(since	captopril	poorly	passes	across	the	blood	brain	barrier	and	angiotensin	
II	is	anorexigenic	when	centrally	administered).	However,	it	could	also	be	driven	by	decreased	
INSL5	secretion	resulting	from	decreased	peripheral	levels	of	angiotensin	II	[229].		
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The	SCFA	butyrate	triggered	calcium	transients	in	spite	of	low	levels	of	Ffar2	expression	in	
INSL5	cells.	This	could	potentially	reflect	SCFA	signalling	through	a	different	pathway,	perhaps	
the	 aforementioned	 FFAR3	 acting	 via	 an	 alternative	 signalling	 pathway	 (i.e.	 not	 via	 Gi-
signalling).	However,	since	the	responses	observed	to	butyrate	were	small	and	recorded	in	
25/38	cells	it	could	be	that	expression	of	Ffar2	is	limited	to	a	subset	of	a	INSL5	cells	and	at	
levels	beyond	the	sensitivity	of	the	RT-qPCR	used.		
	
Comparing	the	intracellular	Ca2+	responses	of	colonic	INSL5	cells	observed	here	with	those	
small	intestinal	L-cells	observed	in	chapter	3	it	appears	that	the	INSL5	cell	responses	are	more	
robust	than	those	the	small	intestinal	L-cells.	The	reasons	behind	this	are	unclear	but	could	
relate	 to	 inherent	 differences	 between	 small	 and	 large	 intestinal	 L-cells	 and/or	
methodological	differences.	Regarding	methodological	differences,	 it	should	be	noted	that	
the	L-cells	examined	in	chapter	3	were	derived	from	organoids	grown	in	ENR	media	whereas	
examined	INSL5	cells	were	derived	from	primary	cultures	grown	in	primary	culture	media.	It	
is	plausible	that	residual	matrigel	or	insufficient	disruption	of	the	3D	organoid	structure	may	
have	impaired	access	of	applied	stimuli	to	the	cell	surface	of	L-cells	in	2D	organoid	cultures	
and	 consequently	 added	 noise	 to	 observed	 intracellular	 Ca2+	 responses	 not	 observed	 in	
primary	 cultures.	 Chronic	 exposure	 of	 organoid	 derived	 L-cells	 to	 ENR	media	 (containing	
multiple	 different	 growth	 factors)	 could	 also	 have	 reduced	 the	 robustness	 of	 observed	
responses	 through	 downregulation	 of	 Gq-signalling	 pathways.	 Beyond	 differences	 in	 the	
culture	 systems	 employed,	 different	 genetically	 encoded	 calcium	 sensors	 were	 used	 to	
examine	intracellular	Ca2+	responses	with	GCaMP3	used	for	the	small	 intestinal	L-cells	and	
GCaMP6F	used	for	INSL5	cells.	GCaMP6F	is	much	more	sensitive	to	Ca2+	and	exhibits	greater	
signal	to	noise	ratios	than	GCaMP3	which	could	explain	why	the	intracellular	Ca2+	responses	
recorded	 from	 INSL5	 cells	 (using	GCaMP6F)	were	more	 robust	 than	 those	 from	 the	 small	
intestinal	L-cells	(using	GCaMP3)	[152].	
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 GLP-1	secretagogues	trigger	concomitant	PYY	and	INSL5	secretion	
The	 stimuli	 applied	 in	 the	 intracellular	 calcium	 imaging	 experiments,	which	 are	 known	 to	
trigger	GLP-1	and	PYY	secretion,	also	triggered	INSL5	secretion	implying	that	the	intracellular	
calcium	 transients	 elicited	 may	 couple	 to	 INSL5	 secretion	 (INSL5	 secretory	 responses	 to	
peptones	could	not	be	tested	as	the	mixture	of	peptides	would	obscure	the	LC/MS	output)	
[73–75,173,221].	Consistent	with	these	previous	studies,	LC/MS	analysis	confirmed	that	GLP-
1	and	PYY	were	also	 secreted.	The	murine	and	human	colonic	 crypt	 cultures	also	 showed	
largely	the	same	secretory	profiles	of	these	three	peptides.	These	results	imply	that	murine	
INSL5	 cells	 are	 a	 faithful	 model	 of	 human	 INSL5	 cells,	 at	 least	 in	 the	 context	 of	 peptide	
secretion.	Interestingly	only	4/11	human	crypt	cultures	examined	had	measurable	levels	of	
INSL5	in	the	secretory	supernatants.	This	could	reflect	smaller	INSL5	secretory	responses	in	
some	samples	(below	the	LC/MS	detection	threshold)	or	the	number	of	INSL5	cells	surviving	
in	primary	culture.	Indeed,	in	other	studies,	L-cells	derived	from	human	colonic	crypt	cultures	
appear	 ~4	 times	 less	 responsive	 than	murine	 L-cells	 in	 terms	 of	GLP-1	 and	 PYY	 secretory	
responses	 [70].	Further	 refinement	of	 the	culture	conditions	and	 INSL5	peptide	extraction	
may	 therefore	help	 improve	 INSL5	detection	 for	 future	examinations	of	human	 INSL5	 cell	
responses.	The	 low	number	of	human	crypt	 cultures	 secreting	measurable	 levels	of	 INSL5	
could	also	reflect	the	source	of	the	tissue	samples	used	for	each	crypt	culture,	for	example	
the	precise	region	of	colon	sampled	or	the	particular	patient	that	samples	were	taken	from.	
Any	such	issues	could	be	minimised	by	obtaining	tissue	samples	from	the	same	region	of	colon	
and	from	patients	matched	for	characteristics	such	as	age	and	gender.		
	
 Co-storage	of	INSL5,	PYY	and	GLP-1	likely	underlies	co-secretion	
The	co-release	of	INSL5,	PYY	and	GLP-1	observed	implies	that	the	three	peptides	are	either	
stored	 in	 separate	 vesicle	 pools	 with	 a	 common	 release	 mechanism	 or	 stored	 together	
resulting	in	concomitant	secretion	upon	exocytosis.	Previous	findings	suggest	the	former,	as	
colonic	GLP-1	and	PYY	were	observed	in	separate	vesicles	in	some	studies	[87].	However,	our	
results	 are	 not	 consistent	with	 these	particular	 studies	 as	 3D-SIM	analysis	 illustrated	 that	
INSL5,	PYY	and	GLP-1	are	mostly	co-stored	in	the	same	vesicles.	These	results	suggest	that	co-
secretion	observed	from	human	crypt	cultures	also	arises	as	a	consequence	of	co-storage,	
though	no	immunofluorescent	investigations	were	conducted	here	on	human	L-cells.	These	
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results	fit	with	older	studies	employing	electron	microscopy	and	immunogold	labelling	where	
enteroglucagon	and	PYY	were	found	to	be	co-stored	in	rabbit	colon	[224].	
	
Whilst	studies	which	concluded	GLP-1	and	PYY	are	stored	in	separate	vesicles	also	used	3D-
SIM	 techniques,	 they	used	 a	 volume	based	 approach	 to	 assess	 the	degree	of	 peptide	 co-
storage.	Using	similar	methods	we	similarly	found	a	high	percentage	of	single	labelled	vesicles	
in	primary	crypt	cultures,	albeit	considerably	less	than	found	by	Cho	et	al.	[230].	Application	
of	 this	 method	 to	 samples	 with	 triple	 labelled	 GLP-1	 illuminated	 a	 major	 flaw	 with	 this	
strategy.	The	three	channels	imaged	for	each	of	the	different	AlexaFluor	labels	used	should	
in	theory	overlap	exactly	and	as	such	one	would	expect	the	surfaces	analysis	to	reflect	this.	In	
practice	 however,	 only	 ~45%	 of	 the	 total	 vesicle	 volume	 mapped	 contained	 overlapping	
signals	from	all	three	channels.	This	can,	in	part,	be	explained	by	the	different	wavelengths	of	
the	channels	used.	The	longer	wavelength	channels,	555nm	and	633nm,	will	occupy	greater	
3D	space	when	imaged	than	the	shorter	488nm	channel	due	to	chromatic	aberration.	This	
appears	 to	 have	 occurred	 despite	 correction	 using	 fluorescent	 beads	 as	 the	 largest	
proportions	of	single	labelled	vesicular	volume	were	from	the	633nm	and	555nm	channels	
(figure	6H).	Our	new	methodology	overcame	these	issues	as	evidenced	by	the	>95%	overlap	
between	 the	 channels	 of	 the	 same	 GLP-1	 stained	 samples.	 GLP-1	 vesicles,	 labelled	 with	
AlexaFluor	 488,	 measured	 205±92nm	 in	 diameter	 using	 this	 method,	 which	 is	 ~40-50nm	
larger	than	found	by	Cho	et	al.	(2014)	[87].	This	difference	may	arise	as	a	consequence	of	the	
different	methodology	applied	with	Cho	et	al.	using	spot	detection	to	estimate	the	diameter	
of	the	vesicles.	Alternatively,	it	may	reflect	the	precise	pool	of	vesicles	examined	as	Cho	et	al.	
found	the	diameters	of	the	vesicles	measured	varied	from	90-440nm.	Interestingly,	not	all	
GLP-1,	 PYY	 and	 INSL5	 vesicles	 were	 spherical	 in	 shape,	 with	 some	 (as	 seen	 in	 figure	 10)	
exhibiting	a	ring	of	 fluorescence	around	a	dim	core	similar	 to	a	doughnut.	Similar	 findings	
were	made	by	Cho	et	al.	[87].	The	physiological	significance	of	these	doughnut	shaped	vesicles	
is	unclear	and	they	could	result	from	unusual	restricted	packaging	of	labelled	peptides	into	
the	outer	edges	of	secretory	vesicles	or	staining	artefacts.	
	
Whilst	L-cells	 immunofluorescently	 labelled	 from	crypt	cultures	and	 tissue	sections	 largely	
showed	the	same	proportions	of	triple,	dual	and	single	labelled	GLP-1,	PYY	and	INSL5	vesicles,	
there	 was	 slightly	 greater	 variation	 between	 L-cells	 analysed	 in	 the	 tissue	 sections	 than	
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primary	culture.	One	of	the	cells	in	a	fixed	section	had	36%	single	labelled	vesicles	which	were	
almost	 entirely	 GLP-1	 labelled.	 These	 variations	 may	 have	 resulted	 from	 variations	 in	
immunolabelling	 between	 different	 tissue	 sections,	 which	 exhibit	 greater	 background	
staining	than	primary	cultures.	It	should	be	noted	that	the	primary	antibodies	used	to	target	
GLP-1,	 PYY	 and	 INSL5	 likely	 exhibit	 differing	 detection	 limits	 which,	 despite	 protocol	
optimisation,	may	yield	underestimates	of	the	total	numbers	of	GLP-1,	PYY	and	INSL5	vesicles	
present	 within	 analysed	 cells	 and	 the	 degree	 of	 both	 dual	 and	 triple	 labelled	 vesicles.	
Alternatively,	temporal	differences	in	Insl5,	Pyy,	and	Gcg	expression	(influenced	by	the	age	
and/or	environment	of	the	cell)	could	create	variations	in	the	peptide	constituents	of	the	L-
cell	secretory	vesicles.	Using	tissue	from	transgenic	mice	or	transfected	organoids	whereby	L-
cells	 have	 been	 engineered	 to	 produce	 fluorescently	 tagged	GLP-1,	 PYY	 and	 INSL5	would	
enable	 live	 confocal	 imaging	of	 vesicle	 trafficking.	 In	 the	 case	of	 intestinal	 organoids,	 this	
would	also	enable	long-term	tracing	of	vesicle	peptide	composition	within	L-cells.	
	
 Physiological	Implications	
Given	that	INSL5,	PYY	and	GLP-1	are	co-stored	and	likely	co-secreted	in	vivo	from	INSL5	cells,	
interesting	questions	arise	regarding	how	exactly	the	opposing	effects	of	INSL5	and	PYY/GLP-
1	on	appetite	are	exerted.	One	possible	explanation	relates	to	the	differential	distribution	of	
GLP-1,	PYY	and	INSL5	production	along	the	GI	tract	with	GLP-1	and	PYY	produced	throughout	
the	 small	 and	 large	 intestines	 and	 INSL5	 limited	 to	 the	 large	 intestine	 [88,231].	 Post-
prandially,	acute	delivery	of	 the	nutrients	 to	 the	small	 intestine	 likely	 stimulates	L-cells	 to	
secrete	GLP-1	and	PYY	but	not	 INSL5,	exerting	a	net	anorexigenic	effect.	 In	the	 long	term,	
nutrients	 entering	 the	 colon	 and	 bacterial	 fermentation	 may	 stimulate	 INSL5	 secretion	
(together	with	GLP-1	and	PYY)	with	net	orexigenic	effects.	 It	 is	possible	that	the	combined	
action	of	 the	three	peptides	could	yield	different	effects	on	appetite	to	the	actions	of	 the	
three	 individual	 peptides.	 GLP-1	 and	 PYY	 co-secretion	 with	 INSL5	 may	 also	 provide	
autoinhibitory	feedback	on	the	orexigenic	effects	of	INSL5.		
	
INSL5	may	act	as	an	autoinhibitor	of	L-cell	activities	by	activation	of	the	Gi-coupled	RXFP4.	
Indeed,	 in	 support	 of	 the	 potentially	 auto-inhibitory	 nature	 of	 INSL5,	 in	NCI-H716	 cells	 (a	
model	of	human	L-cells)	 INSL5	application	attenuates	acute	 forskolin-induced	secretion	of	
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GLP-1	[232].	Unpublished	RNA-seq	data	(Cheryl	Brighton),	further	supports	this	hypothesis	as	
enrichment	 of	 Gcg,	 Pyy	 and	 Insl5	 transcripts	 was	 found	 in	 cells	 expressing	 Rxfp4.	 The	
autoinhibitory	 nature	 of	 INSL5	 could	 be	 explored	 by	 application	 of	 a	modified	 version	 to	
murine	crypt	cultures	in	combination	with	a	stimulant	such	as	forskolin,	or	of	murine	INSL5	
to	 human	 crypt	 cultures,	 with	 subsequent	 LC/MS	 analysis	 to	 distinguish	 exogenous	 from	
endogenous	INSL5	peptides.	Using	these	protein	isoforms	would	allow	identification	of	any	
autoinhibitory	effects	on	endogenous	INSL5	secretion.		
	
5-HT	producing	enterochromaffin	cells	were	identified	as	expressing	Rxfp4,	as	transcripts	of	
the	enterochromaffin	marker	Tph1	were	enriched	in	Rxfp4	labelled	cells	(unpublished	work	
by	 Cheryl	 Brighton).	 This	 suggests	 that	 INSL5	 can	 act	 as	 a	 paracrine	 modulator	 of	 5-HT	
secretion	 and	 might	 subsequently	 influence	 motility	 in	 the	 colon,	 likely	 in	 an	 inhibitory	
manner.	Changes	in	colonic	motility	can	influence	the	composition	of	the	present	microbiota	
as	well	as	fermentation,	with	SCFAs	in	particular	affected	[233–235].		
	
Bariatric	surgery	(such	as	RYGB)	increases	delivery	of	dietary	L-cell	stimulants	(including	bile	
acids)	to	more	L-cell	rich	distal	regions	of	the	GI	tract,	modulates	the	microbiota	and	increases	
GLP-1	secretion	which	potentially	underlies	increased	glucose	tolerance	in	people	with	type	
2	diabetes	[48,236].	 It	 is	possible	that	INSL5	levels	are	also	modulated	though	this	has	not	
been	 investigated.	 Given	 that	 plasma	 levels	 of	 the	 other	 known	 orexigenic	 gut	 hormone,	
ghrelin,	are	greatly	attenuated	by	RYGB	and	absent	in	patients	with	gastrectomy,	INSL5	could	
play	a	key	compensatory	role	in	appetite	regulation	in	such	patients	[237].	
	
4.6. Concluding	remarks	
In	 summary,	 INSL5	 cells	 express	 a	 range	 of	 known	 colonic	 L-cell	 GPCRs	 for	 physiological	
stimuli.	 Confirming	 my	 hypothesis	 that	 INSL5	 cells	 exhibit	 responses	 to	 known	 GLP-1	
secretagogues,	 application	 of	 these	 secretatogues	 triggered	 INSL5	 secretion	 and	 a	 Gq-
stimulating	subset	triggered	intracellular	Ca2+	transients	in	INSL5	cells.	Secretion	of	INSL5	was	
observed	in	parallel	with	GLP-1	and	PYY	which	our	results	suggest	arises	from	co-storage	of	
these	peptides	in	the	same	secretory	vesicles	refuting	the	hypothesis	that	INSL5,	GLP-1	and	
PYY	are	stored	in	separate	secretory	vesicle	pools.	The	differential	plasma	dynamics	of	GLP-
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1,	PYY	and	 INSL5	post-prandially	 likely	 reflect	 the	 regional	expression	profile	of	 Insl5	with	
activation	of	different	 L-cell	populations	along	 the	gastrointestinal	 tract.	 The	physiological	
significance	of	the	co-secretion	of	orexigenic	INSL5	with	anorexigenic	GLP-1	and	PYY	is	unclear	
but	we	postulate	that	INSL5	may	modulate	responses	to	GLP-1	and	PYY	potentially	acting	as	
an	 autoinhibitor	 of	 L-cells.	 The	 establishment	 of	 a	 reliable	 LC/MS	method	 for	 quantifying	
INSL5	is	a	significant	step	towards	untangling	INSL5’s	physiological	actions.	Application	of	a	
modified	version	of	this	LC/MS	method	will	be	especially	useful	when	applied	to	further	 in	
vivo	investigations	of	the	physiological	functions	of	INSL5.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 99	
 Chapter	5.	A	single	cell	RNA-seq	based	examination	
of	colonic	enteroendocrine	cells	
5.1. Introduction		
The	 diversity	 of	 EECs	 in	 the	 large	 intestine	 is	 lower	 than	 in	 upper	 regions	 of	 the	
gastrointestinal	 tract,	 predominantly	 consisting	 of	 5-HT-producing	 enterochromaffin	 cells,	
followed	 by	 L-cells	 and	 D-cells	 [238].	 The	 frequency	 of	 L-cells	 is	 particularly	 high	 when	
compared	with	the	rest	of	the	GI	tract	with	highest	abundance	in	the	rectum.	Roughly	50%	of	
these	 L-cells	 express	 Insl5	 [88].	 Whilst	 intracellular	 Ca2+	 and	 INSL5	 secretory	 responses	
detailed	 in	 chapter	4	were	broadly	 consistent	with	 those	 seen	 for	 colonic	 L-cells,	 it	 is	 still	
unclear	whether	Insl5-expressing	cells	form	a	transcriptomically	distinct	subgroup	of	L-cells.	
In	this	chapter,	the	hypothesis	that	the	colonic	EECs	can	be	subdivided	into	distinct	subgroups	
(beyond	the	canonical	L-cell,	D-cell	and	EC	cell	subdivisons)	is	examined	through	single	cell	
RNA-seq	 (scRNA-seq)	 analysis.	 Furthermore,	 using	 a	 combination	 of	 RT-qPCR,	
immunohistochemistry	and	 secretion	experiments	 the	hypotheses	 that	 the	different	 L-cell	
subgroups	exhibit	differences	in	terms	of	regional	distribution	within	the	colon	and	functional	
GPCR	repertoire	were	preliminarily	tested.	
	
5.2. Aims		
1. To	identify	colonic	enteroendocrine	cell	subgroups	using	transcriptomics	
2. To	examine	the	proximal-distal	distribution	of	EEC	subgroups	within	the	colon	
3. To	examine	the	functional	consequences	of	differences	in	GPCR	repertoire	between	
EEC	subgroups		 	
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5.3. Background	
 Colonic	EEC	subtypes:	
Enterochromaffin	cells	
	
5-HT-producing	enterochromaffin	cells	 (EC	cells)	dominate	the	profile	of	EECs	 in	the	colon	
representing	around	70%	of	the	total	EEC	population	in	the	proximal	colon	decreasing	to	40%	
in	the	rectum	[238].	Immunohistological	examination	of	colonic	EC	cells	by	Roth	et	al.	(1992)	
identified	no	overlap	between	5-HT	and	PYY,	GLP-1,	CCK	or	neurotensin	staining	and	imply	
that	EC	cells	derive	from	a	separate	branch	of	EEC	progenitor	differentiation	than	L-cells	[239].		
	
Lund	et	al.	 (2018)	have	recently	 investigated	the	GPCR	repertoire	of	FACS-isolated	murine	
small	intestinal	and	colonic	EC	cells	using	RT-qPCR.	Surprisingly,	unlike	other	EECs,	they	found	
that	small	intestinal	and	colonic	EC	cells	lack	expression	of	receptors	for	dietary	nutrients	such	
as	lipids	(e.g.	FFAR1)	and	protein	metabolites.	However,	colonic	EC	cells	did	express	Ffar2	(the	
receptor	for	the	SCFAs),	Gpbar1	(a	bile	acid	receptor)	and	Glp1r.	Consistent	with	functional	
Glp1r	expression,	application	of	the	GLP-1	analogue	liraglutide	triggered	5-HT	release	from	
isolated	pieces	of	murine	colon	[240].	Physiologically,	5-HT	plays	a	critical	role	in	regulating	
gastrointestinal	motility	and	peristalsis	 [241].	Dysfunction	of	 the	 local	colonic	serotonergic	
system	has	been	implicated	in	a	range	of	gastrointestinal	disorders	including	irritable	bowel	
syndrome	(IBS)	and	inflammatory	bowel	disease	(IBD)	[242].	
	
L-cells	
	
L-cells	 are	 the	 second	most	 abundant	 type	 of	 EEC	 in	 the	 colon	with	 increasing	 frequency	
moving	 through	 the	 proximal-distal	 axis	 [238].	 Roughly	 half	 of	 the	 total	 colonic	 L-cell	
population	express	Insl5	[88].	Immunohistochemistry	experiments	in	mouse	have	shown	that	
the	number	of	INSL5-positive	cells	increases	moving	from	the	caecum	down	to	the	rectum.	
Consistently,	 semi-quantitative	 PCR	 examination	 of	 human	 biopsy	 samples	 indicates	 that	
INSL5	expression	increases	moving	from	the	proximal	to	the	distal	colon	[243].	These	results	
imply	that	at	least	2	subgroups	of	L-cells	exist,	those	which	express	Insl5	and	those	that	do	
not	and	display	discrepancies	in	regional	distribution.	
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Comparison	of	the	nutrient	sensor	expression	profiles	of	small	intestinal	and	colonic	L-cells	
reveals	that	whilst	there	are	similarities,	for	example	in	the	expression	of	functional	FFARs,	
there	are	notable	discrepancies	[86].	For	example,	expression	of	the	key	L-cell	glucose	sensor	
SGLT1	is	9-fold	higher	in	small	intestinal	than	colonic	L-cells.	Reflecting	this,	murine	colonic	
primary	 cultures	 display	 smaller	 GLP-1	 secretory	 responses	 to	 glucose	 and	 to	 the	 non-
metabolisable	glucose	analogue	α-methylglucopyranoside	(transported	by	SGLT1)	than	small	
intestinal	 primary	 cultures	 [59].	 Furthermore,	 in	 in	 vivo	 experiments	 using	 mice,	 direct	
intraluminal	 application	 of	 glucose	 to	 the	 colon	 did	 not	 trigger	 increased	 plasma	 GLP-1	
whereas	 intraluminal	 application	 of	 glucose	 to	 the	 small	 intestine	 did	 [244].	 Likewise,	 no	
significant	increase	in	GLP-1	secretion	was	measured	from	human	colonic	primary	cultures	to	
glucose	application	 [245].	Contrastingly,	Agtr1a	 and	Avpr1b,	 genes	encoding	 receptors	 for	
angiotensin	II	and	AVP	respectively,	are	highly	enriched	in	murine	colonic	L-cells	compared	
with	 small	 intestinal	 L-cells	 [73,74].	 These	 results	 provide	 further	 evidence	 for	 regional	
differences	in	nutrient	sensing	by	intestinal	L-cells.	scRNA-seq	analysis	of	the	total	colonic	EEC	
population	 should	 aid	 identification	 of	 different	 subregional	 populations	 of	 L-cells	 in	 the	
colon.	
	
D-cells	
	
Colonic	D-cells	compose	~3-5%	of	all	colonic	EECs	and	predominantly	produce	the	28	amino	
acid	form	of	somatostatin	(SST-28)	[238].	As	with	EC	cells,	intestinal	D-cells	appear	to	derive	
from	a	separate	branch	of	EEC	progenitor	differentiation	to	L-cells.	Evidence	for	this	comes	in	
part	from	IHC	of	the	small	intestine	showing	that	SST	labelling	does	not	overlap	with	labelling	
of	other	EEC	peptide	products	such	as	GLP-1,	PYY	and	CCK.	Furthermore,	selective	ablation	of	
L-cells,	through	in	vivo	application	of	diphtheria	toxin	to	transgenic	mice	expressing	human	
diphtheria	toxin	receptor	under	the	control	of	the	proglucagon	promoter,	had	no	significant	
effect	on	SST	immunoreactivity	whilst	greatly	reducing	immunoreactivity	for	GLP-1	and	PYY,	
demonstrating	separation	of	SST-producing	D-cells	and	GLP-1/PYY-producing	L-cells	[246].	
	
As	 in	other	 regions	of	 the	gastrointestinal	 tract,	 somatostatin	 acts	 as	 a	 global	 inhibitor	of	
colonic	 enteroendocrine	 secretions,	 including	 INSL5,	 as	 observed	 in	 chapter	 4	 [247].	
Additionally,	somatostatin	regulates	smooth	muscle	contraction	in	the	colon	and	therefore	
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colonic	motility.	However,	previous	findings	are	mixed	as	to	whether	somatostatin	increases	
or	decreases	intestinal	muscle	contractions	and	whether	these	effects	are	due	to	direct	action	
of	 somatostatin	 on	 smooth	muscle	 or	 indirectly	 via	myenteric	 neurons	 [248–250].	 In	 the	
clinical	setting,	colonic	somatostatin	may	be	involved	in	regulating	intestinal	inflammation	in	
IBD	as	the	number	of	immunohistologically	labelled	D-cells	in	colonic	samples	from	patients	
inversely	correlated	with	the	grade	of	mucosal	 inflammation	[251].	Thus,	scRNA-seq	aided	
insights	into	colonic	D-cell	secretory	mechanisms	could	have	implications	for	understanding	
IBD	pathophysiology.	
	
 Single	cell	RNA-seq	techniques		
	
Cell	isolation:	plate-based	vs	droplet-based		
	
Unlike	 bulk	 RNA-seq,	whereby	 transcriptomes	of	 entire	 cell	 populations	 are	 analysed	 and	
compared,	single	cell	RNA-seq	(scRNA-seq)	enables	the	examination	of	the	transcriptome	of	
each	 individual	 cell	 within	 a	 cell	 population.	 Cluster	 analysis	 of	 these	 individual	
transcriptomes	 in	 turn	 enables	 identification	 of	 cellular	 subgroups	 within	 the	 analysed	
population.	Currently	scRNA-seq	techniques	depend	on	separation	of	cells	either	by	FACS	into	
individual	wells	 on	 a	 plate,	microfluidics	 or	 encapsulation	 into	 separate	 reaction	 droplets	
(drop-seq	 based	 techniques).	 Plate-based	 methods	 such	 as	 SMART-seq2	 yield	 higher	
coverage	and	 lower	dropout	rates	(number	of	non-zero	reads	misread	as	zero	reads)	than	
droplet	based	method	such	as	drop-seq	or	10x	Genomic’s	Chromium	platform,	translating	to	
greater	sensitivity	and	ability	to	detect	to	genes	with	low	transcript	abundance	such	as	those	
encoding	GPCRs.	However,	the	throughput	of	SMART-seq2	is	considerably	lower	than	droplet	
based	methods	(100s	vs.	1000-10000s	of	cells)	due	to	the	use	of	plates	(typically	96	or	384	
well	plates)	and	consequently	more	expensive	per	cell	sequenced.		
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Investigating	EEC	diversity	using	scRNA-seq	
Glass	et	al.	(2017)	used	SMART-seq2	to	examine	the	diversity	of	Gcg	expressing	cells	of	the	
murine	 duodenum	 [64].	 Analysis	 of	 transcriptomic	 profiles	 of	 FACS-isolated	 cells	 from	
duodenal	 digests	 generated	 from	 Glu-venus	 mice	 identified	 3	 main	 subgroups.	 The	
predominant	group	(51%)	was	highly	enriched	for	Gcg	and	Pyy	transcripts,	the	second	most	
abundant	 (35%)	was	 identifiable	by	Tph1	 and	Pzp	 enrichment	whilst	 the	 remaining	 group	
(14%	 total)	 was	 particularly	 enriched	 for	Gip	 transcripts.	 These	 results	 imply	 that	 in	 the	
proximal	small	intestine	alongside	the	classical	L-cells,	which	express	high	levels	of	Gcg	and	
Pyy,	a	small	percentage	of	L-cells	overlap	with	K-cells	and	the	remainder	appear	to	overlap	
with	 5-HT	 producing	 EC	 cells	 (Tph1	 encodes	 tyrosine	 hydroxylase	which	 is	 critical	 in	 5-HT	
synthesis).	Meanwhile	Haber	et	al.	(2017)	characterised	epithelial	cells	of	the	small	intestine	
(including	EECs)	using	a	combination	of	high-throughput	drop-seq	and	high	sensitivity	SMART-
seq2	scRNA-seq	[63].	This	enabled	broad	subclustering	of	EECs	by	hormone	expression	profile	
using	the	drop-seq	data	followed	by	comparison	of	the	GPCR	repertoire	of	each	group	using	
the	higher	sensitivity	SMART-seq2	data.	EC	cells,	as	anticipated,	formed	a	separate	subgroup	
from	the	other	EECs	cells.	The	other	EECs	clustered	consisted	of	variations	in	Gcg,	Pyy,	Gip,	
Sst,	Ghrl	and	Cck	co-expression.	Interestingly,	Sct	appeared	to	mark	all	mature	EEC	lineages	
including	 EC	 cells.	 These	 results	 demonstrate	 the	 ability	 of	 scRNA-seq	 to	 identify	 novel	
subclusters	of	EECs.	
	
Here	we	employ	the	use	of	the	Chromium	platform	for	scRNA-seq	analysis	of	colonic	cells	
FACS-isolated	 based	 on	 expression	 of	 the	 mature	 enteroendocrine	 cell	 marker	 NeuroD1	
[139].	 For	 this	 purpose,	 single	 cell	 digests	 were	 prepared	 from	 a	 whole	 colon	 (from	 the	
caecocolic	 junction	to	the	end	of	 the	rectum)	extracted	from	a	NeuroD1-EYFP	mouse	(see	
methods).	The	Chromium	platform	was	chosen	over	plate-based	methods	because	it	allows	
high	 throughput	 analysis	 of	 1000s	 cells	 at	 an	 affordable	 cost	 per	 cell	 screened	 and	 we	
hypothesised	 that	 the	 main	 EEC	 subdivisions	 would	 be	 identifiable	 by	 genes	 with	 high	
transcript	abundance,	such	as	hormones	and	enzymes,	which	are	readily	detectable	by	drop-
seq.	 Use	 of	 the	 lower	 throughput	 of	 plate-based	 techniques	 in	 this	 case	 could	 potential	
restrict	the	ability	to	identify	colonic	EEC	subclusters	as	EC	cells,	which	are	the	most	abundant	
cell	type	making	up	40-70%	of	the	total	EEC	population	in	the	colon,	would	likely	predominate	
[238].	
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5.4. Results	
N.B:	FACS	isolation	of	NeuroD1-EYFP	cells	was	conducted	by	staff	at	the	CIMR	Flow	Cytometry	
Core	and	sorted	cells	were	subsequently	loaded	into	the	Chromium	system	(10x	Genomics)	
by	staff	at	Cancer	Research	UK	Cambridge	Institute.	Quality	control,	read	alignment	and	raw	
count	quantification	for	each	cell	analysed	by	scRNA-seq	was	carried	out	by	Brian	Lam.	
	
Cluster	analysis	of	colonic	NeuroD1	scRNA-seq			Cluster	analysis	of	the	t-SNE	output	from	the	
NeuroD1	scRNA-seq	identified	9	EEC	subgroups	(figure	1B).	edgeR	was	subsequently	used	for	
differential	expression	analysis	allowing	transcriptomic	variations	between	each	subset	to	be	
explored.	The	following	sections	cover	each	of	the	EEC	subgroups	identified	from	this	analysis	
and	key	genes	that	distinguish	them	(figure	2).	
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Figure	1:	 (A)	 FACS	output	 from	 the	NeuroD1	 sort.	 Sorted	 fluorescent	 EYFP	 cells	 ~0.58%	of	
parent	population	following	forward/side	scatter,	DRAQ5	and	DAPI	gating.	7000	EYFP+ve	cells	
were	isolated	in	one	FACS	run	from	one	NeuroD1-EYFP	mouse.	3500	of	these	cells	were	put	
into	the	Chromium	system.		(B)	t-SNE	plot	of	identified	cell	clusters	from	scRNA-seq	analysis	of	
FACS-isolated	NeuroD1	expressing	colonic	cells	(n=1779	cells).	K-means	clustering	was	applied	
to	t-SNE	coordinates	with	k=9.		
NeuroD1+
*488	530/40	eYFP
*3
55
	4
60
/5
0-
DA
PI
A
B
L-cells
D-cells
Goblet Cells
EC cells
	 106	
	
Figure	2:	Heat-map	of	log2	normalised	reads	for	each	cell	for	the	top	differentially	expressed	
genes	 of	 the	 INSL5	 and	 NTS	 L-cells	 together	 with	 the	 secretin,	 Tac1	 and	 piezo2	 EC	 cell	
subgroups,	D-cells	and	goblet	cells.	The	top	10	differentially	expressed	genes	were	identified	
for	 each	 group	 using	 edgeR.	 Likelihood	 ratio	 tests	 were	 applied	 to	 statistically	 examine	
differences	in	transcript	abundance	between	each	cluster	and	all	other	clusters.	Only	genes	
with	an	FDR<0.01	were	included	for	representation.	The	top	10	differentially	expressed	genes	
were	identified	for	each	cluster	by	ranking	calculated	log	fold	changes	in	transcript	abundance	
between	each	group.	Colours	of	top	bar	indicate	cluster	assignment	of	cells.	
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L-cells	
	
The	classical	markers	of	L-cells,	Gcg	and	Pyy	were	both	differentially	enriched	in	clusters	1,	8	
and	 9	 in	 comparison	 to	 the	 other	 clusters,	 identifying	 them	 as	 L-cells	 (figure	 2).	 All	 L-cell	
clusters	(together	with	D-cells)	were	also	enriched	for	Scgn.	Based	on	proximity	on	the	t-SNE	
plot	the	clusters	1	and	9	were	combined	yielding	2	separate	L-cell	subgroups	from	the	cluster	
analysis	(figure	1B).	Differential	expression	analysis	of	all	the	EEC	subgroups	revealed	that	the	
subgroup	comprised	of	clusters	1	and	9	was	enriched	for	Insl5	expression	marking	them	as	
INSL5	cells.	On	the	other	hand,	cluster	8	was	enriched	for	Nts	expression	and	 low	 in	 Insl5	
expression	and	are	referred	to	as	NTS	cells.	385	of	665	cells	(~58%)	L-cells	fell	into	the	INSL5	
cell	 subgroup	 roughly	 consistent	 with	 previous	 data	 implying	 half	 the	 colorectal	 L-cell	
population	 are	 INSL5	 producing	 [88].	 Beyond	 differential	 expression	 of	 Insl5	and	Nts,	 the	
INSL5	cells	are	distinguishable	by	enrichment	in	transcripts	for	various	gut	associated	peptides	
and	 proteins	 such	 as	 Scg2,	 Naaladl1	 and	 Cldn14	 whilst	 NTS	 cells	 are	 distinguished	 by	
enrichment	for	Reg4,	the	transcription	factor	Etv1	and	Cck	expression	(figure	2	and	appendix	
1).	A	subgroup	of	INSL5	cells	(cluster	1)	are	enriched	for	Ppy	transcripts	encoding	pancreatic	
polypeptide	which	is	associated	with	glucose	homeostasis	and	appetite	regulation	[252].		
	
Following	identification,	linear	correlation	between	measured	levels	of	Gcg,	Pyy,	Insl5	and	Nts	
transcripts	were	assessed	for	the	colonic	L-cells.	Correlation	between	Gcg	and	Pyy	(figure	3A)	
in	 L-cells	 was	 negative	 (R=-0.46)	 and	 interestingly,	 whilst	 only	 weak	 positive	 correlation	
(R=0.15)	was	identified	between	Insl5	and	Gcg	levels	(figure	3B),	stronger	positive	correlation	
between	Insl5	and	Pyy	levels	was	found	(R=0.55;	figure	3C).	Contrastingly,	Insl5	was	negatively	
correlated	with	Nts	(R=-0.61;	figure	3D)	and	whilst	Gcg	was	only	weakly	positively	correlated	
with	Nts	 (R=0.093;	 figure	3E),	Pyy	was	negatively	 correlated	with	Nts	 (R=-0.29;	 figure	3F).	
These	 results	 are	 consistent	with	 the	 cluster	 analysis	which	 separated	out	 INSL5	 and	NTS	
producing	L-cells	 into	distinct	subgroups	which	respectively	exhibited	the	highest	 levels	of	
measured	Pyy	and	Nts	(figures	1B	and	2).		
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Figure	3:	Linear	regression	plots	of	log2	normalised	reads	for	(A)	Pyy	vs.	Gcg,	(B)	Insl5	vs.	Gcg,	
(C)	Insl5	vs.	Pyy,	(D)	Insl5	vs.	Nts,	(E)	Nts	vs.	Gcg	and	(F)	Nts	vs.	Pyy	measured	from	all	L-cells.	
R=	Pearson	correlation	coefficient.	n=665	cells.		
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Enterochromaffin	cells	
	
Clusters	2,	3,	4	and	7	were	all	determined	to	be	EC	cells	from	enrichment	of	Tph1	transcripts	
(figure	2).	Tph1	encodes	the	tryptophan	hydroxylase	1,	an	enzyme	which	catalyses	the	rate	
limiting	step	in	serotonin	production	in	EC	cells	[253].	Based	on	the	t-SNE	plot	and	differential	
expression	analysis	of	these	combinations	suggested	existence	of	three	main	subgroups	of	
colonic	EC	cells	represented	by	clusters	2	and	7	and	a	combined	group	of	clusters	3	and	4.		
	
Cluster	2	is	distinguished	by	enriched	Sct	expression	whilst	cluster	7	is	selectively	enriched	for	
Tac1	 and	 Reg4	 transcripts	 (figure	 2).	 Transcripts	 of	 Tac1	 encode	 for	 tachykinin	 peptide	
precursors,	including	substance	P	and	have	been	previously	been	linked	with	EC	cells.	A	subset	
of	these	Tac1-expressing	EC	cells	were	found	to	express	high	levels	of	Reg4	in	other	scRNA-
seq	 based	 studies	 [65].	 Immunohistological	 examinations	 of	 serotonin,	 secretin	 and	
substance	 P	 have	 previously	 identified	 secretin	 and	 substance	 P	 production	 in	 separate	
populations	of	EC	cells,	consistent	with	our	cluster	analysis	results	[254].	Cluster	2	also	shares	
enriched	levels	of	Iapp	expression	with	D-cells.	Iapp	encodes	amylin	and	co-expression	with	
intestinal	Sst	has	been	identified	before	by	scRNA-seq	[63,132].	
	
Contrastingly,	the	third	combined	group	of	EC	cells,	comprised	of	clusters	3	and	4,	is	largely	
distinguished	by	 selective	 enriched	expression	of	 the	 transcription	 factor	Hoxb13	 and	 the	
mechanosensitive	 ion	channel	Piezo2	(figure	2).	As	previously	discussed,	some	EC	cells	are	
mechanosensitive	and	regulate	gastrointestinal	motility	through	5-HT	release.	Recent	Ussing	
chamber	 based	 experiments	 on	murine	 jejeunum	 suggest	 that	 EC	 cell	mechanosensation	
depends	on	Piezo2	activity,	highlighting	this	group	of	EC	cells	as	potentially	mechanosensitive	
[255].	
	
All	 three	groups	of	EC	 cells	were	distinguishable	by	higher	abundance	of	Chgb	 transcripts	
compared	with	the	other	EEC	groups.	
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D-cells	
	
Cluster	5	formed	a	distinctive	and	small	group	of	167	cells	on	the	t-SNE	map	when	compared	
with	the	other	clusters	(figure	1B).	Enrichment	of	Sst	transcripts	within	this	cluster	of	cells	
identifies	 them	 as	 D-cells.	 These	 cells	 are	 also	 distinguishable	 by	 expression	 of	 the	
transcription	factors	Isl1	and	Hhex	(figure	2).	Consistent	with	this	selective	enrichment,	Isl1	
expression	 has	 previously	 been	 identified	 as	 specific	 to	 mature	 D-cells	 in	 the	 murine	
gastrointestinal	 tract	 whilst	 Hhex	 is	 selectively	 expressed	 in	 somatostatin-producing	
pancreatic	delta-cells	where	it	maintains	delta	cell	differentiation	[256,257].		
	
Goblet	Cells	
	
Cluster	6	appears	to	largely	consist	of	goblet	cells	as	this	group	was	differentially	enriched	for	
Muc2	and	Agr2	expression.	Mucin	2	(MUC2)	is	the	predominant	form	of	mucin	produced	and	
secreted	by	intestinal	goblet	cells	forming	a	protective	mucous	barrier	around	the	intestinal	
lumen	[258].	Agr2	encodes	a	protein	essential	for	MUC2	production	by	intestinal	goblet	cells	
and	 is	 therefore	another	marker	of	 intestinal	goblet	cells	 [259].	 	 Likewise,	goblet	cells	are	
known	 to	 express	 high	 levels	 of	 Spink4	 and	Guca2a,	 the	 latter	 of	which	 encodes	 the	 gut	
peptide	guanylin	and	these	two	genes	are	also	enriched	in	cluster	6	[260,261].		
	
 Differential	expression	of	GPCRs	in	colonic	EEC	subgroups	
Differential	expression	analysis	allowed	differences	in	GPCR	repertoires	between	identified	
colonic	EEC	subgroups	to	be	identified.	As	GPCRs	play	a	critical	role	in	EEC	nutrient	sensing	
and	secretory	mechanisms,	identification	of	such	differences	may	reflect	potentially	differing	
secretory	response	profiles	of	EEC	products	to	particular	stimuli.	Figure	4	denotes	expression	
of	the	top	10	GPCRs	 in	each	subgroup	in	heat-map	form	(appendix	3	contains	a	 list	of	the	
GPCRs	 examined).	 The	 following	 sections	 describe	 key	 receptors	 identified	 within	 each	
subgroup:	
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Figure	4:	Heat-map	of	log2	normalised	reads	from	each	cell	for	the	top	differentially	expressed	
GPCRs	for	each	colonic	EEC	subgroup	identified	using	edgeR. 
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Insl5-expressing	L-cells	
	
The	highest	and	most	differentially	expressed	GPCRs	in	Insl5-expressing	L-cells	were	Agtr1a	
and	 Avpr1b	 the	 cognate	 receptors	 for	 angiotensin	 II	 and	 arginine	 vasopressin	 (AVP)	
respectively	(figure	4).	Functional	expression	of	these	receptors	in	Insl5-expressing	L-cells	was	
illustrated	 in	 chapter	 4	 through	 RT-qPCR	 and	 secretion	 experiments.	 Interestingly,	
examination	of	the	scRNA-seq	data	suggests	that	these	receptors	are	largely	absent	from	the	
Nts-expressing	L-cells,	implying	differential	responsiveness	to	angiotensin	II/AVP	by	the	L-cell	
subgroups.	Like	Agtr1a/Avpr1b,	selective	expression	of	the	Gq-coupled	SCFA	receptor	Olfr78,	
the	orphan	GPCR	Gpr85	and	the	galanin	receptor	Galr1	was	found	in	Insl5-expressing	L-cells	
over	 the	 other	 L-cell	 subgroups	 (figure	 4)	 [262–264].	 Previous	 RT-qPCR	 and	
immunohistological	based	studies	indicate	that	Olfr78	is	restricted	to	the	colon	of	mice	and	
overlaps	with	GLP-1	and	PYY	labelling	with	increased	numbers	of	labelled	Olfr78	cells	moving	
distally	 along	 the	 colon.	 Together	with	 evidence	 that	 co-labelling	 of	 Olfr78	with	 PYY	was	
greater	than	with	GLP-1	(35%	of	PYY-labelled	cells	vs.	17%	of	GLP-1	labelled	cells),	the	findings	
are	 consistent	 with	 selective	 expression	 of	 Olfr78	 in	 Insl5-expressing	 L-cells	 which	 are	
enriched	for	Pyy	over	Gcg	expression	[262].	Regarding	Galr1,	functional	expression	of	Galr1	
has	been	 identified	 in	L-cells	of	the	murine	small	and	 large	 intestine	and	has	an	 inhibitory	
effect	 on	 GLP-1	 and	 GIP	 secretion	 through	 Gi-signalling	 [264].	 This	 suggests	 that	 galanin	
application	may	suppress	INSL5	secretory	responses	from	colonic	L-cells.	
	
Nts-expressing	L-cells	
	
Nts-expressing	L-cells	share	expression	of	receptors	such	as	Gpr119,	Gpbar1	and	Sstr5	with	
Insl5-expressing	L-cells	over	the	other	colonic	EEC	subgroups	 (figure	4).	These	findings	are	
reflected	 by	 the	 secretion	 data	 from	 chapter	 4	 which	 indicated	 that	 GPBAR-A,	 a	 specific	
agonist	of	GPBAR-1,	stimulates	simultaneous	colonic	INSL5,	PYY	and	GLP-1	secretion	whilst	
application	of	somatostatin	suppressed	INSL5,	PYY	and	GLP-1	secretory	responses	to	IBMX	
application.	Furthermore,	selective	expression	of	Gpr119,	a	receptor	for	oleoylethanolamide	
(OEA)	has	previously	been	reported	in	intestinal	L-cells	and	appears	to	play	a	key	role	in	OEA-
stimulated	GLP-1	 secretion	 [265].	 Likewise,	Nts	and	 Insl5-expressing	 L-cells	 are	 selectively	
enriched	for	Ffar1	expression,	 reflected	by	co-secretion	of	GLP-1,	PYY	and	 INSL5	observed	
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when	the	selective	FFAR1	agonist	AM-1638	was	added	to	murine	and	human	colonic	crypt	
cultures	(chapter	4).	
	
GPCRs	 transcripts	 differentially	 abundant	 in	 Nts-expressing	 L-cells	 compared	 with	 Insl5-
expressing	L-cells	include	those	for	Gpr27	and	Sucnr1	(figure	4).	The	orphan	GPCR	GPR27	is	a	
poorly	characterised	Gq-coupled	receptor	but	appears	to	modulate	glucose-stimulated	insulin	
secretion	 from	 beta-cells	 since	 knockdown	 of	 Gpr27	 significantly	 attenuated	 glucose-
stimulated	 insulin	 secretion	 from	 isolated	murine	 islets	 [266].	 Likewise,	 glucose-tolerance	
tests	applied	 in	murine	knockout	studies	of	Sucnr1	 (encoding	the	preferentially	Gi-coupled	
succinate	 receptor	 1	 –	 SUCNR1)	 suggest	 that	 SUCNR1	 is	 a	modulator	 of	 insulin	 secretion	
(though	 interestingly	 plasma	 levels	 of	 GLP-1	 appeared	 unaffected	 in	 the	 knockout	 mice)	
[267,268].		
	
Sct-expressing	enterochromaffin	cells	
	
Differentially	expressed	GPCRs	in	Sct-expressing	EC	cells	include	Npy1r,	a	Gi-coupled	NPY/PYY	
receptor	 and	 Adora2a	 which	 encodes	 the	 Gs-coupled	 adenosine	 A2A	 receptor	 [269,270].	
Expression	 of	 both	 receptors	 has	 been	 identified	 previously	 in	 colonic	 EC	 cells	 [240,271].	
Expression	of	Adrb2	encoding	beta-2	adrenergic	receptor,	which	is	Gs-coupled,	was	enriched	
in	Sct-expressing	and	also	in	Piezo2-expressing	EC	cells	(figure	4).		
	
Tac1-expressing	enterochromaffin	cells	
	
Examination	 of	 differentially	 expressed	 GPCRs	 in	 Tac1-expressing	 cells	 found	 limited	
differences.	These	differences	include	Olfr78	and	Olfr558	(figure	4).	Previous	RT-qPCR	analysis	
of	FACS-isolated	colonic	EC	cells	revealed	enrichment	for	both	genes	with	~640	fold	higher	
levels	 of	Olfr78	 than	Olfr558	 [240].	 Our	 results	 appear	 to	 reflect	 these	 findings	 as	Olfr78	
expression	was	higher	in	Tac1-expressing	cells	than	Olfr558	and	unlike	Olfr558,	Olfr78	was	
also	enriched	 in	Piezo2-expressing	EC	cells	 (and	 Insl5-expressing	 L-cells).	Olfr558	 itself	has	
been	poorly	characterised	but	functional	expression	in	intestinal	EC	cells	has	previously	been	
observed	with	Olfr558	appearing	to	respond	to	the	bacterial	metabolite	isovalerate	[119].		
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Piezo2-expressing	enterochromaffin	cells	
	
As	previously	mentioned	Piezo2-expressing	EC	cells	are	enriched	for	Adrb2	and	Olfr78	as	are	
the	Sct	and	Tac1-expressing	subgroups	respectively	(figure	4).	The	Piezo-expressing	group	is	
distinguishable	from	the	other	EC	cell	subgroups	by	enriched	expression	of	Gper1,	Vipr2	and	
Adora3	(figure	4).	Gper1	encodes	a	Gs-coupled	GPCR	for	estrogen	and	has	previously	been	
identified	 in	mucosal	cells	of	the	human	colon.	Expression	 levels	of	Gper1	are	significantly	
higher	in	IBS	patients	relative	to	controls	suggesting	that	GPER1	activity	may	contribute	to	
IBS-related	dysfunctional	gastrointestinal	motility	through	modulation	of	5-HT	secretion	from	
this	particular	subset	of	cells	[272,273].	Vipr2	encodes	vasoactive	intestinal	peptide	receptor	
2	(VIPR2)	which	like	GPER1	is	Gs-coupled.	With	regards	to	the	effects	of	VIP	on	5-HT	secretion,	
findings	 are	mixed	with	one	 study	 indicating	 that	 intravenously	 delivered	VIP	may	 trigger	
colonic	5-HT	secretion	 in	rats	whilst	other	studies	using	 isolated	guinea	pig	small	 intestine	
found	VIP	administration	reduced	5-HT	secretion	[274,275].	Unlike	Adora2a,	which	encodes	
a	Gs-coupled	GPCR	and	was	enriched	in	the	Sct-expressing	EC	cell	subgroup,	Adora3	encodes	
a	Gi-coupled	adenosine	receptor	[276].	This	discrepancy	suggests	that	adenosine	may	have	
differential	 5-HT	 secretory	 effects	 on	 the	 Sct	 and	Piezo2-expressing	 subgroups.	 However,	
stimulation	 of	 Adora3	 could	 actually	 increase	 EC	 cell	 secretory	 activity	 since	 activation	 of	
another	Gi-coupled	GPCR,	alpha-2	adrenergic	receptor	increases	EC	cell	activity	(indicated	by	
triggered	intracellular	Ca2+	transients)	[119].	
	
D-cells	
	
Like	Insl5-expressing	L-cells,	D-cells	were	enriched	with	Agtr1a	transcripts.	Identified	GPCRs	
specifically	enriched	 in	D-cells	 included	Calcrl,	Adra2a	and	Hcar2	 (figure	4).	Calcrl	encodes	
calcitonin	receptor-like	receptor	which	forms	functional	GPCRs	with	different	ligand	affinities	
for	adrenomedullin	and	calcitonin	gene-related	peptide	(CGRP)	when	bound	to	one	of	three	
proteins	known	as	receptor	activity-modifying	proteins	(RAMPs)	[277].	Transcripts	of	Ramp1	
were	enriched	within	the	D-cell	population	(appendix	2)	suggesting	that	CALCRL	and	RAMP1	
form	a	 functional	 receptor	 for	CGRP	 in	colonic	D-cells.	Correspondingly,	Calcrl	and	Ramp1	
expression	 have	 previously	 been	 identified	 in	 gastric	 D-cells	 and	 CGRP	 acted	 as	 a	 potent	
somatostatin	secretagogue	when	applied	to	murine	primary	cultures	of	gastric	pits	[114,115].	
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Adra2a	encodes	the	Gi-coupled	alpha2	adrenergic	receptor	expression	of	which	has	also	been	
previously	identified	in	gastric	D-cells	[115].	RT-qPCR	and	immunohistochemistry	has	found	
that	hydroxycarboxylic	acid	receptor	(HCAR2)	a		Gi-coupled	SCFA	receptor,	encoded	by	Hcar2,	
is	expressed	within	murine	and	human	colonic	epithelial	cells	where	it	potentially	acts	as	a	
tumour	suppressor	[278].	
	
Goblet	cells	
	
The	 purinergic	 receptors	 P2ry1	 and	 P2ry14	 appear	 to	 be	 enriched	 these	 cells	 (figure	 4).	
Consistently,	P2ry1	 expression	has	previously	 been	detected	 in	 the	 rat	 colonic	 epithelium	
[279].		Also	enriched	within	this	population	was	Fzd5	encoding	the	Wnt5A	receptor	frizzled-5	
(figure	4).	One	previous	study	found	that	Fzd5	was	particularly	enriched	within	goblet	cells	
within	the	colonic	mucosa	further	supporting	that	cluster	6	contains	goblet	cells	[280].	
	
 RT-qPCR	examination	of	INSL5	cells	
	
scRNA-seq	analysis	 identified	a	selection	of	genes	for	which	transcripts	were	enriched	and	
other	 genes	 such	 as	Nts	which	had	 a	 low	abundance	of	 transcripts	 specifically	 in	 clusters	
enriched	 for	 INSL5	 transcripts	when	 compared	with	other	 L-cell	 subgroups.	We	 sought	 to	
confirm	 the	 transcriptomic	 profile	 of	 INSL5	 cells	 identified	 by	 scRNA-seq	 using	 RT-qPCR	
analysis	(figure	5).	For	this	analysis,	the	same	cDNA	samples	from	FACS-purified	INSL5	cells	
detailed	in	chapter	4	were	used.	
	
Relative	expression	 (2∆CT,	 +SEM,	 -SEM)	of	 the	peptides	Ppy	and	Nts	was	0.199	 (+0.0902,	 -
0.0836)	and	0.0383	(+0.0319,	-0.0309)	respectively,	reflecting	a	93.2	and	58.5	fold	enrichment	
in	 the	 INSL5	 cells	 compared	 with	 control	 cells.	 Likewise,	 relative	 expression	 of	 the	 SCFA	
receptor	Olfr78	 and	 the	 SCFA	 transporter	Slc5a8	 (see	 appendix	 2)	was	0.0478	 (+0.0276,	 -
0.0269)	and	0.107	 (+0.0295,	 -0.0288)	 respectively,	 representing	expression	1390	and	13.9	
fold	greater	in	INSL5	cells	than	in	the	control	population.	
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Figure	5:	Relative	expression	of	a	selection	of	genes	enriched	within	identified	L-cell	clusters	
by	 FACS-purified	 INSL5	 cells	 (n=3	mice).	 Difference	 in	 cycle	 threshold	 (ΔCT)	was	 evaluated	
between	the	gene	of	interest	and	the	housekeeper	β-actin.	These	values	were	used	to	derive	
relative	expression	as	2ΔCT.	Bars	represent	mean	relative	expression	with	error	bars	reflecting	
SEM	 derived	 from	 ΔCT.	 Black	 coloured	 bars	 represent	 INSL5	 cells	 and	 grey	 coloured	 bars	
represent	control	cells.	Ratio	paired	t-tests	run	on	2ΔCT	values.	*p<0.05,	**p<0.01.	To	obtain	
these	results	RT-qPCR	was	run	on	the	same	cDNA	samples	characterised	in	chapter	4.	
	
 Regional	expression	of	EEC	markers	
	
RT-qPCR	analysis	along	the	proximal-distal	axis	of	the	colon	allowed	regional	profiling	of	key	
gene	markers	of	the	L-cell	subgroups	identified	through	t-SNE	clustering	(figure	6).	For	this	
analysis,	whole	murine	colons	(from	the	caecocolic	junction	to	distal	rectum)	were	sampled	
at	~1cm	intervals	along	the	proximal-distal	axis.	This	yielded	7	segments	for	analysis	denoted	
as,	in	proximal-distal	order,	P1-P7	(see	methods	for	more	details).	For	each	of	the	analysed	L-
cell	markers,	statistically	significant	deviations	were	 identified	between	expression	 in	each	
segment	with	that	of	P1.	
	
Relative	 expression	 of	 Insl5	 was	 highest	 in	 the	 distal	 segments	 of	 colon	 (P4-P7)	 with	
expression	 levels	~50	 times	greater	 than	 in	P1.	Conversely,	 relative	expression	of	Nts	was	
lowest	in	the	distal	segments	of	colon	(P4-P7)	with	expression	levels	~140	times	lower	than	
in	P1.	Relative	expression	of	Gcg	was	significantly	lower	in	P6	and	P7	dropping	to	a	tenth	of	
that	in	P1.	Pyy	expression	was	largely	consistent	in	each	of	the	colonic	segments	examined	
with	peak	expression	(3.6	fold	higher	than	in	P1)	found	in	P5	(figure	6A).	Expression	of	Cck,	
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which	like	Nts	is	enriched	within	the	Nts-expressing	L-cell	subgroup	(appendix	1),	was	lowest	
in	the	distal	colon	(P4-P7)	with	around	one	fifth	of	the	levels	of	expression	seen	in	P1	(figure	
6B).		
	
In	addition	to	markers	of	L-cell	subgroups,	regional	expression	of	Sst	and	Tph1,	markers	of	D-
cells	 and	 EC	 cells	 respectively,	 was	 examined	 (figure	 6B).	 Sst	 expression	 was	 reasonably	
consistent	across	 the	 length	of	 the	colon	though	 in	P7	expression	 levels	were	significantly	
lower	 (6.5	 fold	 lower)	 than	 in	P1.	Tph1	 displayed	 lower	expression	 in	distal	 colon	 (P5-P7)	
relative	to	P1	(dropping	down	~10	fold).	Similarly,	Sct	showed	lowest	levels	of	expression	in	
P6-P7	(28	fold	less	in	P7	compared	with	P1).	These	results	could	reflect	a	decrease	in	total	
mature	EECs	along	the	proximal-distal	axis	particularly	of	EC	cells	and	Nts-expressing	L-cells.	
	
 Regional	expression	of	GPCRs	highlighted	by	scRNA-seq	analysis	
	
Expression	of	genes	encoding	various	functional	L-cell	receptors	highlighted	in	the	scRNA-seq	
cluster	 analysis	 were	 evaluated	 across	 the	 proximal-distal	 axis	 of	 the	 colon	 in	 the	 same	
manner	as	for	the	EEC	markers	(figure	6C).	Expression	of	Agtr1a	(transcripts	of	which	were	
enriched	in	the	INSL5	cluster)	did	not	significantly	differ	between	the	segments	of	colon	along	
the	proximal-distal	axis	analysed	(P1-P7).	Neither	did	expression	of	Ffar1	or	Gpbar1	(receptors	
expressed	 within	 all	 colonic	 L-cell	 subpopulations)	 or	 that	 of	 Calcrl	 (specifically	 enriched	
within	 the	 D-cell	 subcluster).	 On	 the	 other	 hand,	whilst	 expression	 of	Avpr1b	 (which	 like	
Agtr1a	is	highly	enriched	within	the	INSL5-producing	L-cell	subpopulation)	was	notably	lower	
in	all	the	colonic	segments	analysed	than	for	the	other	receptors	examined,	it	was	significantly	
higher	in	more	distal	segments	of	colon	(P3-P7)	relative	to	P1	(peaking	at	34	fold	higher	in	
P6).	
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Figure	6:	 Relative	expression	of	 identified	 L-cell	 subgroup	 (A),	 enterochromaffin	and	D-cell	
markers	along	with	Cck	(B)	and	a	subset	of	identified	GPCRs	(C)	across	the	proximal-distal	axis	
of	the	murine	colon.	Murine	colons	were	sampled	every	1cm	along	the	proximal-distal	axis	
(starting	from	the	caecocolic	junction).	These	samples	are	denoted	as	P1-P7	(proximal-distal).	
Cycle	 threshold	difference	calculated	between	the	gene	of	 interest	and	the	housekeeper	β-
actin	(CTβ-actin-CTGene).	n=3	mice.	Plotted	points	and	bars	represent	mean	±	SEM.	Statistically	
significant	 deviations	 in	 cycle	 threshold	differences	 from	values	 in	 P1	were	assessed	using	
repeated-measures	 one-way	 ANOVA	 with	 Dunnett’s	 correction.	 	 *p<0.05,	 **p<0.01,	
***p<0.001. 	
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 Immunofluorescent	 labelling	of	 INSL5,	PYY	and	NTS	 in	wholemounted	
murine	colon	
	
To	examine	the	distribution	of	L-cell	subgroups	along	the	proximal-distal	axis	of	the	colon	I	
immunofluorescently	labelled	INSL5,	PYY	and	NTS	in	whole-mounted	murine	colons	(figure	
7).	Automated	cell	 counts	were	 then	made	 for	 single,	dual	 and	 triple	 labelled	 cells	within	
proximal	(P1-P2),	intermediate	(P3-P5)	and	distal	(P6-P7)	segments	of	colon	using	HALO	(see	
methods).	The	overall	cell	counts	for	NTS,	PYY	and	INSL5	labelled	cells	(figure	7B)	were	highly	
variable	between	the	different	mice	but	generally	showed	trends	toward	increased	INSL5	and	
PYY	 cell	 density	 in	 the	 distal	 end	 of	 the	 colon	 (71.8	 and	 113.8	 cells/mm2	 respectively)	
compared	with	 in	proximal	colon	(36.6	and	76.2	cells/mm2	respectively).	Contrastingly	the	
density	of	NTS	labelled	cells	was	higher	in	proximal	colon	(19.6	cells/mm2)	than	in	distal	colon	
(3.0	cells/mm2).	In	all	regions,	the	number	of	PYY	and	INSL5	labelled	cells	was	far	greater	than	
those	labelled	for	NTS.		
	
Analysis	of	cells	labelled	for	NTS,	INSL5	and	PYY	revealed	that	roughly	54%	of	the	total	cells	
counted	were	labelled	with	INSL5,	76%	with	PYY	and	7%	with	NTS.	The	majority	of	the	INSL5	
labelled	cells	were	either	dual-labelled	with	PYY	(54%)	or	singularly	labelled	for	INSL5	(42%)	
with	 very	 few	 triple	 labelled	 (4%)	 or	 dual-labelled	 with	 NTS	 (<0.5%;	 figure	 7C).	 Likewise,	
roughly	50%	of	all	NTS	cells	were	dual-labelled	with	PYY,	30%	were	triple	labelled,	<2%	dual	
labelled	with	INSL5	and	the	remaining	18%	single	labelled	for	NTS	(figure	7C).	Unlike	NTS	and	
INSL5	labelled	cells,	roughly	~54%	of	all	PYY	labelled	cells	were	singularly	labelled	whilst	38%	
were	dual	labelled	with	INSL5,	5%	were	dual	labelled	with	NTS	and	3%	were	triple	labelled	
(figure	7C).		
	
Figure	7D	illustrates	the	breakdown	of	single,	dual	and	triple	labelled	colonic	cells	across	the	
proximal-distal	axis.	As	anticipated	from	the	decline	in	NTS-labelled	cells,	the	percentage	of	
triple	 labelled	cells	decreases	dramatically	moving	from	proximal	to	distal	colon	whilst	the	
proportion	of	INSL5	labelled	cells	increases,	particularly	the	single	labelled	variant.	
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 Figure	7:	 Immunofluorescent	 labelled	 INSL5,	PYY	and	NTS	cells	 in	murine	wholemounts	of	
colon	(see	methods).	(A)	Representative	images	of	proximal	(P1-P2),	intermediate	(P3-P5)	and	
distal	(P6-P7)	colon.	Scale	bar	=	50µm.	(B)	Plot	showing	the	density	of	NTS,	PYY	and	INSL5	cells	
observed	within	proximal,	 intermediate	and	distal	colon.	Points	and	bars	plotted	represent	
mean	±	SEM.	n=3	mice.	Statistically	significant	differences	in	cell	density	between	each	region	
and	proximal	colon	were	identified	using	repeated	measures	one-way	ANOVA	run	on	square	
root	transformed	data.	*p<0.05.	(C)	Co-labelling	breakdown	of	identified	INSL5,	NTS	and	PYY	
cells.	Bars	reflect	average	percentage	of	cells	singularly,	dual	or	triple	labelled.	 	(D)	Colour-
coded	co-labelling	breakdown	of	cells	single,	dual	and	triple	labelled	for	INSL5,	PYY	and	NTS	
by	region	of	colon.	
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 Secretory	responses	
	
To	examine	the	physiological	relevance	of	the	proximal-distal	distribution	of	L-cell	subgroups	
identified	in	the	colon,	we	examined	INSL5,	PYY	and	NTS	secretory	responses	of	colonic	crypt	
cultures	generated	from	different	regions	along	the	proximal-distal	axis.	For	these	regional	
crypt	cultures,	murine	colons	were	subdivided	 into	proximal	 (P1-P2),	 intermediate	 (P3-P5)	
and	distal	 (P6-P7)	 fractions	and	 for	each	experiment	 fractions	 from	2	different	mice	were	
pooled	together	and	seeded	onto	12-well	plates.	The	stimuli	tested	were	angiotensin	II,	AM-
1638	and	IBMX.	Angiotensin	II	and	AM-1638	were	selected	based	on	differential	expression	
of	Agtr1a	and	Ffar1	 identified	between	the	L-cell	subgroups	(figure	3).	Responses	to	IBMX	
acted	as	a	positive	control.		
	
Comparison	of	the	basal	levels	of	INSL5	secreted	between	the	different	regions	highlighted	
increasing	 levels	 of	 INSL5	 moving	 along	 the	 proximal-distal	 axis.	 Basal	 INSL5	 levels	 were	
significantly	~21	and	~29	times	higher	in	the	intermediate	and	distal	colon,	respectively,	than	
in	 the	 proximal	 colon.	 Showing	 a	 reverse	 of	 this	 trend,	 basal	 NTS	 levels,	 though	 not	
significantly	different,	were	~5	times	 lower	 in	the	 intermediate	colon	than	 in	the	proximal	
colon	and	below	the	detectable	threshold	in	distal	colonic	samples.	Measurements	of	basal	
PYY	secretion	did	not	identify	any	significant	difference	(p>0.05)	in	basal	secretion	along	the	
proximal-distal	colonic	axis.		
	
Responses	to	the	FFAR1	agonist	AM-1638	largely	reflected	the	regional	pattern	of	basal	INSL5,	
NTS	and	PYY	secretion.	Significant	INSL5	responses	were	only	triggered	from	the	intermediate	
and	distal	regions.	Contrastingly,	though	not	significantly,	there	was	a	trend	towards	elevated	
levels	 of	 NTS	 measured	 following	 AM-1638	 administration	 to	 proximal	 and	 intermediate	
colon	relative	to	basal.	Differences	in	NTS	responses	to	AM-1638	between	the	proximal	and	
intermediate	 colon	were	 significant	 however.	 Given	 that	 no	 significant	 proximal	 INSL5	 or	
intermediate	colonic	NTS	responses	were	recorded	to	the	positive	control	IBMX	(compared	
to	basal),	these	results	either	reflect	insufficient	sensitivity	of	the	assay	to	detect	responses	
to	AM-1638	or	an	absence	of	FFAR1	responsive	INSL5/NTS	producing	cells	in	these	regions.	
On	the	other	hand,	AM-1638	triggered	significant	 responses	 to	PYY	across	all	 regions	 that	
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were	not	significantly	different	 from	one	another.	This	 implies	 that	consistent	numbers	of	
FFAR1	expressing	PYY-producing	cells	are	scattered	along	the	length	of	the	colon.		
	
Recorded	responses	to	angiotensin	II	were	more	variable	than	for	AM-1638.	No	significant	
NTS	 responses	 were	measured	 to	 angiotensin	 II	 application	 in	 any	 region.	 INSL5	 did	 not	
display	significant	responses	to	angiotensin	II	in	the	intermediate	or	distal	colon	(levels	in	the	
proximal	 colon	 were	 undetectable)	 when	 compared	 to	 basal	 secretion	 though	 levels	
measured	 from	 distal	 colon	 were	 significantly	 higher	 than	 from	 intermediate	 colon.	 PYY	
responses	 to	 angiotensin	 II	were	only	 significantly	different	 from	basal	 levels	 in	 the	distal	
colon.	Together	these	results	suggest	differential	L-cell	Agtr1a	expression	along	the	proximal-
distal	axis	of	the	colon	with	specific	enrichment	in	INSL5-producing	cells.	
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Figure	8:	INSL5	A-chain	(A),	PYY	(B)	and	NTS	(C)	secretory	responses	of	murine	colonic	crypt	
cultures	produced	from	proximal,	intermediate	and	distal	regions	of	the	colon	measured	by	
LC/MS.	The	stimuli	tested	(over	1	hour)	were:	3µM	AM-1638,	10nM	angiotensin	II	and	100mM	
IBMX	with	10mM	glucose.	The	basal	condition	was	saline	buffer	with	no	added	glucose.	IBMX	
acted	as	a	positive	control.	Normalised	intensity	reflects	measured	peptide	intensity	(integral	
of	signal	peak	observed	at	each	peptide’s	specific	m/z	and	retention	time)	normalised	to	total	
protein	 content	 for	 each	 well	 measured	 through	 a	 BCA	 assay.	 Statistically	 significant	
responses	 (#p<0.05)	 to	 a	 particular	 stimulus	 were	 assessed	 through	 comparison	 to	 basal	
responses	 in	 each	 region	 using	 one-way	 ANOVA	 tests	 on	 square	 root	 transformed	 data.	
Statistical	 significant	differences	between	 regional	 responses	 to	a	particular	 stimulus	were	
assessed	by	one-way	ANOVA	tests	on	square	root	transformed	data	(one-way	t-tests	used	for	
INSL5	responses	to	angiotensin	II	and	all	NTS	responses).	*p<0.05,	**p<0.01	and	***p<0.001.	
Bars	represent	mean	+	SEM.	Results	derived	from	2	plates	of	crypt	cultures	from	4	separate	
mice	with	 test	 conditions	 run	 in	duplicate	on	each	plate.	N=	4	 independent	wells	with	 the	
following	exceptions:	n=3	for	proximal	NTS	responses	to	angiotensin	 II;	n=2	for	 INSL5	from	
proximal	colon	and	intermediate	colon	for	NTS	in	the	basal	condition	together	with	PYY	from	
the	proximal	colon	and	NTS	 from	 intermediate	colon	 in	 the	angiotensin	 II	 condition.	These	
exceptions	(where	n<4)	reflect	undetectable	levels	of	peptides	in	1	or	more	wells	analysed.	
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5.5. Discussion	
 Colonic	L-cells	split	into	distinct	proximal	Nts-expressing	and	distal	Insl5-
expressing	subgroups	
Consistent	with	evidence	that	~50%	of	colonic	L-cells	express	Insl5,	our	scRNA-seq	analysis	of	
colonic	EECs	indicates	that	colonic	L-cells	can	be	split	into	two	subgroups,	one	enriched	for	
Insl5	and	low	in	Nts	transcripts	and	one	enriched	with	Nts	and	low	in	Insl5	transcripts.	
	
NTS	 has	 previously	 been	 identified	 in	 intestinal	 L-cells	 (by	 immunohistochemistry	 and	
expression	 analysis)	 and	 is	 co-released	 with	 GLP-1	 and	 PYY	 exerting	 anorexigenic	 effects	
[101,239].	In	accordance,	Ratner	et	al.	suggest	that	(from	in	vivo	experiments	with	rats	using	
NTS	 receptor	 antagonists)	 part	 of	 the	 weight	 loss	 following	 RYGB	 results	 from	 increased	
plasma	NTS	[105].	With	respect	to	the	colon,	NTS	has	been	 linked	to	colitis	and	colorectal	
tumours	 due	 to	 enriched	 expression	 of	 NTS	 and	 NTS	 receptor	 1	 together	 with	 known	
proinflammatory	and	trophic	effects	of	NTS	[103,104,281].	The	Nts-expressing	cells	here	may	
exert	these	effects	through	NTS	release.	
	
Regional	RT-qPCR	analysis	of	the	colon	suggests	that	Nts	expression	is	concentrated	in	the	
proximal	part	of	 the	colon	whilst	 Insl5	 expression	 (in	accordance	with	previous	 studies)	 is	
concentrated	 in	 the	distal	colon	 [88].	Meanwhile,	Pyy	expression	was	 relatively	consistent	
between	 colonic	 segments	 but	Gcg	 expression	was	 lower	 in	more	 distal	 segments	 [282].	
Furthermore,	Cck	expression	was	lowest	in	the	most	distal	segments	of	colon	consistent	with	
a	previous	examination	of	regional	expression	and	consistent	with	a	drop	in	Nts-expressing	L-
cells	 (Cck	 expression	 was	 enriched	 in	 Nts-expressing	 L-cells	 –	 see	 appendix	 1)	 	 [282].	
Consistently,	 previous	 investigations	 by	 Fakhry	 et	 al.	 (2017)	 found	 that	 Cck	 expression	
dropped	moving	from	proximal	to	distal	colon	 in	mouse.	Furthermore	Fakhry	et	al.	 (2017)	
using	immunostaining	and	peptidomic	analysis	detected	low	levels	of	bioactive	CCK	peptides	
in	 the	colon	and	that	CCK	 labelled	cells	often	co-stained	 for	PYY	suggesting	 that	 the	L-cell	
enrichment	 for	 CCK	 transcripts	 identified	 in	 the	 scRNA-seq	 analysis	 here	 may	 reflect	
production	 and	 secretion	 of	 bioactive	 CCK	 peptides	 [283].	 Examination	 of	
immunofluorescently	labelled	murine	colonic	wholemounts	yielded	results	largely	matching	
these	expression	patterns	with	the	density	of	NTS	cells	significantly	decreasing	and	density	of	
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INSL5	 cells	 showing	 a	 trend	 towards	 higher	 levels	 towards	 the	 distal	 colon.	 The	 NTS	
distribution	is	supported	by	analysis	of	NTS	content	from	proximal	and	distal	murine	colon	
indicating	a	dramatic	drop	moving	distally	[97].	Furthermore,	whilst	INSL5	and	PYY	labelled	
cells	displayed	considerable	overlap,	 less	than	5%	of	INSL5	cells	were	also	labelled	for	NTS	
although	~30%	of	NTS	cells	were	 labelled	with	 INSL5	(this	discrepancy	 is	due	to	the	 larger	
number	of	cells	labelled	for	INSL5	than	NTS).	The	RT-qPCR	data	suggests	low,	but	significant	
Nts	expression	in	FACS-isolated	INSL5	cells	which	could	reflect	the	small	percentage	of	INSL5	
cells	co-labelled	with	NTS	observed.	When	interpreting	the	observed	pattern	of	co-staining	it	
is	 important	 to	note	 that	 the	accuracy	of	 the	 cell	 counts	depend	on	 the	 sensitivity	of	 the	
antibodies	used	to	their	respective	antigens.	For	example,	the	low	number	of	NTS	labelled	
cells	 identified	 (when	 compared	with	 INSL5	 and	PYY	 labelled	 cells)	 and	 low	proportion	of	
INSL5	and	PYY	labelled	cells	co-stained	for	NTS	could	reflect	that	the	primary	antibody	of	NTS	
used	had	a	low	sensitivity	to	NTS	leading	to	an	underestimation	of	NTS	positive	cells	(both	
single	labelled	and	co-labelled	for	INSL5	and/or	PYY).	Indeed,	this	could	explain	why	despite	
relatively	low	numbers	of	NTS	positive	cells,	in	the	secretion	experiments	the	measured	levels	
of	NTS	often	exceeded	those	of	INSL5	and	PYY	(figure	8).	Alternatively,	though	NTS	cells	might	
be	scarce	they	may	produce	and	secrete	higher	quantities	of	NTS	or	the	higher	levels	of	NTS	
observed	might	relate	to	a	more	effective	extraction	of	NTS	relative	to	INSL5	and	PYY	prior	to	
LC/MS	analysis.	These	caveats	aside,	our	findings	are	consistent	overall	with	the	existence	of	
largely	separate	INSL5	and	NTS-producing	colonic	L-cell	subpopulations.		
	
Intriguingly,	despite	possessing	abundant	levels	of	Pyy	transcripts,	as	indicated	by	RT-qPCR	
(chapter	4)	and	scRNA-seq	analysis	(figure	2),	roughly	42%	of	the	INSL5	labelled	cells	did	not	
stain	for	either	PYY	or	NTS.	On	the	other	hand,	~80%	of	NTS	labelled	cells	co-stained	for	PYY.	
The	reason	for	this	discrepancy	is	unclear	but	could	result	from	sensitivity/specificity	issues	
with	the	immunofluorescent	labelling	of	PYY/INSL5.	An	alternative	explanation	is	that	a	large	
proportion	of	the	Pyy	transcripts	in	the	Insl5-expressing	cells	are	not	translated	into	functional	
protein.	This	second	possibility	highlights	a	central	issue	with	interpreting	transcriptomic	data	
which	is	that	measured	transcript	abundance	does	not	always	correlate	with	protein	product	
abundance	 for	 a	 particular	 gene	 with	 large	 variations	 in	 translational	 efficiency	 between	
different	 genes	 [284].	 Such	 issues	 could	be	overcome	by	profiling	 the	 transcriptomes	and	
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proteomes	of	individual	cells	in	parallel	within	a	single	reaction,	allowing	direct	comparison	
between	expression	of	genes	at	the	transcript	and	protein	level	[285].	
	
Regarding	 identification	 of	 enteroendocrine	 peptides	 other	 than	 GLP-1,	 PYY	 and	 INSL5	
produced	by	 Insl5-expressing	L-cells,	the	scRNA-seq	analysis	highlights	secretogranin	2	and	
pancreatic	polypeptide	as	potential	candidates.	Secretoneurin,	the	active	peptide	derivative	
of	 secretogranin	 2,	 has	 been	 implicated	 in	 a	 diverse	 range	 of	 physiological	 functions	
throughout	 the	 body,	 including	 regulation	 of	 reproductive	 processes,	 angiogenesis	 and	 in	
inflammation	and	has	been	measured	in	the	rat	intestine	by	radioimmunoassays	[286,287].	
Hypothalamic	 expression	 of	 Scg2	 increases	 after	 a	 24-hour	 fast	 in	 mice	 suggesting	
involvement	 in	 appetite	 regulation.	 In	 fact,	 secretogranin	 2	 mediates	 accumulation	 of	
hormones	 such	as	orexin	 into	 secretory	granules	 implying	 that	 it	may	 facilitate	 release	of	
appetite	regulatory	peptides	[288].	Therefore,		Scg2	enrichment	in	Insl5-expressing	cells	could	
indicate	secretogranin	involvement	in	INSL5	packaging	into	secretory	vesicles.	Alternatively,	
these	cells	may	secrete	secretoneurin	directly	 into	the	bloodstream	exerting	direct,	 INSL5-
independent,	physiological	effects.	
	
The	 other	 candidate	 peptide,	 pancreatic	 polypeptide	 (PP)	 is	 predominantly	 produced	 and	
released	from	PP	cells	of	the	pancreatic	islets	but	rare	numbers	of	PP-producing	cells	have	
been	detected,	by	immunohistochemistry,	in	the	human	colon	and	rectum	[67].	Interestingly	
the	 intestinal	 PP	 cells	 do	 not	 appear	 to	 produce	 PYY	 and	 could	 comprise	 some	 of	 the	
immunofluorescently	labelled	INSL5	cells	we	observed	in	murine	colon	wholemounts	that	did	
not	 overlap	 with	 PYY	 [289].	 Regarding	 function,	 PP	 has	 an	 anorexigenic	 effect	 when	
administered	 in	vivo	or	overexpressed	[252].	Physiologically,	PP	release	has	a	cephalic	and	
postprandial	 phase.	 The	 cephalic	 phase	 depends	 on	 vagal	 innervation	 as	 evidenced	 by	
abolished	PP	responses	to	sham-feeding	following	vagotomy	[290].	Post-prandial,	PP	release	
is	stimulated	by	dietary	components	such	as	protein	and	fats	as	well	as	gut	hormones	such	as	
CCK	and	gastrin	[291–293].	Therefore,	the	PP-expressing	subset	of	INSL5	cells	may	contribute	
to	PP	release	following	a	meal	by	secreting	PP	(along	with	INSL5)	in	response	to	dietary	stimuli	
and	circulating	hormones.	
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Regarding	 the	 relevance	 of	 these	 murine	 findings	 to	 human	 physiology,	 whilst	 INSL5-
producing	L-cells	are	found	in	the	large	intestines	of	both	humans	and	mice,	in	humans	NTS-
producing	cells	are	largely	restricted	to	the	jejenum	and	are	scarce	(1	per	100	crypts)	in	the	
large	 intestine	 [98,99,104].	 This	 suggests	 that	 in	 humans	 the	 non-INSL5	producing	 L-cells,	
which	 constitute	 roughly	 half	 all	 colonic	 L-cells,	 are	 unlikely	 to	 be	 distinguished	 by	 NTS.	
However,	it	is	possible	that	these	human	L-cells,	with	the	exception	of	NTS-expression,	exhibit	
the	same	markers	and	differences	in	GPCR	repertoire	as	seen	between	murine	Insl5	and	Nts-
expressing	L-cells.	Murine	colonic	Nts-expressing	L-cells	may	also	serve	as	a	model	of	human	
jejenunal	N-cell	physiology.	Guided	by	the	results	from	the	murine	scRNA-seq	presented	here,	
further	 study	 using	 human	 tissue,	 including	 secretion	 assays,	 should	 help	 clarify	 the	
physiological	relevance	of	murine	colonic	NTS-producing	L-cells.	
	
 Insl5-expressing	 and	 Nts-expressing	 L-cells	 display	 functional	
differences	in	GPCR	repertoire	
The	differential	expression	analysis	highlighted,	amongst	others,	Agtr1a,	Avpr1b,	Olfr78	as	
GPCR	genes	selectively	enriched	(at	least	at	the	transcript	level)	within	Insl5-expressing	cells	
when	 compared	 with	 Nts-expressing	 L-cells.	 Enrichment	 of	 these	 genes	 within	 Insl5-
expressing	L-cells	was	confirmed	by	RT-qPCR	 (figure	4	and	chapter	4).	Contrastingly	many	
GPCR	genes,	such	as	Ffar1,	Gpbar1	and	Sstr1	were	enriched	in	both	Insl5	and	Nts-expressing	
L-cells,	indicating	a	degree	of	GPCR	overlap	between	the	two	populations.		
	
Examination	of	Ffar1,	Gpbar1,	Agtr1a	and	Avpr1b	expression	along	the	proximal-distal	axis	of	
the	colon	revealed	no	significant	differences	in	regional	expression	except	for	Avpr1b	which	
was	expressed	at	higher	levels	in	the	distal	colon.	The	results	concerning	Ffar1	and	Gpbar1	
are	backed	up	by	murine	expression	analysis	by	Symonds	et	al.	(2015)	comparing	expression	
in	the	proximal	(first	half)	and	distal	(2nd	half)	of	colon	which	was	also	replicated	in	human	
colonic	samples	[282].	Based	on	the	concentration	of	Insl5-expression	and	INSL5-producing	
L-cells	 in	 the	 distal	 colon	 and	 the	 enrichment	 of	 Agtr1a	 and	 Avpr1b	 transcripts	 in	 this	
subgroup,	one	might	have	anticipated	Agtr1a	expression	to	also	be	enriched	in	distal	colon.	
This	was	not	found	to	be	the	case.	However,	this	possibility	still	exists	given	that	expression	
was	not	determined	from	isolated	colonic	L-cells	but	a	mix	of	different	cell	types.	L-cell	specific	
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Agtr1a	expression	concentrated	in	the	distal	colon	might	be	obscured	by	Agtr1a	expression	
in	other	more	numerous	cell	types	present	in	the	samples	analysed.	
	
Functional	L-cell	expression	of	Agtr1a	and	Avpr1b	was	described	in	chapter	4	with	angiotensin	
II	and	AVP	triggering	co-secretion	of	INSL5,	PYY	and	GLP-1	from	murine	and	human	colonic	
crypt	 cultures.	 The	 murine	 crypt	 cultures	 were	 produced	 from	 whole	 colons	 from	 the	
caecocolic	junction	down	to	the	end	of	the	rectum.	Therefore,	based	on	the	data	presented	
here	in	chapter	5,	these	cultures	would	contain	a	mix	of	proximal	and	distal	EEC	populations	
including	Nts	and	Insl5-expressing	L-cells.	To	isolate	regional	specific	secretory	responses,	we	
performed	secretion	assays	on	crypt	cultures	produced	from	proximal,	intermediate	(middle)	
and	distal	(rectum)	colon.	In	the	basal	condition,	we	found	that,	as	expected,	NTS	levels	were	
highest	 in	 the	 proximal	 colon	 and	 undetectable	 in	 the	 distal	 colon	 whilst	 INSL5	 levels	
increased	moving	from	the	proximal	to	distal	colon	and	PYY	levels	did	not	significantly	vary	
between	regions.	Similar	regional	differences	of	the	NTS,	INSL5	and	PYY	secretory	responses	
to	AM-1638	and	 the	positive	control	10mM	glucose	+	 IBMX	were	observed.	On	 the	other	
hand,	application	of	angiotensin	 II	appeared	to	trigger	 INSL5	and	PYY	responses	only	from	
distal	 crypt	 cultures	 and	 not	 from	 any	 region	 for	 NTS.	 Consistently,	 no	 significant	 NTS	
responses	 were	 measured	 in	 secretions	 from	 whole	 colon	 generated	 crypt	 cultures	 to	
angiotensin	II	(or	 indeed	AVP)	application	whereas	INSL5,	GLP-1	and	PYY	were	co-secreted	
(unpublished	data	from	Pierre	Larraufie).	Combined	with	the	scRNA-seq	and	RT-qPCR	data	
these	 results	 imply	 specific	 functional	 expression	 of	 Agtr1a	 in	 Insl5-expressing	 over	Nts-
expressing	L-cells	and	non-specific	L-cell	expression	of	Ffar1.	Thus,	the	Insl5-expressing	and	
Nts-expressing	 L-cell	 subsets	 are	 not	 simply	 distinguished	 by	 differential	 EEC	 peptide	
expression	and	production	but	also	functional	GPCR	expression.	
	
Specific	 pharmacological	 targeting	 of	 the	 non-Insl5	 expressing	 L-cell	 population,	 avoiding	
secretion	of	orexigenic	INSL5,	may	enhance	the	anorexigenic	effects	of	stimulated	GLP-1/PYY	
release.	To	this	end,	future	studies	should	examine	the	functionality	of	differentially	enriched	
Gq/Gs-coupled	GPCRs	in	the	NTS	cell	population	such	as	GPR27.		
	
It	should	be	noted	that	generally	expression	levels	of	GPCRs	are	relatively	low	compared	with	
other	gene	families	(including	hormones	and	transcription	factors)	[294–296].	This	is	indeed	
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evident	from	the	low	levels	of	GPCR	transcripts	detected	(figure	4)	when	compared	with	the	
levels	of	detected	transcripts	encoding	hormones	and	other	key	EEC	biomarkers	(appendix	
1).	As	previously	discussed	droplet-based	scRNA-seq	platform	such	as	the	Chromium	system	
employed	 here	 are	 poor	 at	 detecting	 genes	 which	 are	 expressed	 at	 low	 levels	 [297].	
Consequently,	it	is	likely	that	the	scRNA-seq	analysis	detailed	here	did	not	detect	GPCRs	with	
low	expression	levels	within	the	identified	EEC	subgroups.	Such	issues	could	be	avoided	by	
using	by	using	a	platform	with	greater	sensitivity	to	genes	with	low	expression	levels	such	as	
the	plate-based	SMART-seq2	platform.	For	example,	 in	 the	 context	of	 L-cells	 SMART-seq2	
could	be	used	 to	analyse	 the	 transcriptomes	of	 FACS-isolated	 L-cells	 (e.g.	 from	Glu-Venus	
mice	for	example	in	a	similar	manner	to	that	used	by	Glass	et	al.	(2017))	in	order	to	identify	
additional	GPCRs	differentially	expressed	between	the	L-cell	subgroups	described	here	[64].	
	
 Colonic	 enterochromaffin	 cells	 comprise	 of	 three	 subpopulations	
marked	by	Sct,	Tac1	and	Piezo2	expression	
The	 Sct-expressing	 subgroup	 of	 EC	 cells	 identified	 likely	 constitutes	 a	 population	 of	 Sct	
expressing	cells	that	were	previously	found	in	murine	colon	using	in	situ	hybridisation	[298].	
Interestingly,	 these	cells	often	also	co-labelled	 for	Gcg,	Pyy	and	Nts	which	may	reflect	Sct	
enrichment	in	observed	in	a	subset	Nts-expressing	cells	(figure	2).	Our	findings	suggest	that	
although	 Sct-expression,	 as	 postulated	 by	 Haber	 et	 al.,	 appears	 to	 mark	 mature	
enteroendocrine	cells	(transcripts	were	picked	up	in	the	majority	of	the	scRNA-seq	analysed	
NeuroD1	cells),	subsets	of	EECs	appear	to	display	specific	enrichment	for	Sct	expression	[63].	
Whether	this	Sct-expression	reflects	functional	secretin	production	from	these	subgroups	is	
not	 clear.	 Clarification	 could	 be	 obtained	 through	 mass	 spectrometry	 analysis	 of	 colonic	
sample	peptide	content	together	with	immunofluorescent	experiments.	It	should	be	noted	
that	whilst	Lund	et	al.	(2018)	identified	Sct	expression	in	small	intestinal	EC	cells,	they	did	not	
detect	Sct	 expression	 in	 colonic	 EC	 cells	 [240].	 Expression	of	 the	NPY/PYY	 receptor	Npy1r	
raises	 the	 prospect	 of	 L-cell	 modulation,	 via	 PYY	 release,	 of	 5-HT	 release	 from	 the	 Sct-
expressing	subgroup	of	EC	cells.	Sct-expressing	EC	cells	may	therefore	sense	luminal	contents	
indirectly	through	L-cell	activation	[240].	
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The	second	identified	group	of	EC	cells	were	highly	enriched	for	Tac1-expression	and	unlike	
the	other	EC	cells	may	mediate	local	inflammatory	responses	to	bacterial	infection	or	damage	
to	the	mucosa.	This	prediction	derives	from	the	potential	production	and	release	of	substance	
P,	 derived	 downstream	 of	 Tac1	 expression,	 from	 these	 cells	 which	 is	 a	 known	
proinflammatory	 peptide.	 It	 is	 known	 to	 trigger	 cytokine	 production	 and	 release,	 local	
vasodilation	and	algesia	and	even	possesses	antimicrobial	properties	[299–302].	With	regards	
to	 the	 intestine,	 substance	P	has	been	 implicated	 in	 intestinal	 inflammation	with	possible	
significance	 to	 the	 pathphysiology	 of	 IBD	 and	 as	 a	 regulator	 of	 circular	 smooth	 muscle	
contractions	in	human	colon	[303–305].	Therefore,	in	addition	to	potential	mediation	of	local	
inflammatory	 responses,	 substance	 P	 release	 may	 represent	 an	 additional	 means	 of	
modulating	colonic	contractility	to	5-HT	release	in	Tac1-expressing	cells	when	compared	with	
the	other	EC	subgroups.	Together	our	findings	imply	that	further	study	of	this	subgroup	of	
Tac1-expressing	 EC	 cells,	 particularly	 regarding	 differential	 stimulation	 from	 the	 other	 EC	
groups	 by	 OLFR78/558	 stimulation,	 may	 yield	 insight	 into	 inflammatory	 disorders	 of	 the	
intestine	including	IBD.		
	
Recent	findings	from	Beumer	et	al.	(2018)	suggest	that	Sct-expressing	and	Tac1-expressing	EC	
cells	may	occupy	different	positions	within	the	crypt	axis	with	Sct-expressing	EC	cells	clustered	
around	 the	 distal	 crypt	 (i.e.	 closest	 to	 the	 lumen)	 and	 Tac1-expressing	 EC	 cells	 clustered	
around	the	base	of	the	crypt	[132].	In	crypts	of	both	the	small	and	large	intestines,	EECs	(along	
with	 enterocytes/coloncytes	 and	 other	 secretory	 cell	 types)	 are	 derived	 from	 stem	 cells	
located	at	the	base	of	the	crypt.	These	stem	cells	function	to	replenish	epithelial	cells	shed	
into	 the	 intestinal	 lumen.	Newer	cells	produced	 from	division	of	 these	stem	cells	displace	
older	epithelial	cells	which	move	upwards	along	the	crypt	towards	the	lumen	where	they	are	
shed	[306].	Beumer	et	al.	(2018)	found	a	BMP	gradient	across	the	crypt	axis	(highest	levels	in	
the	distal	crypt	and	lowest	at	the	base	of	the	crypt)	that	regulates	the	expression	of	multiple	
different	gut	hormone	genes	 including	Sct,	Tac1,	Nts,	Pyy	and	Gcg	 [132].	Therefore,	Tac1-
expressing	EC	cells	might	represent	new	EC	cells	in	the	base	of	the	crypt	which	become	Sct-
expressing	 EC	 cells	 as	 they	mature	 and	move	 upwards	 along	 the	 crypt	 axis	 (towards	 the	
lumen)	 upregulate	 Sct	 expression	 and	 downregulate	 Tac1	 according	 to	 increasing	 BMP	
exposure.		
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Similarly,	 Nts	 expression	 was	 found	 to	 be	 upregulated	 whilst	 expression	 of	 Gcg	 was	
downregulated	 by	 BMP	 signalling	 by	 Beumer	 et	 al.	 (2018)	 supporting	 previous	
immunohistological	 and	 transcriptomic	 investigations	 by	 Grunddal	 et	 al.	 (2016)	 indicating	
that	 NTS	 cells	 were	 concentrated	 in	 the	 distal	 crypt	 whilst	 GLP-1	 producing	 cells	 were	
concentrated	at	the	crypt	base.	Furthermore,	 in	the	Grunddal	et	al.	 (2016)	study	selective	
ablation	 of	 L-cells	 (via	 diphtheria	 toxin	 administration	 to	 transgenic	 mice	 engineered	 to	
express	of	human	diphtheria	toxin	receptor	under	the	proglucagon	promoter)	revealed	that	
numbers	 of	 GLP-1	 producing	 L-cells	 recovered	 much	 earlier	 than	 those	 of	 PYY	 and	 NTS	
producing	L-cells	[101].	These	findings	imply	that	NTS-producing	L-cells	might	be	located	at	
the	distal	end	of	the	crypt	and	reflect	a	population	of	mature	L-cells	that	have	moved	upwards	
towards	the	lumen	and	acquired	the	ability	to	express	and	produce	NTS	(thus	taking	longer	
to	replenish	following	ablation).	It	should	be	noted	that	the	Beumer	et	al.	(2018)	and	Grunddal	
et	 al.	 (2016)	 studies	 investigated	 small	 intestinal	 EECs	 and	 that	 these	 findings	might	 not	
translate	well	to	colonic	crypts.	Indeed,	given	that	Pyy	expression	was	negatively	correlated	
with	Nts	 expression	 in	 colonic	 L-cells	 (figure	 3E&F)	 one	 might	 have	 anticipated	 that	 Pyy	
expression	would	be	lowest	in	the	distal	crypt,	however	the	opposite	pattern	was	observed	
[101,132].	
	
The	third	and	 largest	group	of	EC	cells	 identified	were	distinguished	by	Piezo2	expression.	
Piezo2	 is	 a	 non-selective	 cationic	 channel	 which	 is	 mechanosensitive,	 meaning	 that	
application	 of	 mechanical	 force	 induces	 Piezo2	 activation	 and	 subsequent	 membrane	
depolarisation	[307].	In	the	context	of	EC	cells,	this	raises	the	possibility	that	distension	of	the	
colonic	mucosa	by	 luminal	contents,	may	stimulate	5-HT	secretion	by	activation	of	Piezo2.	
Indeed,	recent	studies	indicate	that	Piezo2	is	highly	expressed	within	EC	cells	in	both	murine	
and	human	intestines	and	that	it	functions	to	couple	EC	mechanosensation	to	5-HT	release	
[255].	As	a	 result,	 these	cells	may	 reflect	a	mechanosensitive	 subset	of	EC	cells	which	co-
ordinates	colonic	contractility	either	by	direct	effects	of	5-HT	on	colonic	smooth	muscle	or	
indirectly	through	signalling	through	stimulation	of	the	enteric	nervous	system.	
	
The	regional	RT-qPCR	data	suggests	that	colonic	EC	cells	decline	in	number	moving	distally	
across	the	colon	as	Tph1	expression	significantly	drops.	Sct	also	dropped	implying	that	Sct-
expressing	 EC	 cells	might	 be	 concentrated	 in	 the	 proximal	 colon.	 No	 similar	 analysis	was	
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conducted	 for	 Tac1	 or	 Piezo2	 so	 regional	 variations	 in	 the	 distribution	 of	 these	 EC	 cell	
subpopulations	may	exist.	
	
 D-cells	form	a	transcriptomically	distinct	group	of	colonic	EECs	
D-cells	formed	a	clearly	separated	cluster	on	the	t-SNE	plot	and	were	identifiable	by	highly	
specific	expression	of	Sst.	Relative	expression	of	Sst	was	fairly	constant	throughout	the	length	
of	the	colon,	with	a	drop	in	the	most	distal	regions	of	colon,	largely	consistent	with	previous	
immunohistological	data	indicating	that	colonic	D-cells	are	fairly	evenly	scattered	throughout	
the	colon	[238].	Colonic	D-cells	appear	to	possess	similar	expression	profiles	to	D-cells	from	
other	 regions	of	 the	 gastrointestinal	 tract.	 For	 example,	 colonic	D-cells	were	 enriched	 for	
Iapp,	Calcrl	 and	Adra2a	 transcripts,	genes	which	are	also	expressed	 in	gastric	D-cells.	This	
suggests	 that	 intestinal	 D-cells	 may	 not	 display	 regional	 differences	 in	 expression	
[63,114,115,132].	 Direct	 comparisons	 between	 gastric,	 small	 intestinal	 and	 colonic	 D-cell	
transcriptomes	would	enable	D-cell	regional	similarities	and	differences	to	be	assessed.	
	
 Unexpected	identification	of	goblet	cells	in	a	FACS-purified	NeuroD1	cell	
population	
Goblet	cells	and	enteroendocrine	cells	are	derived	from	separate	cell	lineages	diverging	from	
a	 common	 secretory	 precursor	 cell.	Whilst	 expression	 of	Neurog3	 commits	 the	 common	
precursor	cells	to	an	EEC	fate,	expression	of	Gfi1	commits	them	to	either	goblet	cell	or	Paneth	
cell	fates	depending	on	expression	of	FoxA1/2	and	Klf4	for	goblet	cells	or	Sox9	for	Paneth	cells	
[140].	Neurod1	is	specific	transcriptional	marker	of	enteroendocrine	cells	which	are	derived	
from	 Neurog3-expressing	 EEC	 precursors,	 which	 is	 absent	 in	 goblet	 cells,	 therefore	 it	 is	
surprising	that	our	scRNA-seq	analysis	of	cells	 isolated	by	NeuroD1	expression	 identified	a	
cluster	of	goblet	cells.	This	result	could	derive	from	the	Cre-recombination	system	employed	
to	label	NeuroD1	cells	as	all	cells	which	express	NeuroD1	and	their	progeny	will	express	EYFP	
due	to	Cre	recombinase	editing	of	the	genome.	Therefore,	if	precursor	cells	to	these	goblet	
cells	expressed	Neurod1,	even	briefly,	the	resulting	goblet	cells	would	be	EYFP	labelled.	Some	
goblet	cells	may	also	have	produced	Cre	recombinase	in	the	absence	of	Neurod1	expression	
or	due	to	low	levels	of	Neurod1	expression	and	subsequently	acquired	EYFP	labelling.	Indeed,	
from	analysis	of	the	scRNA-seq	data	the	goblet	cell	group	appears	to	express	low	levels	of	
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Neurod1	(data	not	shown).	Goblet	cells	may	also	have	been	isolated	due	to	issues	with	the	
FACS-purification	 itself.	 For	 example,	 a	 few	 autofluorescent	 goblet	 cells	 or	 doublets	
containing	goblet	cells	may	have	been	isolated.	Alternatively,	the	goblet	cell	population	may	
derive	from	transdifferentiation	of	mature	EECs.	To	the	author’s	knowledge	however,	this	has	
not	been	observed	in	vivo	although	transdifferentiation	of	EECs	to	insulin-producing	beta-like	
cells	has	been	achieved	through	genetic	modification	in	murine	stomach	[308].		
	
 Concluding	remarks	
In	sum,	scRNA-seq	analysis	of	 the	colonic	enteroendocrine	cell	population	 identified	three	
main	EEC	groups:	L,	D	and	EC	cells.	Cluster	analysis	and	differential	expression	identified	that	
whilst	D-cells	formed	a	fairly	homogenous	group	the	L	and	EC	cell	groups	could	be	divided	
into	 subgroups.	 L-cells	 divided	 into	 two	 main	 groups	 consisting	 of	 distally	 located	 Insl5-
expressing	and	proximally	 located	Nts-expressing	cells	with	 functional	differences	 in	GPCR	
repertoire.	Meanwhile	EC	cells	divided	into	three	groups	distinguished	by	expression	of	Sct,	
Tac1	and	Piezo2.	We	postulate	that	the	Tac1	and	Piezo2	groups	may	reflect	pro-inflammatory	
and	mechanosensitive	 EC	 subpopulations	 respectively.	 Together	 the	 findings	presented	 in	
this	chapter	largely	confirm	my	initial	hypotheses	about	colonic	EECs	though	the	distribution,	
functional	GPCR	repertoires	and	clinical	relevance	of	all	the	different	EEC	subgroups	identified	
(particularly	of	the	EC	cell	subgroups)	require	further	clarification.	Significantly	these	findings	
suggest	 that	 selective	 pharmacological	 targeting	 of	 particular	 subsets	 of	 colonic	 EEC	 cells	
might	be	possible,	with	potential	implications	for	obesity,	diabetes	and	IBD	treatment.	
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 Chapter	6.	General	discussion	
6.1. Summary	of	key	findings	
 GPBAR-1	activation	potentiates	FFAR1-mediated	GLP-1	secretion	
In	 chapter	 3,	 concomitant	GPBAR-1	 activation	was	 found	 to	 potentiate	 L-cell	 intracellular	
calcium	 responses	 to	 FFAR1	 activation	 and	 30mM	 KCl	 application.	 Likewise,	 GPBAR-1	
activation	 potentiated	 FFAR1-mediated	 GLP-1	 secretion.	 This	 suggests	 coupling	 of	 the	
potentiated	intracellular	calcium	responses	observed	to	increased	GLP-1	secretion	(since	GLP-
1	 secretion	 is	 calcium	 dependent).	 These	 findings	 were	 achieved	 using	 small	 intestinal	
organoids	which	appear	to	recapitulate	native	L-cell	physiology.	Further	application	of	these	
small	 intestinal	 organoids	 in	 secretion	 and	 electrophysiological	 experiments	 suggests	
involvement	of	TRPC3	and	L-type	VGCCs	in	the	synergy	seen	between	the	GPBAR-1	and	FFAR1	
signalling	 pathways	 [201].	 However,	 the	 precise	 molecular	 basis	 of	 these	 synergistic	
interactions	has	yet	to	be	determined.	
	
Our	findings	compliment	previous	findings	by	Ekberg	et	al.	(2016)	that	activation	of	the	Gs-
coupled	GPR119	 (receptor	 for	2-monoacylglycerol)	potentiated	GLP-1	 secretory	 responses	
from	colonic	crypt	cultures	to	Gq-coupled	FFAR1	activation	[160].	Furthermore,	Hauge	et	al.	
(2016)	similarly	found	that	GPBAR-1	activation	potentiates	FFAR1-dependent	GLP-1	secretion	
and	found	a	similar	effect	on	plasma	GLP-1	levels	in	vivo	using	mouse	models	[199].	Therefore,	
co-activation	of	Gq	and	Gs	 signalling	pathways	 in	 L-cells	 could	provide	a	novel	 therapeutic	
approach	to	type	2	diabetes	management.		
	
Future	investigations	could	elucidate	the	molecular	basis	of	synergy	between	GPBAR-1	and	
FFAR1	signalling	in	L-cells	through	a	combination	of	pharmacological	experiments	and	genetic	
modification.	 	 Pharmacological	 experiments	 could	 examine	 PKA-independent	 effects	 of	
GPBAR-1	 stimulation	 through	 the	 cAMP	 effector	 EPAC2	 by	 applying	 the	 EPAC2	 selective	
antagonist	ESI-05	in	intracellular	calcium	and	secretion	assays	[309].	Likewise,	 inhibition	of	
PKC	using	sphingosine	could	identify	potential	involvement	of	PKC	[310].	Concerning	genetic	
modification,	 CRISPR/Cas9	mediated	 genetic	 knockout	 in	 intestinal	 organoids	would	 allow	
identification	of	the	key	VGCC	subtypes	underlying	GPBAR-1	potentiation	of	FFAR1-mediated	
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GLP-1	secretion	[210].	Using	such	genetic	knockouts	would	avoid	potential	off-target	effects	
of	VGCC	pharmacological	modulators	such	as	on	potassium	channels	by	the	L-type	calcium	
channel	 agonist	 Bayk8644	 [203].	 Future	 experiments	 should	 also	 establish	 the	 clinical	
relevance	 of	 these	 findings	 through	 secretion	 experiments	 on	 primary	 cultures	 of	 human	
intestine.	
	
 INSL5,	PYY	and	GLP-1	are	co-stored	and	co-released	from	L-cells	
In	 chapter	 4,	 the	 physiology	 of	 INSL5-producing	 subset	 of	 L-cells	 was	 initially	 considered	
through	a	combination	of	transcriptomic	profiling,	intracellular	calcium	imaging	and	secretion	
assays.	RT-qPCR	revealed	that	INSL5	cells	express	GPCRs	previously	characterised	in	L-cells	
including	FFAR1,	Agtr1a	and	Avpr1b	[73,74,127].	The	functionality	of	a	Gq-coupled	subset	of	
these	 GPCRs,	 was	 confirmed	 by	 intracellular	 calcium	 transients	 elicited	 upon	 specific	
pharmacological	 activation.	 Consistently,	 stimulation	 of	 these	 GPCRs	 along	 with	 other	
previously	characterised	L-cell	GPCRs	stimulated	INSL5	release	from	both	murine	and	human	
crypt	 cultures.	 The	 use	 of	 LC/MS	 peptide	 quantification	 enabled	 INSL5	 secretion	 to	 be	
accurately	measured	 from	colonic	 crypt	 cultures	 for	 the	 first	 time	 (Pierre	 Larraufie).	 Such	
techniques	revealed	that	GLP-1,	PYY	and	INSL5	were	co-released	in	response	to	the	subset	of	
physiological	stimuli	tested	from	both	murine	and	human	primary	cultures	of	colonic	crypts.	
	
It	was	hypothesised	that	GLP-1,	PYY	and	INSL5	co-release	either	arose	from	largely	separate	
populations	 of	 GLP-1,	 PYY	 and	 INSL5	 secretory	 vesicles	 regulated	 by	 a	 common	 release	
mechanism.	 This	 hypothesis	 was	 explored	 in	 chapter	 4	 by	 3D-SIM	 analysis	 of	
immunofluorescently	labelled	primary	cultures	and	sections	of	murine	colonic	tissue.	Overlap	
between	 identified	GLP-1,	 PYY	 and	 INSL5	 vesicles	within	 imaged	 L-cells	was	 examined	 by	
fitting	 3D	 Gaussian	 distributions	 (method	 developed	 by	 Christopher	 Smith)	 [153].	 This	
method	revealed	that	the	majority	(more	than	80%)	of	identified	vesicles	were	triple	labelled	
for	GLP-1,	PYY	and	INSL5.	Consequently,	it	was	concluded	that	co-release	of	GLP-1,	PYY	and	
INSL5	resulted	from	co-storage	in	mouse	and	likely	also	in	humans	(though	similar	3D-SIM	
experiments	should	be	carried	out	on	human	tissue	to	confirm	this).	
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In	contrast,	Cho	et	al.	(2014)	found	only	a	~8.2%	overlap	between	GLP-1	and	PYY	vesicles	in	
murine	L-cells	of	the	colon	[87].	Discrepancies	between	the	findings	detailed	in	chapter	4	and	
those	of	Cho	et	al.	(2014)	likely	arise	from	the	different	analytical	methods	applied.	Cho	et	al.	
(2014)	 used	 an	 approach	 (dubbed	 the	 surfaces	 analysis)	which	 examined	 volume	 overlap	
between	vesicles	rendered	in	3D	using	Imaris	(Bitplane).	Applying	a	similar	approach	to	our	
data	 indicated	roughly	50%	of	vesicles	were	single	 labelled	 for	GLP-1,	PYY	and	 INSL5.	One	
potential	 concern	 with	 the	 surfaces	 analysis	 was	 under-representation	 of	 dual	 or	 triple	
labelled	 vesicles	 due	 to	 differences	 in	 the	 excitation	 wavelengths	 of	 the	 fluorophores	
conjugated	 to	 the	 secondary	antibodies	used.	We	hypothesised	 that	 the	 surfaces	method	
would	 yield	 different	 vesicle	 size	 estimates	 when	 labelled	 with	 fluorophores	 with	 long	
compared	 with	 shorter	 excitation	 wavelengths.	 To	 test	 this	 hypothesis,	 we	 applied	 the	
surfaces	analysis	to	3D-SIM	images	of	L-cells	labelled	for	GLP-1	with	three	different	secondary	
antibodies	conjugated	to	AlexFluor	488,	555	and	633.	In	theory	the	488,	555	and	633	channel	
profiles	should	exhibit	complete	overlap	as	each	channel	labels	the	same	vesicles.	However,	
only	45%	of	total	mapped	vesicle	volume	was	triple	labelled	confirming	our	hypothesis.	On	
the	other	hand,	using	our	method	based	on	3D	Gaussian	fitting,	more	than	95%	of	all	GLP-1	
vesicles	identified	were	triple	labelled.	
	
Given	that	INSL5	has	an	orexigenic	effect	whilst	GLP-1	and	PYY	have	anorexigenic	effects,	the	
significance	 of	 simultaneous	 GLP-1,	 PYY	 and	 INSL5	 secretion	 on	 food	 intake	 regulation	 is	
unclear	[88,211,212].	One	could	hypothesise	that	the	restriction	of	INSL5-producing	L-cells	to	
the	 distal	 colon	may	 help	 explain	 this	 apparent	 paradox	 through	 differences	 in	 the	 post-
prandial	plasma	dynamics	of	INSL5,	GLP-1	and	PYY.	Under	this	hypothesis	during	the	acute	
phase	following	a	meal,	GLP-1	and	PYY	secretion	is	stimulated	from	L-cells	of	the	proximal	
gastrointestinal	tract	suppressing	further	food	intake.	In	between	meals	and	during	fasting,	
INSL5	 secretion	 from	 colonic	 L-cells,	 perhaps	 stimulated	 by	 bacterial	 fermentation	 by-
products	(e.g.	SCFAs),	results	in	food	seeking	behaviour.	In	support	of	this,	fasted	mice	exhibit	
elevated	plasma	levels	of	INSL5	reversible	upon	refeeding	(though	there	have	been	reported	
issues	with	the	INSL5	immunoassays	used	in	this	study)	[88,311].		
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 Murine	 colonic	 L-cells	 divide	 into	 Insl5-expressing	 and	Nts-expressing	
cells	
scRNA-seq	 analysis	 of	 colonic	 enteroendocrine	 cells	 in	 chapter	 5	 enabled	 further	
characterisation	of	 INSL5-producing	 L-cells.	Cluster	and	 subsequent	differential	 expression	
analysis	revealed	2	subpopulations	of	colonic	L-cells;	one	characterised	by	 Insl5	expression	
and	the	other	characterised	by	Nts	expression.	Interestingly,	the	Insl5-expressing	L-cells	were	
particularly	enriched	with	Pyy	expression	relative	to	Nts-expressing	L-cells.	Gcg	expression	
showed	 the	 converse	 relationship	 to	Pyy	 expression	with	highest	 expression	 found	 in	 the	
Insl5-expressing	L-cells.	Additionally,	the	two	subsets	appear	to	differentially	express	other	
appetite	 regulating	 peptides	 with	 a	 subset	 of	 Insl5-expressing	 cells	 enriched	 for	 Ppy	
expression	 whilst	 Nts-expressing	 cells	 were	 enriched	 for	 Cck	 expression	 [92,252].	 These	
results	 suggest	 that	 Insl5-expressing	 and	Nts-expressing	 L-cells	 may	 produce	 and	 secrete	
different	subsets	of	gut	peptides	with	potential	physiological	consequences.	
	
Through	examination	of	immunofluorescently	labelled	colon	wholemounts	and	RT-qPCR	Nts-
expressing	L-cells	were	identified	as	proximally	distributed	whilst	Insl5-expressing	L-cells	were	
distally	distributed	along	the	colon	(fitting	with	findings	by	Grosse	et	al.)	[88].	The	relevance	
of	 the	 identified	 NTS-producing	 L-cells	 to	 human	 physiology	 is	 unclear,	 since,	 unlike	 in	
rodents,	 Nts	 is	 scarcely	 found	 in	 the	 human	 large	 intestine	 (figure	 1)	 [97–99].	 However,	
colonic	murine	Nts-expressing	L-cells	may	act	as	a	useful	model	for	a	known	subset	of	human	
small	 intestinal	 L-cells	 that	 co-produce	NTS	with	GLP-1	and	PYY	 [101].	 Characterisation	of	
these	cells	might	be	clinically	relevant,	particularly	for	obesity	research,	since	NTS	appears	to	
potentiate	the	anorexigenic	actions	of	GLP-1	and	PYY	[101].	
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Figure	1:	Heatmap	representation	of	gut	hormones	across	 the	gastrointestinal	 tract	of	 (A)	
humans	 and	 (B)	mouse.	 P12	 =	 stomach	 lesser	 curvature.	 P1-P7	 =	 proximal	 to	 distal	 small	
intestine	sampled	every	5cm.	P8-P10	=	large	intestine	(proximal,	middle	and	distal).	Adapted	
from	Roberts	et	al.	(2018)	[296].	
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 Colonic	enterochromaffin	cells	split	into	3	distinct	subpopulations	
The	scRNA-seq	analysis	detailed	in	chapter	5	identified	3	main	subpopulations	of	colonic	EC	
cells	 distinguished	 by	 Sct,	Tac1	 or	Piezo2	expression.	 The	Sct-expressing	 EC	 cell	 subgroup	
differentially	express	the	PYY	activated	receptor	Npy1r	potentially	reflecting	regulation	of	this	
subpopulation	by	L-cell	 secretions	 [269].	This	 is	consistent	with	 recent	 findings	 that	GLP-1	
stimulates	5-HT	secretion	from	intestinal	ECs.	Interestingly,	the	same	study	found	expression	
of	Sct	was	 restricted	 to	 small	 intestinal	 EC	 cells,	 contrasting	with	 the	 results	presented	 in	
chapter	5	[240].	The	reasons	for	this	discrepancy	are	unclear.	
	
We	hypothesise	that	the	Tac1-expressing	EC	cell	subpopulation	responds	to	local	intestinal	
inflammation.	This	is	based	on	the	production	of	the	pro-inflammatory	peptide	substance	P	
downstream	 of	 Tac1	 expression	 [299].	 Accordingly,	 Tac1	 expression	 and	 substance	 P	
production	 have	 previously	 been	 identified	 in	 intestinal	 enterochromaffin	 cells	 by	
transcriptomic	and	 immunohistological	analysis	 [65,254].	Since	substance	P	has	previously	
been	implicated	in	inflammatory	bowel	disease	pathophysiology,	these	Tac1-expressing	EC	
cells	may	play	a	critical	role	in	the	development	of	inflammatory	disorders	of	the	intestine	
[303].		
	
Piezo2	encodes	the	mechanosensitive	cation	channel	Piezo2	[307].	Recent	investigations	by	
Wang	et	al.	(2017)	suggest	that	the	mechanosensitivity	of	EC	cells	depends	on	the	activity	of	
Piezo2,	 with	 activation	 stimulating	 5-HT	 secretion	 [255].	 In	 turn,	 5-HT	 regulates	
gastrointestinal	motility	and	peristaltic	contractions	[118].	Given	this	background,	the	Piezo2-
expressing	EC	subset	identified	in	our	scRNA-seq	could	reflect	a	subset	of	mechanosensitive	
colonic	ECs	that	responds	to	local	intestinal	distension	and	modulates	gastrointestinal	motility	
accordingly.	 Such	 local	 feedback	 may	 play	 a	 critical	 role	 in	 co-ordinating	 peristaltic	
contractions	and	transit	of	luminal	contents	through	the	gastrointestinal	tract.	
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 Colonic	enteroendocrine	cells	exhibit	distinct	GPCR	repertoires	
Differentially	expressed	GPCRs	are	identified	for	each	identified	EEC	subpopulation	in	chapter	
5.	Insl5-expressing	L-cells	for	example	were	particularly	enriched	for	Agtr1a	and	Avpr1b	when	
compared	with	Nts-expressing	L-cells.	This	difference	was	found	to	be	functionally	relevant	
since	stimulation	of	Agtr1a	and	Avpr1b,	by	angiotensin	II	and	AVP	respectively,	triggered	GLP-
1,	PYY	and	INSL5	but	not	NTS	secretion	from	murine	colonic	crypt	cultures	(unpublished	data	
from	Pierre	Larraufie).	This	was	backed	up	further	in	chapter	5	by	examining	PYY,	INSL5	and	
NTS	 secretion	 from	crypt	 cultures	prepared	 from	different	 regions	of	 the	 colon	 along	 the	
proximal-distal	axis.	Under	these	conditions,	whilst	angiotensin	II	appeared	to	stimulate	INSL5	
and	PYY	secretion	from	distal	colon,	NTS	secretion	did	not	appear	to	be	stimulated	from	any	
region.	Contrastingly,	application	of	AM-1638	(FFAR1	agonist)	triggered	PYY	secretion	from	
all	 regions,	 INSL5	 from	 distal	 colon	 and	 NTS	 from	 proximal	 colon.	 The	 peptide	 secretion	
profiles	 resulting	 from	FFAR1	activation	are	consistent	with	previous	results	 in	which	NTS,	
GLP-1	and	PYY	were	co-secreted	in	response	to	AM-5262	(FFAR1	agonist)	application	from	
small	 intestinal	 and	 colonic	 crypt	 cultures	 [101].	 Together	 the	 secretion	 results	 support	
functional	 differences	 in	 the	 proximal-distal	 colonic	 distribution	 and	 GPCR	 repertoires	 of	
INSL5	and	NTS-producing	L-cells.	
	
Regarding	 GPCRs	 differentially	 expressed	 in	 the	 other	 EECs	 subgroups,	 as	 previously	
mentioned,	Sct-expressing	EC	cells	express	Npy1r	potentially	reflecting	L-cell	regulation	of	this	
subset	 of	 EC	 cells.	 Tac1-expressing	 EC	 cells	 were	 enriched	 with	 transcripts	 for	 the	 SCFA	
receptor	Olfr78	consistent	with	findings	by	Lund	et	al.	(2018)	and	suggests	that	this	subset	of	
EC	cells	responds	to	the	bacterial	microbiota	[240].	Olfr78	was	also	highly	enriched	within	
Insl5-expressing	 (but	 not	 in	 Nts-expressing)	 L-cells	 which	 probably	 reflects	 previous	
identification	 of	Olfr78	 expression	 in	 a	 subpopulation	 of	 colonic	 L-cells	 by	 Fleischer	 et	 al.	
(2015)	[262].	Concerning	GPCRs	of	colonic	D-cells,	these	cells	were	enriched	for	transcripts	
for	Calcrl	and	Ramp1	suggesting	that	they	express	the	receptor	for	the	neuropeptide	CGRP.	
Functional	expression	of	this	receptor	has	previously	been	identified	in	gastric	D-cells.	Indeed,	
CGRP	 application	 was	 found	 to	 potently	 stimulate	 somatostatin	 secretion	 from	 gastric	
primary	cultures	[115].	Therefore,	since	CGRP	is	produced	and	released	by	enteric	neurons,	
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under	physiological	conditions	colonic	D-cells	might	be	 in	part	be	regulated	by	the	enteric	
nervous	system	through	CGRP	activity	[312].		
	
In	summary,	these	results	suggest	that	differences	in	GPCR	repertoire	might	enable	selective	
pharmacological	targeting	of	specific	EEC	subpopulations	for	potential	therapeutic	benefit.	
	
6.2. Future	directions	
 Establishing	the	physiological	roles	of	INSL5	
The	precise	physiological	role	of	INSL5	has	not	been	clearly	elucidated	with	various	reports	
suggesting	 that	 INSL5	 is	 orexigenic,	 potentiates	 glucose-stimulated	 insulin	 secretion	 and	
modulates	hepatic	glucose	production	[88,90,91].	In	part,	these	studies	have	been	hampered	
by	unreliable	INSL5	quantification	using	current	 immunoassays	[311].	The	LC-MS	approach	
presented	 in	 this	 thesis	 presents	 a	 solution	 to	 this	 long-running	 issue.	 Members	 of	 the	
Gribble/Reimann	 lab	are	optimising	an	LC-MS	method	 to	measure	plasma	 INSL5.	By	using	
such	a	method	in	vivo	changes	in	plasma	INSL5	could	be	quantified	in	both	mice	and	humans	
following	different	experimental	interventions	including	bariatric	surgery.		
	
A	novel	approach	for	investigating	INSL5	physiology	would	be	to	develop	transgenic	mouse	
models	 expressing	 designer	 receptors	 exclusively	 activated	 by	 designer	 drugs	 (DREADDs)	
specifically	in	Insl5	and	Rxfp4-expressing	cells.	Activation	of	DREADDs	by	the	physiologically	
inert	drug	CNO	can	stimulate	or	inhibit	secretory	processes	depending	on	coupling	to	Gq	or	Gi	
respectively.	Selective	expression	of	these	DREADDs	in	Insl5	and	Rxfp4	has	been	achieved	in	
the	 Gribble/Reimann	 lab	 through	 the	 use	 of	 Cre-dependent	 DREADDs	 [313].	 Through	
administration	of	CNO	to	such	mice,	selective	stimulation	of	Insl5-expressing	cells	(through	
Gq-coupled	DREADDs)	triggering	INSL5	secretion	and	imitation	of	elicited	Gi	signalling	by	INSL5	
in	Rxfp4-expressing	cells	(through	Gi-coupled	DREADD)	could	be	achieved	in	vivo.	It	is	hoped	
such	experiments	will	elucidate	the	physiological	effects	attributable	to	INSL5.		
	
Alternatively,	identification	of	the	cell	types	and	tissues	expressing	Rxfp4	would	yield	clues	as	
to	the	physiological	role	of	Rxfp4’s	cognate	ligand	INSL5	and	guide	future	investigations.	To	
this	end,	bulk	RNA-seq	of	Rxfp4	cells	FACS	purified	from	novel	Rxfp4-cre/Rosa26-EYFP	and	
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Rxfp4-cre/Rosa26-RFP	 mice	 was	 carried	 out	 by	 Cheryl	 Brighton	 (unpublished	 data).	 This	
transcriptomic	 analysis	 identified	 enrichment	 in	 Rxfp4	 cells	 of	 Tph1,	 Pyy,	 Gcg	 and	 Insl5.	
Subsequent	immunofluorescent	labelling	of	colonic	tissue	from	the	Rxfp4-cre/Rosa26-EYFP	
mice	indicated	that	whilst	a	small	proportion	of	L-cells	(stained	for	INSL5/proglucagon)	co-
stained	for	EYFP	(Rxfp4	cells),	~60%	of	all	colonic	EC	cells	(labelled	by	staining	5-HT)	co-stained	
with	EYFP.	Similar	experiments	also	identified	EYFP	fluorescence	in	nodose	ganglia	extracted	
from	Rxfp4-cre/Rosa26-EYFP	mice.	 This	 profile	 of	 Rxfp4	 labelling	 suggests	 that	 INSL5	may	
autoinhibit	 a	 subset	 of	 L-cells	 (through	 Gi-coupled	 signalling),	 regulate	 gastrointestinal	
motility	 (through	 modulation	 of	 EC	 cells)	 and	 modulate	 activities	 of	 the	 enteric	 nervous	
system.	However,	 it	 should	be	noted	 that	 levels	of	Rxfp4	 transcripts	detected	by	RT-qPCR	
were	very	low	or	undetectable	in	FACS-purified	L-cells	and	nodose	ganglia	(unpublished	data	
from	Cheryl	Brighton).	This	discrepancy	likely	reflects	historical	and	transient	expression	of	
Rxfp4	 yielding	 permanent	 expression	 of	 RFP/EYFP	 in	 the	 precursors	 of	 labelled	 cells.	
Development	of	a	transgenic	mouse	line	in	which	selective	expression	of	RFP/EYFP	in	Rxfp4	
cells	is	achieved	using	the	conditional	Tet-on	system	would	avoid	such	issues	[228].		
	
 Selective	pharmacological	targeting	of	EEC	subtypes	
Building	 on	 the	 results	 from	 chapter	 5,	 future	 experiments	 could	 attempt	 to	 selectively	
stimulate/inhibit	 specific	 subsets	 of	 EECs	 with	 secretory	 responses	 quantified	 by	 LC/MS	
analysis.	For	example,	the	scRNA-seq	analysis	indicates	that	subunits	of	the	CGRP	receptor	
are	specifically	expressed	in	D-cells.	This	suggests	that	selective	secretion	of	SST-28	might	be	
achieved	 by	 CGRP	 application.	 Furthermore,	 enrichment	 of	Galr1,	 the	 Gi-coupled	 galinin	
receptor	 mRNA,	 in	 Insl5-expressing	 over	 Nts-expressing	 L-cells	 suggests	 that	 selective	
inhibition	of	INSL5	secretion	might	be	achievable	[264].	Given	the	orexigenic	effects	of	INSL5,	
suppression	of	 INSL5	secretion	may	yield	therapeutic	benefits	 to	obese	patients.	Likewise,	
selective	 stimulation	of	non-INSL5	producing	 L-cells	may	prove	advantageous	 through	 the	
stimulated	release	of	anorexigenic	GLP-1	and	PYY	without	release	of	orexigenic	INSL5.	To	this	
end,	 the	 Gq-coupled	 orphan	 receptor	 GPR27	 appears	 to	 be	 a	 potential	 target	 for	 further	
investigation	[266].		
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Technical	limitations	restrict	droplet-based	scRNA-seq	reads	to	a	relative	shallow	depth,	likely	
hiding	further	differences	in	GPCR	repertoire	between	the	different	EEC	subtypes.	Using	more	
sensitive	 scRNA-seq	 techniques	 such	 as	 SMART-seq2	 could	 therefore	 enable	 detection	 of	
further	differences	in	GPCR	repertoire	between	different	EEC	subtypes.	For	example,	FACS-
purified	 colonic	 cells	 from	 Glu-Venus	mice	 could	 be	 analysed	 by	 SMART-seq2	 to	 identify	
differences	in	GPCR	expression	between	Insl5-expressing	L-cells	and	other	L-cell	subgroups.		
	
All	the	scRNA-seq	investigations	into	EEC	physiology	detailed	so	far,	including	this	thesis,	have	
examined	murine	EECs.	 In	order	to	examine	the	single	cell	 transcriptomes	of	human	EECs,	
differentiated	 intestinal	 organoids	 could	 be	 analysed.	 By	 using	 intestinal	 organoids	 rather	
than	 primary	 tissue	 for	 scRNA-seq	 analysis,	 the	 transcriptomes	 of	 epithelial	 cells	 can	 be	
isolated	without	contamination	with	other	cell	 types	e.g.	 smooth	muscle	cells	and	enteric	
neurons	 [65].	 To	 enhance	 this	 approach,	 fluorescent	 tags	 expressed	 under	 the	 control	 of	
specific	 cell-type	markers	 (e.g.	NeuroD1	 for	EECs)	could	be	knocked	 into	human	 intestinal	
organoids	using	CRISPR/Cas9	genome	editing	[314].	This	would	enable	selective	scRNA-seq	
analysis	 of	 human	 EECs	 isolated	 through	 FACS-purification.	 Such	 analyses	 of	 human	 EECs	
would	yield	direct	insight	into	human	EEC	physiology	and	allow	comparison	with	murine	EECs	
to	examine	the	relevance	of	murine	models.	
	
6.3. Concluding	remarks	
This	 thesis	 has	 expanded	 the	 current	 comprehension	 of	 synergy	 between	 the	Gs	 and	Gq-
coupled	signalling	pathways	in	L-cells	and	colonic	enteroendocrine	cell	diversity.	It	is	hoped	
that	by	pharmacologically	replicating	the	synergistic	effects	of	GPBAR-1	activation	on	FFAR1-
mediated	GLP-1	 secretion	 new	 type	 2	 diabetes	 treatments	 could	 be	 developed.	 Similarly,	
pharmacological	 exploitation	 of	 identified	 differences	 between	 enteroendocrine	 cell	
subtypes	 in	GPCR	repertoire	may	yield	 therapeutic	benefits	 through	modulated	release	of	
specific	enteroendocrine	hormones.	This	thesis	has	additionally	provided	novel	insight	into	
the	secretory	mechanisms	of	INSL5-producing	L-cells.	Further	complimentary	studies	in	vivo	
will	help	to	clarify	the	physiological	significance	of	INSL5,	a	hitherto	poorly	characterised	gut	
peptide.	
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 Appendices	
	
Appendix	1:	Heat-map	of	log2	normalised	reads	from	each	cell	for	the	scRNA-seq	analysis	of	
colonic	EECs	for	a	selection	of	known	EEC	markers.		
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Appendix	2:	Heat-map	of	log2	normalised	reads	across	all	scRNA-seq	analysed	cells	for	the	top	
differentially	expressed	transporter	genes	from	each	colonic	EEC	subgroup	as	identified	using	
edgeR.	
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Ensembl	ID		 Gene	 Protein	Product	
ENSMUSG00000000194	 Gpr107	 G	Protein-Coupled	Receptor	107	
ENSMUSG00000000562	 Adora3	 Adenosine	A3	Receptor	
ENSMUSG00000001761	 Smo	 Smoothened,	Frizzled	Class	Receptor	
ENSMUSG00000002871	 Tpra1	 Transmembrane	Protein,	Adipocyte	Asscociated	1	
ENSMUSG00000002885	 Adgre5	 Adhesion	G	Protein-Coupled	Receptor	E5	
ENSMUSG00000004730	 Adgre1	 Adhesion	G	Protein-Coupled	Receptor	E1	
ENSMUSG00000005823	 Gpr108	 G	Protein-Coupled	Receptor	108	
ENSMUSG00000007989	 Fzd3	 Frizzled	Class	Receptor	3	
ENSMUSG00000008734	 Gprc5b	 G	Protein-Coupled	Receptor,	Class	C,	Group	5,	Member	B	
ENSMUSG00000011171	 Vipr2	 Vasoactive	Intestinal	Peptide	Receptor	2	
ENSMUSG00000013033	 Adgrl1	 Adhesion	G	Protein-Coupled	Receptor	L1	
ENSMUSG00000016028	 Celsr1	 Cadherin,	Egf	Lag	Seven-Pass	G-Type	Receptor	1	
ENSMUSG00000018500	 Adora2b	 Adenosine	A2B	Receptor	
ENSMUSG00000019429	 Ffar3	 Free	Fatty	Acid	Receptor	3	
ENSMUSG00000019464	 Ptger1	 Prostaglandin	E	Receptor	1	(Subtype	Ep1),	42Kda	
ENSMUSG00000019828	 Grm1	 Glutamate	Receptor,	Metabotropic	1	
ENSMUSG00000019905	 Gprc6a	 G	Protein-Coupled	Receptor,	Class	C,	Group	6,	Member	A	
ENSMUSG00000020090	 Npffr1	 Neuropeptide	Ff	Receptor	1	
ENSMUSG00000020123	 Avpr1a	 Arginine	Vasopressin	Receptor	1A	
ENSMUSG00000020178	 Adora2a	 Adenosine	A2A	Receptor	
ENSMUSG00000020793	 Galr2	 Galanin	Receptor	2	
ENSMUSG00000020963	 Tshr	 Thyroid	Stimulating	Hormone	Receptor	
ENSMUSG00000021298	 Gpr132	 G	Protein-Coupled	Receptor	132	
ENSMUSG00000021678	 F2rl1	 Coagulation	Factor	Ii	(Thrombin)	Receptor-Like	1	
ENSMUSG00000021886	 Gpr65	 G	Protein-Coupled	Receptor	65	
ENSMUSG00000022122	 Ednrb	 Endothelin	Receptor	Type	B	
ENSMUSG00000022297	 Fzd6	 Frizzled	Class	Receptor	6	
ENSMUSG00000022755	 Adgrg7	 Adhesion	G	Protein-Coupled	Receptor	G7	
ENSMUSG00000023473	 Celsr3	 Cadherin,	Egf	Lag	Seven-Pass	G-Type	Receptor	3	
ENSMUSG00000024027	 Glp1r	 Glucagon-Like	Peptide	1	Receptor	
ENSMUSG00000024462	 Gabbr1	 Gamma-Aminobutyric	Acid	(Gaba)	B	Receptor,	1	
ENSMUSG00000024553	 Galr1	 Galanin	Receptor	1	
ENSMUSG00000025127	 Gcgr	 Glucagon	Receptor	
ENSMUSG00000025496	 Drd4	 Dopamine	Receptor	D4	
ENSMUSG00000025804	 Ccr1	 Chemokine	(C-C	Motif)	Receptor	1	
ENSMUSG00000025905	 Oprk1	 Opioid	Receptor,	Kappa	1	
ENSMUSG00000026180	 Cxcr2	 Chemokine	(C-X-C	Motif)	Receptor	2	
ENSMUSG00000026237	 Nmur1	 Neuromedin	U	Receptor	1	
ENSMUSG00000026271	 Gpr35	 G	Protein-Coupled	Receptor	35	
ENSMUSG00000026322	 Htr4	 5-Hydroxytryptamine	(Serotonin)	Receptor	4,	G	Protein-Coupled	
ENSMUSG00000026343	 Gpr39	 G	Protein-Coupled	Receptor	39	
ENSMUSG00000026424	 Gpr37l1	 G	Protein-Coupled	Receptor	37	Like	1	
ENSMUSG00000026432	 Avpr1b	 Arginine	Vasopressin	Receptor	1B	
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ENSMUSG00000026469	 Xpr1	 Xenotropic	And	Polytropic	Retrovirus	Receptor	1	
ENSMUSG00000026525	 Opn3	 Opsin	3	
ENSMUSG00000027584	 Oprl1	 Opiate	Receptor-Like	1	
ENSMUSG00000027762	 Sucnr1	 Succinate	Receptor	1	
ENSMUSG00000027765	 P2ry1	 Purinergic	Receptor	P2Y,	G-Protein	Coupled,	1	
ENSMUSG00000028004	 Npy2r	 Neuropeptide	Y	Receptor	Y2	
ENSMUSG00000028012	 Rrh	 Retinal	Pigment	Epithelium-Derived	Rhodopsin	Homolog	
ENSMUSG00000028172	 Tacr3	 Tachykinin	Receptor	3	
ENSMUSG00000028184	 Adgrl2	 Adhesion	G	Protein-Coupled	Receptor	L2	
ENSMUSG00000028738	 Tas1r2	 Taste	Receptor,	Type	1,	Member	2	
ENSMUSG00000028950	 Tas1r1	 Taste	Receptor,	Type	1,	Member	1	
ENSMUSG00000029072	 Tas1r3	 Taste	Receptor,	Type	1,	Member	3	
ENSMUSG00000029090	 Adgra3	 Adhesion	G	Protein-Coupled	Receptor	A3	
ENSMUSG00000029193	 Cckar	 Cholecystokinin	A	Receptor	
ENSMUSG00000029530	 Ccr9	 Chemokine	(C-C	Motif)	Receptor	9	
ENSMUSG00000029778	 Adcyap1r1	 Adenylate	Cyclase	Activating	Polypeptide	1	(Pituitary)	Receptor	Type	I	
ENSMUSG00000030324	 Rho	 Rhodopsin	
ENSMUSG00000030406	 Gipr	 Gastric	Inhibitory	Polypeptide	Receptor	
ENSMUSG00000031070	 Mrgprf	 Mas-Related	Gpr,	Member	F	
ENSMUSG00000031210	 Gpr165	 G	Protein-Coupled	Receptor	165	
ENSMUSG00000031298	 Adgrg2	 Adhesion	G	Protein-Coupled	Receptor	G2	
ENSMUSG00000031364	 Grpr	 Gastrin-Releasing	Peptide	Receptor	
ENSMUSG00000031390	 Avpr2	 Arginine	Vasopressin	Receptor	2	
ENSMUSG00000031486	 Adgra2	 Adhesion	G	Protein-Coupled	Receptor	A2	
ENSMUSG00000031785	 Adgrg1	 Adhesion	G	Protein-Coupled	Receptor	G1	
ENSMUSG00000031861	 Lpar2	 Lysophosphatidic	Acid	Receptor	2	
ENSMUSG00000031932	 Gpr83	 G	Protein-Coupled	Receptor	83	
ENSMUSG00000032259	 Drd2	 Dopamine	Receptor	D2	
ENSMUSG00000032492	 Pth1r	 Parathyroid	Hormone	1	Receptor	
ENSMUSG00000032528	 Vipr1	 Vasoactive	Intestinal	Peptide	Receptor	1	
ENSMUSG00000032641	 Gpr19	 G	Protein-Coupled	Receptor	19	
ENSMUSG00000032773	 Chrm1	 Cholinergic	Receptor,	Muscarinic	1	
ENSMUSG00000032860	 P2ry2	 Purinergic	Receptor	P2Y,	G-Protein	Coupled,	2	
ENSMUSG00000033446	 Lpar6	 Lysophosphatidic	Acid	Receptor	6	
ENSMUSG00000033470	 Cysltr2	 Cysteinyl	Leukotriene	Receptor	2	
ENSMUSG00000033569	 Adgrb3	 Adhesion	G	Protein-Coupled	Receptor	B3	
ENSMUSG00000033717	 Adra2a	 Adrenoceptor	Alpha	2A	
ENSMUSG00000034677	 Gpr142	 G	Protein-Coupled	Receptor	142	
ENSMUSG00000034881	 Tbxa2r	 Thromboxane	A2	Receptor	
ENSMUSG00000034987	 Hrh2	 Histamine	Receptor	H2	
ENSMUSG00000035431	 Sstr1	 Somatostatin	Receptor	1	
ENSMUSG00000035773	 Kiss1r	 Kiss1	Receptor	
ENSMUSG00000036362	 P2ry13	 Purinergic	Receptor	P2Y,	G-Protein	Coupled,	13	
ENSMUSG00000036381	 P2ry14	 Purinergic	Receptor	P2Y,	G-Protein	Coupled,	14	
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ENSMUSG00000036437	 Npy1r	 Neuropeptide	Y	Receptor	Y1	
ENSMUSG00000036904	 Fzd8	 Frizzled	Class	Receptor	8	
ENSMUSG00000037605	 Adgrl3	 Adhesion	G	Protein-Coupled	Receptor	L3	
ENSMUSG00000037661	 Gpr160	 G	Protein-Coupled	Receptor	160	
ENSMUSG00000037759	 Ptger2	 Prostaglandin	E	Receptor	2	(Subtype	Ep2),	53Kda	
ENSMUSG00000038390	 Gpr162	 G	Protein-Coupled	Receptor	162	
ENSMUSG00000038668	 Lpar1	 Lysophosphatidic	Acid	Receptor	1	
ENSMUSG00000039059	 Hrh3	 Histamine	Receptor	H3	
ENSMUSG00000039167	 Adgrl4	 Adhesion	G	Protein-Coupled	Receptor	L4	
ENSMUSG00000039809	 Gabbr2	 Gamma-Aminobutyric	Acid	(Gaba)	B	Receptor,	2	
ENSMUSG00000039904	 Gpr37	 G	Protein-Coupled	Receptor	37	(Endothelin	Receptor	Type	B-Like)	
ENSMUSG00000039942	 Ptger4	 Prostaglandin	E	Receptor	4	(Subtype	Ep4)	
ENSMUSG00000040016	 Ptger3	 Prostaglandin	E	Receptor	3	(Subtype	Ep3)	
ENSMUSG00000040229	 Gpr34	 G	Protein-Coupled	Receptor	34	
ENSMUSG00000040432	 Ltb4r2	 Leukotriene	B4	Receptor	2	
ENSMUSG00000040495	 Chrm4	 Cholinergic	Receptor,	Muscarinic	4	
ENSMUSG00000040836	 Gpr161	 G	Protein-Coupled	Receptor	161	
ENSMUSG00000041075	 Fzd7	 Frizzled	Class	Receptor	7	
ENSMUSG00000041293	 Adgrf1	 Adhesion	G	Protein-Coupled	Receptor	F1	
ENSMUSG00000041347	 Bdkrb1	 Bradykinin	Receptor	B1	
ENSMUSG00000041468	 Gpr12	 G	Protein-Coupled	Receptor	12	
ENSMUSG00000041762	 Gpr155	 G	Protein-Coupled	Receptor	155	
ENSMUSG00000041907	 Gpr45	 G	Protein-Coupled	Receptor	45	
ENSMUSG00000042262	 Ccr8	 Chemokine	(C-C	Motif)	Receptor	8	
ENSMUSG00000042429	 Adora1	 Adenosine	A1	Receptor	
ENSMUSG00000042804	 Gpr153	 G	Protein-Coupled	Receptor	153	
ENSMUSG00000043366	 Olfr78	 Olfactory	Receptor,	Family	51,	Subfamily	E,	Member	2	
ENSMUSG00000043398	 Gpr135	 G	Protein-Coupled	Receptor	135	
ENSMUSG00000043880	 Olfr323	 Olfactory	Receptor,	Family	11,	Subfamily	L,	Member	1	
ENSMUSG00000043895	 S1pr2	 Sphingosine-1-Phosphate	Receptor	2	
ENSMUSG00000043953	 Ccrl2	 Chemokine	(C-C	Motif)	Receptor-Like	2	
ENSMUSG00000043999	 Gpr75	 G	Protein-Coupled	Receptor	75	
ENSMUSG00000044017	 Adgrd1	 Adhesion	G	Protein-Coupled	Receptor	D1	
ENSMUSG00000044052	 Ccr10	 Chemokine	(C-C	Motif)	Receptor	10	
ENSMUSG00000044067	 Gpr22	 G	Protein-Coupled	Receptor	22	
ENSMUSG00000044199	 S1pr4	 Sphingosine-1-Phosphate	Receptor	4	
ENSMUSG00000044288	 Cnr1	 Cannabinoid	Receptor	1	(Brain)	
ENSMUSG00000044337	 Ackr3	 Atypical	Chemokine	Receptor	3	
ENSMUSG00000044338	 Aplnr	 Apelin	Receptor	
ENSMUSG00000044359	 P2ry4	 Pyrimidinergic	Receptor	P2Y,	G-Protein	Coupled,	4	
ENSMUSG00000044453	 Ffar1	 Free	Fatty	Acid	Receptor	1	
ENSMUSG00000044674	 Fzd1	 Frizzled	Class	Receptor	1	
ENSMUSG00000044819	 Oxgr1	 Oxoglutarate	(Alpha-Ketoglutarate)	Receptor	1	
ENSMUSG00000044933	 Sstr3	 Somatostatin	Receptor	3	
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ENSMUSG00000045005	 Fzd5	 Frizzled	Class	Receptor	5	
ENSMUSG00000045092	 S1pr1	 Sphingosine-1-Phosphate	Receptor	1	
ENSMUSG00000045267	 Tas2r119	 Taste	Receptor,	Type	2,	Member	1	
ENSMUSG00000045281	 Gpr20	 G	Protein-Coupled	Receptor	20	
ENSMUSG00000045382	 Cxcr4	 Chemokine	(C-X-C	Motif)	Receptor	4	
ENSMUSG00000045502	 Hcar2	 Hydroxycarboxylic	Acid	Receptor	2	
ENSMUSG00000045509	 Gpr150	 G	Protein-Coupled	Receptor	150	
ENSMUSG00000045730	 Adrb2	 Adrenoceptor	Beta	2,	Surface	
ENSMUSG00000045824	 Olfr574	 Olfactory	Receptor,	Family	51,	Subfamily	T,	Member	1	
ENSMUSG00000045967	 Gpr158	 G	Protein-Coupled	Receptor	158	
ENSMUSG00000046159	 Chrm3	 Cholinergic	Receptor,	Muscarinic	3	
ENSMUSG00000046733	 Gprc5a	 G	Protein-Coupled	Receptor,	Class	C,	Group	5,	Member	A	
ENSMUSG00000046856	 Gpr1	 G	Protein-Coupled	Receptor	1	
ENSMUSG00000046908	 Ltb4r1	 Leukotriene	B4	Receptor	
ENSMUSG00000046922	 Gpr6	 G	Protein-Coupled	Receptor	6	
ENSMUSG00000046985	 Tapt1	 Transmembrane	Anterior	Posterior	Transformation	1	
ENSMUSG00000047259	 Mc4r	 Melanocortin	4	Receptor	
ENSMUSG00000047415	 Gpr68	 G	Protein-Coupled	Receptor	68	
ENSMUSG00000047875	 Gpr157	 G	Protein-Coupled	Receptor	157	
ENSMUSG00000047904	 Sstr2	 Somatostatin	Receptor	2	
ENSMUSG00000048216	 Gpr85	 G	Protein-Coupled	Receptor	85	
ENSMUSG00000048337	 Npy4r	 Neuropeptide	Y	Receptor	Y4	
ENSMUSG00000048376	 F2r	 Coagulation	Factor	Ii	(Thrombin)	Receptor	
ENSMUSG00000048521	 Cxcr6	 Chemokine	(C-X-C	Motif)	Receptor	6	
ENSMUSG00000048779	 P2ry6	 Pyrimidinergic	Receptor	P2Y,	G-Protein	Coupled,	6	
ENSMUSG00000048965	 Mrgpre	 Mas-Related	Gpr,	Member	E	
ENSMUSG00000049103	 Ccr2	 Chemokine	(C-C	Motif)	Receptor	2	
ENSMUSG00000049112	 Oxtr	 Oxytocin	Receptor	
ENSMUSG00000049115	 Agtr1a	 Angiotensin	Ii	Receptor,	Type	1	
ENSMUSG00000049130	 C5ar1	 Complement	Component	5A	Receptor	1	
ENSMUSG00000049241	 Hcar1	 Hydroxycarboxylic	Acid	Receptor	1	
ENSMUSG00000049511	 Htr1b	 5-Hydroxytryptamine	(Serotonin)	Receptor	1B,	G	Protein-Coupled	
ENSMUSG00000049551	 Fzd9	 Frizzled	Class	Receptor	9	
ENSMUSG00000049608	 Gpr55	 G	Protein-Coupled	Receptor	55	
ENSMUSG00000049649	 Gpr3	 G	Protein-Coupled	Receptor	3	
ENSMUSG00000049741	 Rxfp4	 Relaxin/Insulin-Like	Family	Peptide	Receptor	4	
ENSMUSG00000049791	 Fzd4	 Frizzled	Class	Receptor	4	
ENSMUSG00000050075	 Gpr171	 G	Protein-Coupled	Receptor	171	
ENSMUSG00000050147	 F2rl3	 Coagulation	Factor	Ii	(Thrombin)	Receptor-Like	3	
ENSMUSG00000050158	 Olfr165	 Olfactory	Receptor,	Family	2,	Subfamily	M,	Member	5	
ENSMUSG00000050164	 Mchr1	 Melanin-Concentrating	Hormone	Receptor	1	
ENSMUSG00000050232	 Cxcr3	 Chemokine	(C-X-C	Motif)	Receptor	3	
ENSMUSG00000050288	 Fzd2	 Frizzled	Class	Receptor	2	
ENSMUSG00000050350	 Gpr18	 G	Protein-Coupled	Receptor	18	
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ENSMUSG00000050511	 Oprd1	 Opioid	Receptor,	Delta	1	
ENSMUSG00000050534	 Htr5b	 5-Hydroxytryptamine	(Serotonin)	Receptor	5B	
ENSMUSG00000050541	 Adra1b	 Adrenoceptor	Alpha	1B	
ENSMUSG00000050824	 Sstr5	 Somatostatin	Receptor	5	
ENSMUSG00000050921	 P2ry10	 Purinergic	Receptor	P2Y,	G-Protein	Coupled,	10	
ENSMUSG00000051043	 Gprc5c	 G	Protein-Coupled	Receptor,	Class	C,	Group	5,	Member	C	
ENSMUSG00000051182	 Olfr655	 Olfactory	Receptor	655	
ENSMUSG00000051209	 Gpr119	 G	Protein-Coupled	Receptor	119	
ENSMUSG00000051314	 Ffar2	 Free	Fatty	Acid	Receptor	2	
ENSMUSG00000051980	 Casr	 Calcium-Sensing	Receptor	
ENSMUSG00000052336	 Cx3cr1	 Chemokine	(C-X3-C	Motif)	Receptor	1	
ENSMUSG00000052821	 Cysltr1	 Cysteinyl	Leukotriene	Receptor	1	
ENSMUSG00000053004	 Hrh1	 Histamine	Receptor	H1	
ENSMUSG00000053164	 Gpr21	 G	Protein-Coupled	Receptor	21	
ENSMUSG00000053251	 Olfr212	 Olfactory	Receptor	212	
ENSMUSG00000053368	 Rxfp2	 Relaxin/Insulin-Like	Family	Peptide	Receptor	2	
ENSMUSG00000053647	 Gper1	 G	Protein-Coupled	Estrogen	Receptor	1	
ENSMUSG00000054200	 Ffar4	 Free	Fatty	Acid	Receptor	4	
ENSMUSG00000054764	 Mtnr1a	 Melatonin	Receptor	1A	
ENSMUSG00000054988	 Agtr1b	 Angiotensin	Ii	Receptor,	Type	1B	
ENSMUSG00000056492	 Adgrf5	 Adhesion	G	Protein-Coupled	Receptor	F5	
ENSMUSG00000056529	 Ptafr	 Platelet-Activating	Factor	Receptor	
ENSMUSG00000056679	 Gpr173	 G	Protein-Coupled	Receptor	173	
ENSMUSG00000058396	 Gpr182	 G	Protein-Coupled	Receptor	182	
ENSMUSG00000059588	 Calcrl	 Calcitonin	Receptor-Like	
ENSMUSG00000059867	 Olfr960	 Olfactory	Receptor	960	
ENSMUSG00000060470	 Adgrg3	 Adhesion	G	Protein-Coupled	Receptor	G3	
ENSMUSG00000060509	 Xcr1	 Chemokine	(C	Motif)	Receptor	1	
ENSMUSG00000061039	 Olfr920	 Olfactory	Receptor	920	
ENSMUSG00000061577	 Adgrg5	 Adhesion	G	Protein-Coupled	Receptor	G5	
ENSMUSG00000061972	 Olfr99	 Olfactory	Receptor	99	
ENSMUSG00000062585	 Cnr2	 Cannabinoid	Receptor	2	(Macrophage)	
ENSMUSG00000062905	 Vmn1r32	 Vomeronasal	1	Receptor	32	
ENSMUSG00000063239	 Grm4	 Glutamate	Receptor,	Metabotropic	4	
ENSMUSG00000064272	 Gpbar1	 G	Protein-Coupled	Bile	Acid	Receptor	1	
ENSMUSG00000067586	 S1pr3	 Sphingosine-1-Phosphate	Receptor	3	
ENSMUSG00000067714	 Lpar5	 Lysophosphatidic	Acid	Receptor	5	
ENSMUSG00000068740	 Celsr2	 Cadherin,	Egf	Lag	Seven-Pass	G-Type	Receptor	2	
ENSMUSG00000069170	 Adgrv1	 Adhesion	G	Protein-Coupled	Receptor	V1	
ENSMUSG00000070337	 Gpr179	 G	Protein-Coupled	Receptor	179	
ENSMUSG00000070423	 Olfr558	 Olfactory	Receptor,	Family	51,	Subfamily	E,	Member	1	
ENSMUSG00000070687	 Htr1d	 5-Hydroxytryptamine	(Serotonin)	Receptor	1D,	G	Protein-Coupled	
ENSMUSG00000071489	 Ptgdr	 Prostaglandin	D2	Receptor	(Dp)	
ENSMUSG00000071893	 Vmn1r4	 Vomeronasal	1	Receptor	4	
	 186	
ENSMUSG00000072875	 Gpr27	 G	Protein-Coupled	Receptor	27	
ENSMUSG00000073964	 Olfr570	 Olfactory	Receptor	570	
ENSMUSG00000073966	 Olfr561	 Olfactory	Receptor	561	
ENSMUSG00000074037	 Mc1r	 Melanocortin	1	Receptor	(⍺-MSH	Receptor)	
ENSMUSG00000074361	 C5ar2	 Complement	Component	5A	Receptor	2	
ENSMUSG00000078698	 Mrgpra3	 Mas-Related	Gpr,	Member	A3	
ENSMUSG00000079227	 Ccr5	 Chemokine	(C-C	Motif)	Receptor	5	(Gene/Pseudogene)	
ENSMUSG00000079355	 Ackr4	 Atypical	Chemokine	Receptor	4	
ENSMUSG00000081683	 Fzd10	 Frizzled	Class	Receptor	10	
ENSMUSG00000091735	 Gpr62	 G	Protein-Coupled	Receptor	62	
ENSMUSG00000094295	 Olfr819	 Olfactory	Receptor	247	
ENSMUSG00000095730	 Vmn2r29	 Vomeronasal	2,	Receptor	32	
	
Appendix	3:	Table	of	annotated	GPCR	genes	examined	in	the	differential	expression	analysis.	
	
	
